<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10k.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<HTML>
<HEAD>
   <TITLE>Anavex Life Sciences Corp.: Form 10-K - Filed by newsfilecorp.com</TITLE>
</HEAD>
<BODY style="font-size:10pt;">
<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES </FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION </FONT></B><BR>Washington, D.C.
20549<B> </B></P>
<P align=center><B><FONT size=5>FORM 10-K </FONT></B></P>
<P align=center>(Mark One)</P>
<P align=center>[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 <BR>For the fiscal year ended: <B><U>September
30, 2011</U></B><B> <BR></B>or </P>
<P align=center>[&nbsp; &nbsp;] TRANSITION REPORT PURSUANT TO SECTION 13 OR
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 <BR>For the transition period from
__________________ to __________________</P>
<P align=center>Commission file number: <B><U>000-51652</U></B></P>
<P align=center><B><U><FONT size=5>ANAVEX LIFE SCIENCES CORP.</FONT></U></B><B>
</B><BR>(Exact name of registrant as specified in its charter) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>Nevada </U></B></TD>
    <TD align=center width="50%"><B><U>20-8365999 </U></B></TD></TR>
  <TR vAlign=top>
    <TD align=center>State or other jurisdiction of </TD>
    <TD align=center width="50%">(I.R.S. Employer </TD></TR>
  <TR vAlign=top>
    <TD align=center>incorporation or organization </TD>
    <TD align=center width="50%">Identification No.) </TD></TR></TABLE>
<P align=center><B><U>45 Tintern Lane, Portola Valley, California
84028</U></B><B> </B><BR>
  (Address of principal executive offices)( Zip Code)</P>
<P align=center>Registrant&#146;s telephone number, including area code
<B><U>1-800-689-3939</U></B><B> </B></P>
<P align=center>Securities registered pursuant to Section 12(b) of the Act </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center>Title of each class </TD>
    <TD align=center width="50%">Name of each exchange on which registered
  </TD></TR>
  <TR vAlign=top>
    <TD align=center><B><U>Nil </U></B></TD>
    <TD align=center width="50%"><B><U>Nil </U></B></TD></TR></TABLE>
<P align=center>Securities registered pursuant to Section 12(g) of the Act
<BR><B><U>Common Stock</U></B><B> </B><BR>
  (Title of Class) </P>
<P align=center>Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities Act. <BR>Yes [&nbsp;
&nbsp;]&nbsp;&nbsp;&nbsp;&nbsp; No [X]</P>
<P align=center>Indicate by check mark if the registrant is not required to file
reports pursuant to Section 13 or Section 15(d) of the Act. <BR>Yes [&nbsp;
&nbsp;]&nbsp;&nbsp;&nbsp;&nbsp; No [X] </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=center>ii </P>
<P align=center>Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. <BR>Yes [X]&nbsp;&nbsp;&nbsp;&nbsp; No
[&nbsp;&nbsp; ] </P>
<P align=center>Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation
S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such
shorter period that the registrant was required to submit and post such
files).<BR>Yes [X]&nbsp;&nbsp;&nbsp; &nbsp;No [&nbsp; &nbsp;] </P>
<P align=center>Indicate by check mark if disclosure of delinquent filers
pursuant to Item 405 of Regulation S-K (&#167; 229.405 of this chapter) is not
contained herein, and will not be contained, to the best of registrant&#146;s
knowledge, in definitive proxy or information statements incorporated by
reference in Part III of this Form 10-K or any amendment to this Form 10-K.
[&nbsp;&nbsp; ]</P>
<P align=center>Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of &#147;large accelerated filer,&#148;
&#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the
Exchange Act </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center>Large accelerated filer [&nbsp; &nbsp;] </TD>
    <TD align=center width="50%">Accelerated
      filer [&nbsp;&nbsp; ] </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>Non-accelerated filer [&nbsp;&nbsp; ]<br>
(Do not check if a smaller
      reporting company) </TD>
  <TD align=center width="50%">Smaller reporting company [X]</TD></TR></TABLE>
</DIV>
<P align=center>Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Act). <BR>Yes [&nbsp;
&nbsp;]&nbsp;&nbsp;&nbsp;&nbsp; No [X]</P>
<P align=center>State the aggregate market value of the voting and non-voting
common equity held by non-affiliates computed by reference to the price at which
the common equity was last sold, or the average bid and asked price of such
common equity, as of the last business day of the registrant&#146;s most recently
completed second fiscal quarter. $64,321,329<B> </B></P>
<P align=center>Indicate the number of shares outstanding of each of the
registrant&#146;s classes of common stock, as of the latest practicable date:
27,187,174 shares of common stock are issued and outstanding as of December 19,
2011. </P>
<P align=center>DOCUMENTS INCORPORATED BY REFERENCE </P>
<P align=center>List hereunder the following documents if incorporated by
reference and the Part of the Form 10-K (e.g., Part I, Part II, etc.) into which
the document is incorporated: (1) Any annual report to security holders; (2) Any
proxy or information statement; and (3) Any prospectus filed pursuant to Rule
424(b) or (c) under the Securities Act of 1933. The listed documents should be
clearly described for identification purposes (e.g., annual report to security
holders for fiscal year ended December 24, 1980). <br>
<B><U>Not applicable.
</U></B></P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_3></A>
<P align=center>iii </P>
<P align=center>TABLE OF CONTENTS </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_5">PART
      I </A></TD>
    <TD align=right width="5%" bgColor=#eeeeee ><A
      href="#page_5">1
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_5">ITEM
      1. BUSINESS </A></TD>
    <TD align=right width="5%" ><A
      href="#page_5">1
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_17">ITEM
      1 A. RISK FACTORS </A></TD>
    <TD align=right width="5%" bgColor=#eeeeee ><A
      href="#page_17">13
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_30">ITEM
      1B. UNRESOLVED STAFF COMMENTS </A></TD>
    <TD align=right width="5%" ><A
      href="#page_30">26
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_30">ITEM
      2. PROPERTIES </A></TD>
    <TD align=right width="5%" bgColor=#eeeeee ><A
      href="#page_30">26
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_30">ITEM
      3. LEGAL PROCEEDINGS </A></TD>
    <TD align=right width="5%" ><A
      href="#page_30">26
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_31">ITEM
      4. (REMOVED AND RESERVED) </A></TD>
    <TD align=right width="5%" bgColor=#eeeeee ><A
      href="#page_31">27
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_31">PART
      II </A></TD>
    <TD align=right width="5%" ><A
      href="#page_31">27
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_31">ITEM
      5. MARKET FOR REGISTRANT&#146;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND
      ISSUER PURCHASES OF EQUITY SECURITIES </A></TD>
    <TD align=right width="5%"  bgColor=#eeeeee ><A
      href="#page_31">27
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_33">ITEM
      6 SELECTED FINANCIAL DATA </A></TD>
    <TD align=right width="5%" ><A
      href="#page_33">29
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_33">ITEM
      7 MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
      OF OPERATION </A></TD>
    <TD align=right width="5%"  bgColor=#eeeeee ><A
      href="#page_33">29
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_39">ITEM
      7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </A></TD>
    <TD align=right width="5%"  ><A
      href="#page_39">35
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_40">ITEM
      8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </A></TD>
    <TD align=right width="5%" bgColor=#eeeeee ><A
      href="#page_40">36
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_41">ITEM
      9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
      FINANCIAL MATTERS </A></TD>
    <TD align=right width="5%" ><A
      href="#page_41">37
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_41">ITEM
      9A. CONTROLS AND PROCEDURES </A></TD>
    <TD align=right width="5%" bgColor=#eeeeee ><A
      href="#page_41">37
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_43">ITEM
      9B OTHER INFORMATION </A></TD>
    <TD align=right width="5%" ><A
      href="#page_43">39
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_43">PART
      III </A></TD>
    <TD align=right width="5%" bgColor=#eeeeee ><A
      href="#page_43">39
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_43">ITEM
      10 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </A></TD>
    <TD align=right width="5%" ><A
      href="#page_43">39
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_48">ITEM
      11. EXECUTIVE COMPENSATION </A></TD>
    <TD align=right width="5%" bgColor=#eeeeee ><A
      href="#page_48">44
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_52">ITEM
      12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
      RELATED STOCKHOLDER MATTERS </A></TD>
    <TD align=right width="5%" ><A
      href="#page_52">48
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_54">ITEM
      13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
      INDEPENDENCE </A></TD>
    <TD align=right width="5%" bgColor=#eeeeee ><A
      href="#page_54">50
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_55">ITEM
      14. PRINCIPAL ACCOUNTING FEES AND SERVICES </A></TD>
    <TD align=right width="5%" ><A
      href="#page_55">51
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_55">PART
      IV </A></TD>
    <TD align=right width="5%" bgColor=#eeeeee ><A
      href="#page_55">51
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left><A
      href="#page_55">ITEM
      15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES </A></TD>
    <TD align=right width="5%" ><A
      href="#page_55">51
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><A
      href="#page_61">SIGNATURES
      </A></TD>
    <TD align=right width="5%" bgColor=#eeeeee ><A
      href="#page_61">57
      </A></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_4></A>
<P align=center>iv</P>
<P align=left><B><I>Forward-Looking Statements</I></B></P>
<P align=justify>This Annual Report on Form 10-K includes forward-looking
statements. All statements other than statements of historical facts contained
in this Annual Report on Form 10-K, including statements regarding our
anticipated future clinical and regulatory milestone events, future financial
position, business strategy and plans and objectives of management for future
operations, are forward-looking statements. The words &#147;believe,&#148; &#147;may,&#148;
&#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;expect&#148; and similar
expressions, as they relate to us, are intended to identify forward-looking
statements. Such forward-looking statements include, without limitation,
statements regarding the anticipated start dates, durations and completion dates
of our ongoing and future clinical studies, statements regarding the anticipated
designs of our future clinical studies, statements regarding our anticipated
future regulatory submissions and statements regarding our anticipated future
cash position. We have based these forward-looking statements largely on our
current expectations and projections about future events, including the
responses we expect from the U.S. Food and Drug Administration, or FDA, and
other regulatory authorities and financial trends that we believe may affect our
financial condition, results of operations, business strategy, preclinical and
clinical trials and financial needs. These forward-looking statements are
subject to a number of risks, uncertainties and assumptions including without
limitation the risks described in &#147;Risk Factors&#148; in Part I, Item 1A of this
Annual Report on Form 10-K. These risks are not exhaustive. Other sections of
this Annual Report on Form 10-K include additional factors which could adversely
impact our business and financial performance. Moreover, we operate in a very
competitive and rapidly changing environment. New risk factors emerge from time
to time and it is not possible for our management to predict all risk factors,
nor can we assess the impact of all factors on our business or the extent to
which any factor, or combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements. You should
not rely upon forward-looking statements as predictions of future events. We
cannot assure you that the events and circumstances reflected in the
forward-looking statements will be achieved or occur and actual results could
differ materially from those projected in the forward-looking statements. Except
as required by applicable laws including the securities laws of the United
States and Canada, we assume no obligation to update or supplement
forward-looking statements.</P>
<P align=justify>As used in this annual report, the terms &#147;we&#148;, &#147;us&#148;, &#147;our&#148;, and
&#147;Anavex&#148; mean Anavex Life Sciences Corp., unless the context clearly requires
otherwise. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_5></A>
<P align=center>1</P>
<P align=center><B>PART I</B></P>
<P align=justify><B>ITEM 1. BUSINESS </B></P>
<P align=justify><B><I>Our Current Business</I></B></P>
<P align=justify>We are a biopharmaceutical company engaged in the discovery and
development of novel drug targets to treat serious diseases for which there are
urgent unmet medical needs. The ANAVEX portfolio involves novel compounds
(ligands) directed to sigma receptor in preclinical and clinical stages of
development that target neurodegenerative diseases and cancer. Our lead drug
candidate, ANAVEX 2-73, targeting Alzheimer&#146;s disease (AD), entered first Human
Clinical Trials (HCT) in the first quarter of 2011. This study was conducted in
Germany in collaboration with ABX-CRO Advanced Pharmaceutical Services. On
November 14, 2011, we announced the successful completion of a Phase 1 single
ascending dose (SAD) clinical trial of ANAVEX 2-73. We plan to continue
preclinical work on other CNS compounds targeting epilepsy, depression and
neuropathic pain provided sufficient capital is available. Additionally, we
intend to further develop compounds in earlier preclinical phases, which target
various types of cancer and continue to develop and expand our SIGMACEPTOR&#153;
Discovery platform. </P>
<P align=justify><I>Our Pipeline</I></P>
<P align=justify>Our proprietary SIGMACEPTOR&#153; Discovery Platform has resulted in
and continues to generate small molecule drug candidates with unique modes of
action, by making use of our leading understanding of sigma receptors. Sigma
receptors represent potential targets for therapeutics to potentially combat
many human diseases, including AD. When bound by the appropriate ligands, these
receptors influence the functioning of multiple biochemical signals that are
involved in the pathogenesis (origin or development) of disease.</P>
<P align=justify>With our SIGMACEPTOR&#153;-N program, we are focused on developing
disease-modifying treatments for CNS conditions using ligands that activate
sigma-1 receptors. Among our lead CNS drug candidates, we have made significant
progress with ANAVEX 2-73, our lead drug candidate for the treatment of AD, and
ANAVEX 19-144, the only and active metabolite of ANAVEX 2-73.</P>
<P align=justify>Our molecules may offer a disease-modifying approach in AD.
Preclinical data reveals that ANAVEX 2-73 and ANAVEX 19-144 exhibit significant
anti-amnesic, neuroprotective and anticonvulsant properties in a variety of
<I>in vitro</I> systems and specialized animal models. These activities involve
sigma-1, muscarinic and NMDA receptors as well as ion channels, indicating a
unique mode of action. In AD animal models, ANAVEX 2-73 has shown
pharmacological, histological and behavioral evidence as a potential
neuroprotective, anti-amnesic, anti-convulsive and anti-depressive therapeutic
agent, due to its potent affinity to sigma-1 receptors and moderate affinities
to M1-4 type muscarinic receptors. ANAVEX 2-73 has shown a potential dual
mechanism which may impact both amyloid and tau pathology. ANAVEX 19-144
controls seizures and the epileptogenesis process in animal models. Moreover,
its neuroprotective properties may prevent the process that causes long-term
damage to tissue and cells as well as biochemical and physiological alterations
to the brain from epileptic seizures. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_6></A>
<P align=center>2<BR></P>
<P align=justify>On November 14, 2011 we announced the successful completion of
a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX 2-73. In this
Phase 1 SAD trial, the maximum tolerated single dose was defined per protocol as
55-60 mg. This dose is above the equivalent dose shown to have positive effects
in mouse models of AD. There were no significant changes in laboratory or
electrocardiogram (ECG) parameters. ANAVEX 2-73 was well tolerated below the
55-60 mg dose with only mild adverse events in some volunteers. Observed adverse
events at doses above the maximum tolerated single dose included headache and
dizziness, which were moderate in severity and reversible. These side effects
are often seen with drugs that target central nervous system (CNS) conditions,
including AD. </P>
<P align=justify>The ANAVEX 2-73 Phase 1 SAD trial was conducted as a
randomized, placebo-controlled study. Healthy male volunteers between the ages
of 18 and 55 received single, ascending oral doses over the course of the trial.
Study endpoints included safety and tolerability together with pharmacokinetic
parameters. Pharmacokinetics includes the absorption and distribution of a drug,
the rate at which a drug enters the blood and the duration of its effect, as
well as chemical changes of the substance in the body. This study was conducted
in Germany in collaboration with ABX-CRO, a clinical research organization that
has conducted several Alzheimer&#146;s disease studies, and the Technical University
of Dresden. </P>
<P align=justify>We have also reported promising developments with ANAVEX 1-41,
which is a sigma-1 agonist. Preclinical tests revealed significant
neuroprotective benefits (i.e., protects nerve cells from degeneration or death)
through the modulation of endoplasmic reticulum, mitochondrial and oxidative
stress, which damages and destroys cells and is believed by some scientists to
be a primary cause of AD. In addition, in animal models, ANAVEX 1-41 prevented
the expression of caspase-3, an enzyme that plays a key role in apoptosis
(programmed cell death) and loss of cells in the hippocampus, the part of the
brain that regulates learning, emotion and memory. These activities involve both
muscarinic and sigma-1 receptor systems through a novel mechanism of action.</P>
<P align=justify>Our SIGMACEPTOR&#153;-C program leverages the unique properties of
sigma-1 and/or sigma-2 receptor ligands, which may allow for the development of
a new class of promising drug candidates designed to combat various types of
solid tumors. Sigma receptors are highly expressed in different tumor cell
types. Binding by appropriate sigma-1 and/or sigma-2 ligands can induce
selective apoptosis. In addition, through tumor cell membrane reorganization and
interactions with ion channels, our drug candidates are believed to play an
important role in inhibiting the processes of metastasis (spreading of cancer
cells from the original site to other parts of the body), angiogenesis (the
formation of new blood vessels) and tumor cell proliferation. The compounds in
our oncology program are in pre-clinical testing, and there is no guarantee that
the activity demonstrated in pre-clinical models will be shown in human
testing.</P>
<P align=justify>ANAVEX 7-1037, our lead drug candidate for the treatment of
prostate cancer, is a low molecular weight, synthetic compound exhibiting high
affinity for sigma-1 receptors at nanomolar levels and moderate affinity for
sigma-2 receptors and sodium channels at micromolar levels. In advanced
preclinical studies, this compound revealed antitumor potential with no toxic
side effects. It has also been shown to selectively kill human cancer cells
without affecting normal/healthy cells and also to significantly suppress tumor
growth in immune-deficient mice models. Scientific publications emphasize the
promise of sigma receptor ligands, highlighting the fact that these ligands may stop tumor growth
and induce selective cell death in various tumor cell lines, including leukemia,
melanoma and cancers of the colon, breast, prostate, lung, brain, ovary and
kidney. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_7></A>
<P align=center>3</P>
<P align=justify>Numerous additional compounds are currently in the early discovery
  and lead optimization stages of our SIGMACEPTOR&#153;-N and SIGMACEPTOR&#153;-C
programs.</P>
<P align=justify><I>Diseases of the Central Nervous System</I></P>
<P align=justify>We believe that our compounds may be useful for the treatment
of diseases of the central nervous system and cancer. We expect that the market
for treatments for diseases of the central nervous system will grow over the
next several decades. We believe that this expansion will be driven by the
introduction of new technologies and products which will be developed as a
result of a clearer understanding of the underlying biochemical mechanisms that
cause neurological disorders. We believe that this enhanced understanding has
led, and will continue to lead to the development of rationally designed drugs
specifically targeted to the neuropharmacological mechanisms responsible for
central nervous system disorders.</P>
<P align=justify>The market for treatments for diseases of the central nervous
system is expected to be the fastest growing disease area over the next two
decades for several reasons:</P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>Improved patient and physician awareness of central nervous system
  disorders </P>
  <LI>
  <P>Aging of the general population and greater risk of, for example,
  Alzheimer&#146;s disease and other neurological conditions associated with aging
  </P>
  <LI>
  <P>A better understanding of the neuropharmacological mechanisms underlying
  those disorders. </P></LI></UL>
<P align=justify>Central nervous system disorders include many of the classic
diseases of old age, e.g., Parkinson&#146;s and Alzheimer&#146;s. Central nervous system
disorders also include psychiatric disorders such as depression and
schizophrenia.</P>
<P align=justify><U>Alzheimer&#146;s disease</U></P>
<P align=justify>According to the World Health Organization, dementia currently
affects an estimated 37 million people worldwide and approximately 50% of these
cases are caused by Alzheimer&#146;s disease (AD). The worldwide prevalence of AD was
over 26 million in 2006, as reported by Johns Hopkins University. By 2050, it is
anticipated to quadruple and 1 in 85 people worldwide are anticipated to be
living with the disease. AD is considered to be a healthcare system &#145;time-bomb&#146;.
Medications on the market today only treat the symptoms of AD -- they do not
have the ability to stop its onset or its progression. Meanwhile, the majority
of AD treatments currently in development are focused on reducing or dissolving
amyloid-beta plaques. To date there have been several well-publicized failures
of therapies that were highly effective at clearing amyloid-beta plaques but
which had no impact on the disease.<B> </B></P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_8></A>
<P align=center>4</P>
<P align=justify><U>Depression</U></P>
<P align=justify>Depression is a major cause of morbidity worldwide according to
the World Health Organization (&#147;WHO&#148;). According to statistics published by the
WHO, lifetime prevalence varies widely, from 3% in Japan to 17% in the US. In
most countries the number of people who would suffer from depression during
their lives falls within an 8&#150;12% range. In North America the probability of
having a major depressive episode within a year-long period is 3&#150;5% for males
and 8&#150;10% for females. Population studies have consistently shown major
depression to be about twice as common in women as in men, although it is
unclear why this happens. The relative increase in occurrence is related to
pubertal development rather than chronological age which reaches adult ratios
between the ages of 15 and 18, and appears associated with psychosocial more
than hormonal factors. </P>
<P align=justify>The depression market is dominated by a large number of
blockbuster brands, with the leading nine brands accounting for approximately
75% of total sales. However, the dominance of the leading brands is waning,
largely due to the effects of patent expiration and generic competition. </P>
<P align=justify><U>Epilepsy</U></P>
<P align=justify>Epilepsy is a common chronic neurological disorder
characterized by recurrent unprovoked seizures. These seizures are transient
signs and/or symptoms of abnormal, excessive or synchronous neuronal activity in
the brain. It has been estimated that about 50 million people worldwide suffer
from epilepsy, according to the International Bureau for Epilepsy, with almost
90% of these people located in developing countries. Epilepsy is more likely to
occur in young children or people over the age of 65 years; however it can occur
at any time. Epilepsy may be controlled, but not cured, with medication,
although surgery may be considered in difficult cases. Nevertheless, over 30% of
people with epilepsy do not have seizure control even with the best available
medications. </P>
<P align=justify>The epilepsy market features two classes of drugs: older
traditional Anti Epileptic Drugs and second generation Anti Epileptic Drugs,
with the former marketed before 1980, and the latter marketed in the early 1990s
and developed through intelligent synthetic design techniques. They are
currently the driving force of the market. However, second generation
anti-convulsants offer limited benefits in terms of efficacy over traditional
anticonvulsants but often confer improvements in side effects and dosing.
Because epilepsy afflicts sufferers in several different ways, there is
considerable need for an array of drugs that can be used in combination with
both traditional Anti Epileptic Drugs and second generations Anti Epileptic
Drugs. Furthermore, with additional benefits in supplementary indications such
as migraine prophylaxis, bipolar disorder and neuropathic pain,
second-generation Anti Epileptic Drugs have greatly expanded the potential of
the market for epilepsy treatments and are the driving force behind sales.</P>
<P align=justify>According to the International Bureau for Epilepsy, the world
market for epilepsy therapies was estimated at US $ 10.4 billion in 2004 while
this number is projected to increase to US $ 13.2 billion by 2010 and to US $
15.3 billion by 2015. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_9></A>
<P align=center>5</P>
<P align=justify><U>Neuropathic Pain</U></P>
<P align=justify>Neuralgia or neuropathic pain can be defined as a pain that is
not related to activation of pain receptor cells in any part of the body.
Neuralgia is a pain produced by a change in neurological structure or function.
Unlike nociceptive pain, neuralgia exists with no continuous nociceptive input.
Neuralgia falls into two categories: central neuralgia and peripheral neuralgia.
This unusual pain is thought to be linked to four possible mechanisms: ion gate
malfunctions; the nerve becomes mechanically sensitive and creates an ectopic
signal; cross signals between large and small fibers; and malfunction due to
damage in the central processor.</P>
<P align=justify>Neuralgia is often difficult to diagnose, and most treatments
show little or no effectiveness. Diagnosis typically involves locating the
damaged nerve by identifying missing sensory or motor function. Neuralgia is
more difficult to be treated than other types of pain because it does not
respond well to normal pain medications. Special medications have become more
specific to neuralgia and typically fall under the category of membrane
stabilizing drugs or antidepressants. </P>
<P align=justify><U>Cancer</U></P>
<P align=justify>Cancer is the second leading cause of mortality worldwide, with
seven million deaths per year globally. In the US, one in two men and one in
three women are anticipated to develop cancer during their lifetime. From
diagnosis, five year survival is estimated at 64% in the US and even lower in
other countries. Currently available treatments are not effective for all
patients, and have limited impact on survival for patients with metastatic
disease. New treatments with novel mechanisms of action that can overcome
resistance mechanisms, inhibit tumor cell proliferation, and trigger tumor cell
death could offer greater therapeutic benefit and improved survival. </P>
<P align=justify>IMS estimates that the market for cancer drugs will reach $ 80
billion annually by 2012, almost double the 2007 value (IMS Global Oncology
Forecast, 2008). </P>
<P align=justify><U>Malignant Melanoma</U></P>
<P align=justify>Malignant melanoma is due to uncontrolled growth of pigment
cells, called melanocytes. It is predominantly a skin cancer, but can also occur
in melanocytes found in the bowel and the eye. It is one of the less common
types of skin cancer but causes the majority of skin cancer related deaths,
accounting for 75% of all deaths associated with skin cancer. The treatment
includes surgical removal of the tumor, adjuvant treatment, chemo and
immunotherapy, or radiation therapy. Despite many years of intensive laboratory
and clinical research, the sole effective cure is surgical resection of the
primary tumor before it achieves a Breslow thickness greater than 1 mm. Around
160,000 new cases of melanoma are diagnosed each year, and it is more frequent
in males. According to a World Health Organization (WHO) report about 48,000
melanoma related deaths occur worldwide per year.</P>
<P align=justify><U>Prostate Cancer</U></P>
<P align=justify>Prostate cancer is a form of cancer that develops in the
prostate, a gland in the male reproductive system. The cancer cells may
metastasize from the prostate to other parts of the body, particularly the bones
and lymph nodes.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_10></A>
<P align=center>6</P>
<P align=justify>Rates of detection of prostate cancers vary widely across the
world, with South and East Asia detecting less frequently than in Europe, and
especially the United States.</P>
<P align=justify>Over 65% of men over the age of 70 estimated to carry
microscopic evidence of the disease in their bodies. The growth in the number of
cases of prostate cancer is expected to continue to be high in relation to other
cancer types, with the market for treatments projected to reach $7 billion by
2015 as determined by IMS. </P>
<P align=justify><U>Pancreatic Cancer</U></P>
<P align=justify>Pancreatic cancer is a malignant neoplasm of the pancreas. In
the United States approximately 42,000 new cases of pancreatic cancer were
diagnosed and approximately 35,000 patients died in 2009 as a result. The
prognosis is in general poor, as less than 5% of those diagnosed live for more
than five years after diagnosis. Complete remission is extremely rare. About 95%
of exocrine pancreatic cancers are adenocarcinomas. The remaining 5% include
adenosquamous carcinomas, squamous cell carcinomas, and giant cell carcinomas.
Exocrine pancreatic cancers are far more common than endocrine pancreatic
cancers (islet cell carcinomas), which make up about 1% of total cases. </P>
<P align=justify><I>The Market in General</I></P>
<P align=justify>In 2010, IMS Health forecasts American annual spending on all
pharmaceuticals to reach $880 billion in 2011. </P>
<P align=justify>In 2011, Medical Expenditure Panel Survey described a market
for outpatient pharmaceutical prescriptions in America in excess of $230
billion, with CNS prescriptions as the second largest therapeutic expenditure at
more than $35 billion. </P>
<P align=justify>The leading AD pharmaceutical treatment is Aricept&#174;
(donepezil). In 2010, Aricept&#174; went &#145;off patent&#146; with annual sales in excess of
$3.5 billion.</P>
<P align=justify><I>Competition </I></P>
<P align=justify>The biopharmaceutical industry is intensely competitive in
general. Furthermore, our business strategy is to target large unmet medical
needs, and those markets are even more highly competitive </P>
<P align=justify>At this time, we view our competition as other biomedical
development companies that are also trying to discover compounds to be used in
the treatment of Alzheimer&#146;s disease, and those companies already doing so.
Those companies include Prana Biotechnology Limited (NASDAQ:PRAN), Elan
Corporation, plc. (NYSE:ELN), Pfizer Inc. (NYSE:PFE), Forest Pharmaceuticals,
Inc. (NYSE:FRX), Novartis AG (NYSE:NVS), GlaxoSmithKline Inc. (NYSE:GSK), Merck
&amp; Co., Inc. (NYSD:MRK), and F. Hoffman-La Roche Ltd. (SIX:ROG). </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_11></A>
<P align=center>7</P>
<P align=justify>Each of our competitors have greater capital resources, larger
overall research and development staffs and facilities, and a longer history in
drug discovery and development, obtaining regulatory approval, and
pharmaceutical product manufacturing and marketing than we do. With these additional resources, our competitors will be able to
respond to the rapid and significant technological changes in the biotechnology
and pharmaceutical industries faster than we can. Our future success will depend
in large part on our ability to acquire funding for our research and
development. To continue to acquire funding for our research and development, we
will likely have to show progress toward our goals and will eventually be
expected to develop a compound that may result in a transaction with a major
pharmaceutical company.</P>
<P align=justify>Our research and development is highly speculative and we may
never discover or develop any compounds that we are capable of selling to
pharmaceutical companies.</P>
<P align=justify>Rapid technological development, as well as new scientific
developments, may result in our compounds becoming obsolete before we can
recover any of the expenses incurred to develop them. </P>
<P align=justify><I>Patents, Trademarks and Intellectual Property</I></P>
<P align=justify> We currently own the following patents: </P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>
    <TR vAlign=bottom bgcolor="#EEEEEE">
      <TD colspan="3" align=center>&nbsp;<B>ANAVEX INTELLECTUAL PROPERTY ASSETS</B>
      </TD>
    </TR>
    <TR vAlign=top bgcolor="#EEEEEE">
      <TD align=center><B>Title of Application/</B> <BR> <B>Patent No./Jurisdiction</B>
      </TD>
      <TD width="25%" align=center><B>Filing/</B> <BR> <B>Expiration</B> </TD>
      <TD width="50%" align=center ><BR> <B>Claims</B> </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Patent No. <BR>
        1002616/Greece </TD>
      <TD align=left width="25%">February 21, 1996 <BR>
        February 22, 2016 </TD>
      <TD align=left width="50%" >Synthesis and method of synthesis of molecule
        Tetrahydro - N, N - dimethyl - 2,2 - diphenyl - 3 - furanemethanamine
        (AE 37), with anticonvulsant, antidepressant and nootropic activity </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Patent No. <BR>
        1004208/Greece </TD>
      <TD align=left width="25%">October 15, 2001 <BR>
        October 14, 2021 </TD>
      <TD align=left width="50%" >Aminotetrahydrofuran derivatives, muscarinic/sigma/sodium
        channel ligands, with synergic sigma/muscarinic (neuroactivating) and
        sigma/sodium channel (neuroprotective) components, as prototypical activating
        &#150; neuroprotectors and neuroregenerative drugs </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Patent No. <BR>
        1004868/Greece </TD>
      <TD align=left width="25%">April 22, 2003 <BR>
        April 21, 2023 </TD>
      <TD align=left width="50%" >Aminotetrahydrofuran derivatives, muscarinic/sigma/sodium
        channel ligands, ortho-and allo-sterically operating, as prototypical
        neuromodulating and neuroregenerative drugs </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Patent No. <BR>
        1005865/ Greece </TD>
      <TD align=left width="25%">January 17, 2007 <BR>
        January 16, 2027 </TD>
      <TD align=left width="50%" >New sigma (&#963;) receptor ligands with anti-apoptotic
        and/or pro- apoptotic properties over cellular biochemical mechanisms,
        with neuroprotective, anti-cancer, anti- metastatic and anti-(chronic)
        inflammatory action </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Patent No. <BR>
        1006794/Greece </TD>
      <TD align=left width="25%">February 26, 2009 <BR>
        February 27, 2029 </TD>
      <TD align=left width="50%" >Sigma (&#963;) receptor ligands with anti-apoptotic
        and/or pro-apoptotic properties, over cellular mechanisms, exhibiting
        prototypical cytoprotective and also anticancer activity </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Patent Application <BR>
        201100100140 <BR>
        Greece </TD>
      <TD align=left width="25%">March 9, 2010 <BR>
        March 10, 2030 </TD>
      <TD align=left width="50%" >Synthesis and method of synthesis of molecules
        1- methylo-4-[4,4-difainylo-4(Adantylo1-boutylo)] piperzine and its structural
        analogues with anticancer properties </TD>
    </TR>
  </TABLE>
</DIV><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_12></A>
<P align=center>8 </P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>
    <TR vAlign=top>
      <TD align=left>Patent Application <BR>
        20110100397 <BR>
        Greece </TD>
      <TD align=left width="25%">July 8, 2011 <BR>
        July 7, 2031 </TD>
      <TD align=left width="50%" >Synthesis of (+) and (-) 1-(5,5-difainylotetraydrofourane-
        <BR>
        3-yl)-<I>&#925;</I>,<I>&#925;</I>-dimethylomethylamine, (+) and (-) 1-(2,2-
        <BR>
        difainylotetraydrofourane-3-yl)-<I>&#925;</I>,<I>&#925;</I>- <BR>
        dimethylomethylamine, and (+) and (-) 1-(2,2- <BR>
        difainylotetraydrofourane-3-yl)-<I>&#925;</I>- methylomethylamine </TD>
    </TR>
    <TR vAlign=top>
      <TD colspan="3" align=center><B>PATENTS AND PATENTS APPLICATIONS REGISTERED
        WITH THE WORLD INTELLECTUAL</B> <BR> <B>ORGANISATION (WIPO) UNDER THE
        PATENT COOPERATION TREATY (PCT)</B> </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>PCT/ National Phase <BR>
        - GR 2008/000002 <BR> <BR>
        Europe &#150; 08702158.0 <BR>
        USA &#150; 12/522.761 <BR>
        Russia &#150; 2009125211 <BR>
        India &#150; 2392/KOLNP/2009 <BR>
        China &#150; 200880002334.5 <BR>
        Hong Kong 004800011111 </TD>
      <TD align=left width="25%">January 17, 2007 <BR> <BR> <BR>
        May 28, 2009 <BR>
        July 10, 2009 <BR>
        June 26, 2009 <BR>
        June 29, 2009 <BR>
        July 16, 2009 <BR>
        July 2, 2010 </TD>
      <TD align=left width="50%" >On basis of Greek Patent 1005865 <BR>
        (Application 20070100020/17-01-2007) </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>PCT Request <BR>
        International Filing <BR>
        GR2010/000009 <BR> <BR>
        India &#150; 3266/KOLNP/2011 <BR>
        Russia &#150; 2011131708 <BR>
        USA &#150; 13/201.271 <BR>
        China &#150; 201080009029.6 <BR>
        Europe &#150; 10706348.9 </TD>
      <TD align=left width="25%">February 17, 2010 <BR> <BR> <BR> <BR>
        July 19, 2011 <BR>
        July 28, 2011 <BR>
        August 12, 2011 <BR>
        August 23, 2011 <BR>
        August 30, 2011 </TD>
      <TD align=left width="50%" >On basis of Greek Patent 1006794 <BR>
        (Application 20090100115/26-02-2009) </TD>
    </TR>
  </TABLE>
</DIV>
<P align=justify>We regard patents and other proprietary technology rights a key
element in our goal of building a successful biomedical company. Accordingly, we
plan to protect all of our key technology, inventions and improvements to our
inventions by filing patent applications in a timely fashion. We are currently
seeking patent protection in the United States, China, Russia, India and Europe
and intend to seek protection for additional countries on a selective basis for
our compounds or other inventions and improvements. However, we note that filing
and prosecuting patent applications are expensive processes and we have very
limited financial resources.</P>
<P align=justify>We also rely on trade secrets and unpatentable know-how that we
seek to protect, in part, by confidentiality agreements. It is now our policy to
require our employees, consultants, contractors, manufacturers, outside
scientific collaborators and sponsored researchers, and other advisors to
execute confidentiality agreements upon the commencement of employment,
advisory, or consulting relationships with us. We expect that these agreements
will provide that all confidential information developed or made known to the
individual during the course of the individual&#146;s relationship with us is to be
kept confidential and not disclosed to third parties except in specific limited
circumstances. </P>
<P align=justify>We also intend to require signed confidentiality or material
transfer agreements from any company that is to receive our confidential
information. In the case of employees, consultants and contractors, the
agreements will generally provide that all inventions conceived by the
individual while rendering services to us shall be assigned to us as our
exclusive property. There can be no assurance, however, that all persons who we desire to
sign such agreements will sign, or if they do, that these agreements will not be
breached, that we would have adequate remedies for any breach, or that our trade
secrets or unpatentable know-how will not otherwise become known or be
independently developed by competitors.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_13></A>
<P align=center>9</P>
<P align=justify>Our patent position, like that of many biomedical companies, is
uncertain and involves complex legal and technical questions for which important
legal principles are unresolved. Much of our intellectual property is still only
filed with the Greek National Office of Industrial Property and we plan to file
additional patent applications in Canada and the U.S. for further inventions. We
may not be successful in obtaining critical claims or in protecting our
potential drug compounds or processes. Even if we do obtain patents, they may
not adequately protect the technology we own or have licensed. In addition,
others may challenge, seek to invalidate, infringe or circumvent any patents we
own or license, and rights we receive under those patents may not provide
competitive advantages to us. Further, the manufacture, use or sale of our
potential drug compounds may infringe the patent rights of others.</P>
<P align=justify>Our success will also depend in part on our ability to
commercialize our compounds without infringing the proprietary rights of others.
We have not conducted extensive freedom of use patent searches and no assurance
can be given that patents do not exist or could not be filed which would have an
adverse affect on our ability to market our technology or maintain our
competitive position with respect to our technology. If our compounds or other
subject matter are claimed under other existing United States or other patents
or are otherwise protected by third party proprietary rights, we may be subject
to infringement actions. In such event, we may challenge the validity of such
patents or other proprietary rights or we may be required to obtain licenses
from such companies in order to develop, manufacture or market our technology.
There can be no assurances that we would be able to obtain such licenses or that
such licenses, if available, could be obtained on commercially reasonable terms.
Furthermore, the failure to either develop a commercially viable alternative or
obtain such licenses could result in delays in marketing all of our potential
drug compounds based on our drug technology or the inability to proceed with the
development, manufacture or sale of potential drug compounds requiring such
licenses, which could have a material adverse affect on our business, financial
condition and results of operations. If we are required to defend ourselves
against charges of patent infringement or to protect our proprietary rights
against third parties, substantial costs will be incurred regardless of whether
we are successful. Such proceedings are typically protracted with no certainty
of success. An adverse outcome could subject us to significant liabilities to
third parties and force us to curtail or cease our research and development of
our technology.</P>
<P align=justify><I>Government Approval</I></P>
<P align=justify>Regulation by governmental authorities in the United States and
foreign countries is a significant factor in the development, manufacture, and
expected marketing of our potential drug compounds and in our ongoing research
and development activities. The nature and extent to which such regulation will
apply to us will vary depending on the nature of any potential drug compounds
developed. We anticipate that all of our potential drug compounds will require
regulatory approval by governmental agencies prior to commercialization. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_14></A>
<P align=center>10</P>
<P align=justify>In particular, human therapeutic products are subject to
rigorous non-clinical and clinical testing and other approval procedures of the
FDA and similar regulatory authorities in other countries. Various federal
statutes and regulations also govern or influence testing, manufacturing,
safety, labeling, storage, and record-keeping related to such products and their
marketing. The process of obtaining these approvals and the subsequent
compliance with the appropriate federal statutes and regulations requires
substantial time and financial resources. Any failure by us or our collaborators
to obtain, or any delay in obtaining, regulatory approval could adversely affect
the marketing of any potential drug compounds developed by us, our ability to
receive product revenues, and our liquidity and capital resources.</P>
<P align=justify>The steps ordinarily required before a new drug may be marketed
in the United States, which are similar to steps required in most other
countries, include:</P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>non-clinical laboratory tests, non-clinical studies in animals, formulation
  studies and the submission to the FDA of an investigational new drug
  application; </P>
  <LI>
  <P>adequate and well-controlled clinical trials to establish the safety and
  efficacy of the drug; </P>
  <LI>
  <P>the submission of a new drug application or biologic license application to
  the FDA; and </P>
  <LI>
  <P>FDA review and approval of the new drug application or biologics license
  application. </P></LI></UL>
<P align=justify>Non-clinical tests include laboratory evaluation of potential
drug compound chemistry, formulation and toxicity, as well as animal studies.
The results of non-clinical testing are submitted to the FDA as part of an
investigational new drug application. A 30-day waiting period after the filing
of each investigational new drug application is required prior to commencement
of clinical testing in humans. At any time during the 30-day period or at any
time thereafter, the FDA may halt proposed or ongoing clinical trials until the
FDA authorizes trials under specified terms. The investigational new drug
application process may be extremely costly and substantially delay the
development of our potential drug compounds. Moreover, positive results of
non-clinical tests will not necessarily indicate positive results in subsequent
clinical trials. The FDA may require additional animal testing after an initial
investigational new drug application is approved and prior to Phase III trials.
</P>
<P align=justify>Clinical trials to support new drug applications are typically
conducted in three sequential phases, although the phases may overlap. During
Phase I, clinical trials are conducted with a small number of subjects to assess
metabolism, pharmacokinetics, and pharmacological actions and safety, including
side effects associated with increasing doses. Phase II usually involves studies
in a limited patient population to assess the efficacy of the drug in specific,
targeted indications; assess dosage tolerance and optimal dosage; and identify
possible adverse effects and safety risks.</P>
<P align=justify>If a compound is found to be potentially effective and to have
an acceptable safety profile in Phase I and II evaluations, Phase III trials are
undertaken to further demonstrate clinical efficacy and to further test for
safety within an expanded patient population at geographically dispersed
clinical trial sites.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_15></A>
<P align=center>11</P>
<P align=justify>After successful completion of the required clinical trials, a
new drug application is generally submitted. The FDA may request additional
information before accepting the new drug application for filing, in which case
the new drug application must be resubmitted with the additional information.
Once the submission has been accepted for filing, the FDA reviews the new drug
application and responds to the applicant. The FDA&#146;s requests for additional
information or clarification often significantly extend the review process. The
FDA may refer the new drug application to an appropriate advisory committee for
review, evaluation, and recommendation as to whether the new drug application
should be approved, although the FDA is not bound by the recommendation of an
advisory committee.</P>
<P align=justify><I>The Food and Drug Administration&#146;s Modernization Act</I>
codified the FDA&#146;s policy of granting &#147;fast track&#148; review of certain therapies
targeting &#147;orphan&#148; indications and other therapies intended to treat severe or
life threatening diseases and having potential to address unmet medical needs.
Orphan indications are defined by the FDA as having a prevalence of less than
200,000 patients in the United States. We anticipate that certain
neurodegenerative diseases which could potentially be treated using our
technology could qualify for fast track review under these revised
guidelines.</P>
<P align=justify>Previously, the FDA approved cancer therapies primarily based
on patient survival rates or data on improved quality of life. The FDA
considered evidence of partial tumor shrinkage, while often part of the data
relied on for approval was insufficient by itself to warrant approval of a
cancer therapy, except in limited situations. Under the FDA&#146;s revised policy,
which became effective in 1998, the FDA has broadened authority to consider
evidence of partial tumor shrinkage or other clinical outcomes for approval.
This revised policy is intended to facilitate the study of solid tumor therapies
and shorten the total time for marketing approvals. We intend to take advantage
of this policy; however, it is too early to tell what effect, if any, these
provisions may have on the approval of our potential drug compounds.</P>
<P align=justify>Sales outside the United States of potential drug compounds we
develop will also be subject to foreign regulatory requirements governing human
clinical trials and marketing for drugs. The requirements vary widely from
country to country, but typically the registration and approval process takes
several years and requires significant resources. In most cases, if the FDA has
not approved a potential drug compound for sale in the United States, the
potential drug compound may be exported for sale outside of the United States,
only if it has been approved in any one of the following: the European Union,
Canada, Australia, New Zealand, Japan, Israel, Switzerland and South Africa.
There are specific FDA regulations that govern this process.</P>
<P align=justify>We are also subject to various federal, state, local, and
foreign laws, regulations and recommendations relating to safe working
conditions, laboratory and manufacturing practices, and the use and disposal of
hazardous or potentially hazardous substances, including radioactive compounds
and infectious disease agents, used in connection with our research work. We
cannot accurately predict the extent of government regulation that might result
from future legislation or administrative action.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_16></A>
<P align=center>12</P>
<P align=justify><I>Research and Development Expenses</I></P>
<P align=justify>A significant portion of our operating expenses is related to
research and development, and we intend to maintain a strong commitment to
research and development activities. See Item 8 &#147;Financial Statements and
Supplementary Data&#148; of this Annual Report on Form 10-K for costs and expenses
related to research and development, and other financial information for fiscal
years 2011 and 2010. </P>
<P align=justify><I>Scientific Advisory Board</I></P>
<P align=justify>We maintain a Scientific Advisory Board comprised of scientists
with experience relevant to our company and our product candidates. Members of
our Scientific Advisory Board have agreed to consult and advise us in their
respective areas of expertise. We have placed special emphasis on identifying
members of our Scientific Advisory Board with expertise in the treatment of the
clinical indications targeted by our programs. Our Scientific Advisory Board
consists of the following members:<B><I> </I></B></P>
<P align=justify><I>Alexandre Vamvakides, Ph.D.</I> Dr. Vamvakides has spent 30
years in research, focusing on the therapeutic/pharmacological areas of
anti-neurodegenerative, antiepileptic and anti-depressive molecules. The author
of more than 80 scientific papers, he has worked at the Institut national de la
sant&#233; et de la recherche m&#233;dicale (INSERM), the University of Athens, Ciba-Geigy
(now Novartis), Sanofi (now sanofi-aventis) and many other research laboratories
throughout Europe, for the discovery and development of new concepts in the
therapeutic areas of CNS, oncology and anti-inflammatory diseases. Dr.
Vamvakides entered into an agreement by which he transferred intellectual
property to Anavex in exchange for certain consideration. His consideration
includes a royalty on commercial sales based on the intellectual property
transferred. To date, the Company&#146;s product development has been based
exclusively on intellectual property received in the transfer. </P>
<P align=justify><I>Tangui Nicolas Maurice, Ph.D</I>. Dr. Maurice has spent 15
years in the field of neurosciences, including behavioral and molecular
neuropharmacology, sigma receptors, neuropeptides, neurosteroids, neurotrophic
factors, normal/pathological aging models for Alzheimer&#146;s and related disorders,
and behavioural phenotyping of rodent models. Previously, Dr. Maurice held
research positions with INSERM U710 at Montpellier, CNRS, INSERM U336, the
department of neuropsychopharmacology and hospital pharmacy at Meijo University
(Nagoya, Japan), and Jouveinal Research Institute (Fresnes, France). A past
recipient of the CNRS bronze medal, Dr. Maurice holds a Ph.D. in cellular and
molecular biology with a specialty in neuropharmacology from Universit&#233;
Montpellier. </P>
<P align=justify><I>Dr. Paul Aisen</I>. Dr. Aisen is a leading clinician and
researcher in Alzheimer&#146;s disease clinical trials and is on the faculty of the
University of California, San Diego (UCSD) School of Medicine&#146;s Department of
Neurosciences. His primary research interests focus on the development of new
strategies for the treatment of Alzheimer&#146;s disease. Since 2007, Dr. Aisen has
been Director of the Alzheimer&#146;s Disease Cooperative Study, a consortium funded
by the National Institute on Aging (NIA) to develop assessment instruments and
conduct clinical trials. Dr. Aisen is Associate Editor of Alzheimer&#146;s Research
and Therapy, a major international peer-reviewed journal, and sits on the editorial board of BMC
Medicine. He has published more than 180 peer-reviewed papers. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_17></A>
<P align=center>13</P>
<P align=justify><I>Dr. Rachelle Doody</I>. Dr. Doody is the Effie Marie Cain
Chair in Alzheimer&#146;s Disease Research and Professor of Neurology at Baylor
College of Medicine, where she received an M.D. She completed internship and
residency training at the Royal Victoria Hospital and Montreal Neurologic
Institute in Montreal, and at Baylor College of Medicine. Dr. Doody has a Ph.D.
in Cognitive Anthropology from Rice University and has published over 135
original articles. She participates in national and international collaborative
efforts, review boards, and advisory boards including Steering Committees for
the NIH AD Cooperative Study and the AD Neuroimaging Initiative. </P>
<P align=justify><I>Dr. Jeffrey Cummings</I>. Dr. Cummings is Professor of
Neurotherapeutics and Drug Development in the Neurological Institute, Cleveland
Clinic and Director of the Cleveland Clinic Lou Ruvo Center for Brain Health,
Las Vegas, Nevada and Cleveland, Ohio. Dr. Cummings was formerly the Augustus S.
Rose Professor of Neurology and Professor of Psychiatry and Biobehavioral
Sciences at the David Geffen School of Medicine at UCLA, Los Angeles,
California. He was Director of the Mary S. Easton Center for Alzheimer&#146;s Disease
Research and Director of the Deane F. Johnson Center for Neurotherapeutics at
UCLA. Dr. Cummings has expertise in neuropsychiatric assessment, outcomes in
clinical trials, clinical trial design and analysis, and global clinical trials
and is an experienced consultant to industry. </P>
<P align=justify><I>Officers</I></P>
<P align=justify>We currently engage the services of two consultants who act for
our company in the capacity of president, secretary, chief operating officer and
interim chief financial officer, and executive director respectively. We also
have 14 consultants assisting us in our research and development activities.</P>
<P align=justify><B>ITEM 1 A. RISK FACTORS</B></P>
<P align=justify>In addition to other information in this annual report, the
following risk factors should be carefully considered in evaluating our business
because such factors may have a significant impact on our business, operating
results, liquidity and financial condition. As a result of the risk factors set
forth below, actual results could differ materially from those projected in any
forward-looking statements. Additional risks and uncertainties not presently
known to us, or that we currently consider to be immaterial, may also impact our
business, operating results, liquidity and financial condition. If any such
risks occur, our business, operating results, liquidity and financial condition
could be materially affected in an adverse manner. Under such circumstances, the
trading price of our securities could decline, and you may lose all or part of
your investment.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_18></A>
<P align=center>14</P>
<P align=justify><B><I>Risks Related to our Company</I></B></P>
<P align=justify><I>We have had a history of losses and no revenue, which raise
substantial doubt about our ability to continue as a going concern.</I></P>
<P align=justify>Since inception on January 23, 2004, we have incurred aggregate
net losses of $ 28,652,417 from operations. We can offer no assurance that we
will ever operate profitably or that we will generate positive cash flow in the
future. To date, we have not generated any revenues from our operations. Our
history of losses and no revenues raise substantial doubt about our ability to
continue as a going concern. As a result, our management expects the business to
continue to experience negative cash flow for the foreseeable future and cannot
predict when, if ever, our business might become profitable. We will need to
raise additional funds, and such funds may not be available on commercially
acceptable terms, if at all. If we are unable to raise funds on acceptable
terms, we may not be able to execute our business plan, take advantage of future
opportunities, or respond to competitive pressures or unanticipated
requirements. This may seriously harm our business, financial condition and
results of operations. </P>
<P align=justify><I>We are an early development stage pharmaceutical research
and development company and may never be able to successfully develop marketable
products or generate any revenue. We have a very limited relevant operating
history upon which an evaluation of our performance and prospects can be made.
There is no assurance that our future operations will result in profits. If we
cannot generate sufficient revenues, we may suspend or cease operations.</I></P>
<P align=justify>We are an early development stage company and have not
generated any revenues to date and have no operating history. All of our
potential drug compounds are in the concept stage or early clinical development
stage. Moreover, we cannot be certain that our research and development efforts
will be successful or, if successful, that our potential drug compounds will
ever be approved for sales to pharmaceutical companies or generate commercial
revenues. We have no relevant operating history upon which an evaluation of our
performance and prospects can be made. We are subject to all of the business
risks associated with a new enterprise, including, but not limited to, risks of
unforeseen capital requirements, failure of potential drug compounds either in
non-clinical testing or in clinical trials, failure to establish business
relationships and competitive disadvantages as against larger and more
established companies. If we fail to become profitable, we may suspend or cease
operations.</P>
<P align=justify><I>We will need additional funding and may be unable to raise
additional capital when needed, which would force us to delay, reduce or
eliminate our research and development activities.</I></P>
<P align=justify>We will need to raise additional funding, but the current
economic condition will most likely have a negative impact on our ability to
raise additional needed capital on terms that are favorable to our company or at
all. We do not anticipate that we will generate significant revenues for several
years, if at all. Until we can generate significant revenues, if ever, we expect
to satisfy our future cash needs through equity or debt financing. We cannot be
certain that additional funding will be available on acceptable terms, or at
all. If adequate funds are not available, we may be required to delay, reduce
the scope of, or eliminate one or more of our research and development
activities.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_19></A>
<P align=center>15</P>
<P align=justify><I>We may be unable to continue as a going concern in which
case our securities will have little or no value.</I></P>
<P align=justify>Our independent auditors have noted in their report concerning
our annual financial statements for the fiscal year ended September 30, 2011
that we have incurred substantial losses since inception, which raises
substantial doubt about our ability to continue as a going concern. In the event
we are not able to continue operations you will likely suffer a complete loss of
your investment in our securities.</P>
<P align=justify><B><I>Risks Related to our Business</I></B></P>
<P align=justify><I>Even if we are able to develop our potential drug compounds,
we may not be able to receive regulatory approval, or if approved, we may not be
able to generate significant revenues or successfully commercialize our
products, which will adversely affect our financial results and financial
condition and we will have to delay or terminate some or all of our research and
development plans and we may be forced to cease operations.</I></P>
<P align=justify>All of our potential drug compounds will require extensive
additional research and development, including non-clinical testing and clinical
trials, as well as regulatory approvals, before we can market them. We cannot
predict if or when any of the potential drug compounds we intend to develop will
be approved for marketing. There are many reasons that we may fail in our
efforts to develop our potential drug compounds. These include:</P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>the possibility that non-clinical testing or clinical trials may show that
  our potential drug compounds are ineffective and/or cause harmful side
  effects; </P>
  <LI>
  <P>our potential drug compounds may prove to be too expensive to manufacture
  or administer to patients; </P>
  <LI>
  <P>our potential drug compounds may fail to receive necessary regulatory
  approvals from the United States Food and Drug Administration or foreign
  regulatory authorities in a timely manner, or at all; </P>
  <LI>
  <P>even if our potential drug compounds are approved, we may not be able to
  produce them in commercial quantities or at reasonable costs; </P>
  <LI>
  <P>even if our potential drug compounds are approved, they may not achieve
  commercial acceptance; </P>
  <LI>
  <P>regulatory or governmental authorities may apply restrictions to any of our
  potential drug compounds, which could adversely affect their commercial
  success; and </P>
  <LI>
  <P>the proprietary rights of other parties may prevent us or our potential
  collaborative partners from marketing our potential drug compounds.
</P></LI></UL>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_20></A>
<P align=center>16</P>
<P align=justify>If we fail to develop our potential drug compounds, our
financial results and financial condition will be adversely affected, we will
have to delay or terminate some or all of our research and development plans and
may be forced to cease operations.</P>
<P align=justify><I>Our research and development plans will require substantial
additional future funding which could impact our operational and financial
condition. Without the required additional funds, we will likely cease
operations.</I></P>
<P align=justify>It will take several years before we are able to develop
potentially marketable products, if at all. Our research and development plans
will require substantial additional capital, arising from costs to: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>conduct research, non-clinical testing and human studies; </P>
  <LI>
  <P>establish pilot scale and commercial scale manufacturing processes and
  facilities; and </P>
  <LI>
  <P>establish and develop quality control, regulatory, marketing, sales,
  finance and administrative capabilities to support these programs.
</P></LI></UL>
<P align=justify>Our future operating and capital needs will depend on many
factors, including:</P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>the pace of scientific progress in our research and development programs
  and the magnitude of these programs; </P>
  <LI>
  <P>the scope and results of preclinical testing and human studies; </P>
  <LI>
  <P>the time and costs involved in obtaining regulatory approvals; </P>
  <LI>
  <P>the time and costs involved in preparing, filing, prosecuting, maintaining
  and enforcing patent claims; </P>
  <LI>
  <P>competing technological and market developments; </P>
  <LI>
  <P>our ability to establish additional collaborations; </P>
  <LI>
  <P>changes in our existing collaborations; </P>
  <LI>
  <P>the cost of manufacturing scale-up; and </P>
  <LI>
  <P>the effectiveness of our commercialization activities. </P></LI></UL>
<P align=justify>We base our outlook regarding the need for funds on many
uncertain variables. Such uncertainties include the success of our research
initiatives, regulatory approvals, the timing of events outside our direct
control such as negotiations with potential strategic partners and other
factors. Any of these uncertain events can significantly change our cash
requirements as they determine such one-time events as the receipt or payment of
major milestones and other payments.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_21></A>
<P align=center>17</P>
<P align=justify>Additional funds will be required to support our operations and
if we are unable to obtain them on favorable terms, we may be required to cease
or reduce further research and development of our drug product programs, sell
some or all of our intellectual property, merge with another entity or cease
operations. </P>
<P align=justify><I>If we fail to demonstrate efficacy in our non-clinical
studies and clinical trials our future business prospects, financial condition
and operating results will be materially adversely affected.</I></P>
<P align=justify>The success of our research and development efforts will be
greatly dependent upon our ability to demonstrate potential drug compound
efficacy in non-clinical studies, as well as in clinical trials. Non-clinical
studies involve testing potential drug compounds in appropriate non-human
disease models to demonstrate efficacy and safety. Regulatory agencies evaluate
these data carefully before they will approve clinical testing in humans. If
certain non-clinical data reveals potential safety issues or the results are
inconsistent with an expectation of the potential drug compound&#146;s efficacy in
humans, the regulatory agencies may require additional more rigorous testing,
before allowing human clinical trials. This additional testing will increase
program expenses and extend timelines. We may decide to suspend further testing
on our potential drug compounds if, in the judgment of our management and
advisors, the non-clinical test results do not support further development.</P>
<P align=justify>Moreover, success in non-clinical testing and early clinical
trials does not ensure that later clinical trials will be successful, and we
cannot be sure that the results of later clinical trials will replicate the
results of prior clinical trials and non-clinical testing. The clinical trial
process may fail to demonstrate that our potential drug compounds are safe for
humans and effective for indicated uses. This failure would cause us to abandon
a drug candidate and may delay development of other potential drug compounds.
Any delay in, or termination of, our non-clinical testing or clinical trials
will delay the filing of an investigational new drug application and new drug
application with the Food and Drug Administration or the equivalent applications
with pharmaceutical regulatory authorities outside the United States and,
ultimately, our ability to commercialize our potential drug compounds and
generate product revenues. In addition, we expect that our early clinical trials
will involve small patient populations. Because of the small sample size, the
results of these early clinical trials may not be indicative of future results.
</P>
<P align=justify>Following successful non-clinical testing, potential drug
compounds will need to be tested in a clinical development program to provide
data on safety and efficacy prior to becoming eligible for product approval and
licensure by regulatory agencies. From the first human trial through to
regulatory approval can take many years and 10-12 years is not unusual for
certain compounds. </P>
<P align=justify>If any of our future clinical development potential drug
compounds become the subject of problems, our ability to sustain our development
programs will become critically compromised. For example, efficacy or safety
concerns may arise, whether or not justified, that could lead to the suspension
or termination of our clinical programs. Examples of problems that could arise
include, among others: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>efficacy or safety concerns with the potential drug compounds, even if not
  justified; </LI></UL>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_22></A>
<P align=center>18</P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>manufacturing difficulties or concerns; </P>
  <LI>
  <P>regulatory proceedings subjecting the potential drug compounds to potential
  recall; </P>
  <LI>
  <P>publicity affecting doctor prescription or patient use of the potential
  drug compounds; </P>
  <LI>
  <P>pressure from competitive products; or </P>
  <LI>
  <P>introduction of more effective treatments. </P></LI></UL>
<P align=justify>Each clinical phase is designed to test attributes of the drug
and problems that might result in the termination of the entire clinical plan
can be revealed at any time throughout the overall clinical program. The failure
to demonstrate efficacy in our clinical trials would have a material adverse
effect on our future business prospects, financial condition and operating
results. </P>
<P align=justify><I>If we do not obtain the support of qualified scientific
collaborators, our revenue, growth and profitability will likely be limited,
which would have a material adverse effect on our business.</I></P>
<P align=justify>We will need to establish relationships with leading scientists
and research institutions. We believe that such relationships are pivotal to
establishing products using our technologies as a standard of care for various
indications. Additionally, although in discussion, there is no assurance that
our current research partners will continue to work with us or that we will be
able to attract additional research partners. If we are not able to establish
scientific relationships to assist in our research and development, we may not
be able to successfully develop our potential drug compounds. If this happens,
our business will be adversely affected.</P>
<P align=justify><I>We may not be able to develop market or generate sales of
our products to the extent anticipated. Our business may fail and investors
could lose all of their investment in our company.</I></P>
<P align=justify>Assuming that we are successful in developing our potential
drug compounds and receiving regulatory clearances to market our products, our
ability to successfully penetrate the market and generate sales of those
products may be limited by a number of factors, including the following: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>If our competitors receive regulatory approvals for and begin marketing
  similar products in the United States, the European Union, Japan and other
  territories before we do, greater awareness of their products as compared to
  ours will cause our competitive position to suffer; </P>
  <LI>
  <P>Information from our competitors or the academic community indicating that
  current products or new products are more effective or offer compelling other
  benefits than our future products could impede our market penetration or
  decrease our future market share; and, </P>
  <LI>
  <P>The pricing and reimbursement environment for our future products, as well
  as pricing and reimbursement decisions by our competitors and by payers, may
  have an effect on our revenues. </P></LI></UL>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_23></A>
<P align=center>19</P>
<P align=justify>If this happens, our business will be adversely affected.</P>
<P align=justify><I>None of our potential drug compounds may reach the
commercial market for a number of reasons and our business may fail.</I></P>
<P align=justify>Successful research and development of pharmaceutical products
is high risk. Most products and development candidates fail to reach the market.
Our success depends on the discovery of new drug compounds that we can
commercialize. It is possible that our products may never reach the market for a
number of reasons. They may be found ineffective or may cause harmful
side-effects during non-clinical testing or clinical trials or fail to receive
necessary regulatory approvals. We may find that certain products cannot be
manufactured at a commercial scale and, therefore, they may not be economical to
produce. Our potential products could also fail to achieve market acceptance or
be precluded from commercialization by proprietary rights of third parties. Our
patents, trademarks and other intellectual property may be challenged and this
may delay or prohibit us from effectively commercializing our products.
Furthermore, we do not expect our potential drug compounds to be commercially
available for a number of years, if at all. If none of our potential drug
compounds reach the commercial market, our business will likely fail and
investors will lose all of their investment in our company. If this happens, our
business will be adversely affected.</P>
<P align=justify><I>If our competitors succeed in developing products and
technologies that are more effective or with a better profile than our own, or
if scientific developments change our understanding of the potential scope and
utility of our potential products, then our technologies and future products may
be rendered undesirable or obsolete.</I></P>
<P align=justify>We face significant competition from industry participants that
are pursuing technologies in similar disease states to those that we are
pursuing and are developing pharmaceutical products that are competitive with
our products. Nearly all of our industry competitors have greater capital
resources, larger overall research and development staffs and facilities, and a
longer history in drug discovery and development, obtaining regulatory approval
and pharmaceutical product manufacturing and marketing than we do. With these
additional resources, our competitors may be able to respond to the rapid and
significant technological changes in the biotechnology and pharmaceutical
industries faster than we can. Our future success will depend in large part on
our ability to maintain a competitive position with respect to these
technologies. Rapid technological development, as well as new scientific
developments, may result in our products becoming obsolete before we can recover
any of the expenses incurred to develop them. For example, changes in our
understanding of the appropriate population of patients who should be treated
with a targeted therapy like we are developing may limit the drug&#146;s market
potential if it is subsequently demonstrated that only certain subsets of
patients should be treated with the targeted therapy. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_24></A>
<P align=center>20</P>
<P align=justify><I>Our reliance on third parties, such as university
laboratories, contract manufacturing organizations and contract or clinical
research organizations, may result in delays in completing, or a failure to
complete, non-clinical testing or clinical trials if they fail to perform under
our agreements with them.</I></P>
<P align=justify>In the course of product development, we may engage university
laboratories, other biotechnology companies or contract or clinical
manufacturing organizations to manufacture drug material for us to be used in
non-clinical and clinical testing and contract research organizations to conduct
and manage non-clinical and clinical studies. If we engage these organizations
to help us with our non-clinical and clinical programs, many important aspects
of this process have been and will be out of our direct control. If any of these
organizations we may engage in the future fail to perform their obligations
under our agreements with them or fail to perform non-clinical testing and/or
clinical trials in a satisfactory manner, we may face delays in completing our
clinical trials, as well as commercialization of any of our potential drug
compounds. Furthermore, any loss or delay in obtaining contracts with such
entities may also delay the completion of our clinical trials, regulatory
filings and the potential market approval of our potential drug compounds. </P>
<P align=justify><I>If we fail to compete successfully with respect to
partnering, licensing, mergers, acquisitions, joint venture and other
collaboration opportunities, we may be limited in our ability to research and
develop our potential drug compounds. </I></P>
<P align=justify>Our competitors compete with us to attract established
biotechnology and pharmaceutical companies or organizations for partnering,
licensing, mergers, acquisitions, joint ventures or other collaborations.
Collaborations include contracting with academic research institutions for the
performance of specific scientific testing. If our competitors successfully
enter into partnering arrangements or license agreements with academic research
institutions, we will then be precluded from pursuing those specific
opportunities. Since each of these opportunities is unique, we may not be able
to find a substitute. Other companies have already begun many drug development
programs, which may target diseases that we are also targeting, and have already
entered into partnering and licensing arrangements with academic research
institutions, reducing the pool of available opportunities. </P>
<P align=justify>Universities and public and private research institutions also
compete with us. While these organizations primarily have educational or basic
research objectives, they may develop proprietary technology and acquire patents
that we may need for the development of our potential drug compounds. We will
attempt to license this proprietary technology, if available. These licenses may
not be available to us on acceptable terms, if at all. If we are unable to
compete successfully with respect to acquisitions, joint venture and other
collaboration opportunities, we may be limited in our ability to develop new
products. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_25></A>
<P align=center>21</P>
<P align=justify><I>The use of any of our products in clinical trials may expose
us to liability claims, which may cost us a significant amounts of money to
defend against or pay out, causing our business to suffer. </I></P>
<P align=justify>The nature of our business exposes us to potential liability
risks inherent in the testing, manufacturing and marketing of our products. We
currently have one drug compound in clinical trials, however, when any of our
products enter into clinical trials or become marketed products they could
potentially harm people or allegedly harm people and we may be subject to costly
and damaging product liability claims. Some of the patients who participate in
clinical trials are already ill when they enter a trial or may intentionally or
unintentionally fail to meet the exclusion criteria. The waivers we obtain may
not be enforceable and may not protect us from liability or the costs of product
liability litigation. Although we intend to obtain product liability insurance
that we believe is adequate, we are subject to the risk that our insurance will
not be sufficient to cover claims. The insurance costs along with the defence or
payment of liabilities above the amount of coverage could cost us significant
amounts of money and management distraction from other elements of the business,
causing our business to suffer.</P>
<P align=justify><I>The patent positions of biopharmaceutical products are
complex and uncertain and we may not be able to protect our patented or other
intellectual property. If we cannot protect this property, we may be prevented
from using it or our competitors may use it and our business could suffer
significant harm. Also, the time and money we spend on acquiring and enforcing
patents and other intellectual property will reduce the time and money we have
available for our research and development, possibly resulting in a slow down or
cessation of our research and development.</I></P>
<P align=justify>We own patents related to our potential drug compounds.
However, these patents do not ensure the protection of our intellectual property
for a number of reasons, including the following: </P>
<P align=justify>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Competitors may interfere with our patent process in a variety of ways.
Competitors may claim that they invented the claimed invention prior to us.
Competitors may also claim that we are infringing their patents and restrict our
freedom to operate as claimed under our patents and patent applications.
Competitors may also contest our patents and patent application, if issued, by
showing the patent examiner that the invention was not original, was not novel
or was obvious. In litigation, a competitor could claim that our patents and
patent application are not valid for a number of reasons. If a court agrees, we
would lose that patents or patent application. As a company, we have no
meaningful experience with competitors interfering with our patents or patent
applications. </P>
<P
align=justify>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because
of the time, money and effort involved in obtaining and enforcing patents, our
management may spend less time and resources on developing potential drug
compounds than they otherwise would, which could increase our operating expenses
and delay product programs. </P>
<P
align=justify>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receipt
of a patent may not provide much practical protection. If we receive a patent
with a narrow scope, then it will be easier for competitors to design products
that do not infringe our patent(s). </P>
<P align=justify>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;Our patents are not issued in all possible geographies where our products
may be marketed. Currently, we have submitted for patent protection and have
been issued patents for certain claims in Greece. We have submitted for patent
protection on all of the major markets in the world. We may not necessarily be
successful in securing patents for further claims and products in Greece, nor
may we necessarily be successful in securing the existing claims and product
patents in countries and jurisdictions where we have applied but have not yet
had those patents issued. If we do not receive issued patents in these other key
markets, our ability to advance our compounds will be severely hampered and we
will be much less attractive to potential partners. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_26></A>
<P align=center>22</P>
<P align=justify>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, competitors also seek patent protection for their inventions. Due to
the number of patents in our field, we cannot be certain that we do not infringe
on existing patents or that we will not infringe on patents granted in the
future. If a patent holder believes our potential drug compound infringes on
their patent, the patent holder may sue us even if we have received patent
protection for our technology. If someone else claims we infringe on their
patent, we would face a number of issues which could cause a slow down or
cessation of our research and development, including the following: </P>
<P
align=justify>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Defending
a lawsuit takes significant time and can be very expensive. </P>
<P align=justify>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If
the court decides that our potential drug compound infringes on the competitor&#146;s
patent, we may have to pay substantial damages for past infringement. </P>
<P
align=justify>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
court may prohibit us from selling or licensing the potential drug compound
unless the patent holder licenses the patent to us. The patent holder is not
required to grant us a license. If a license is available, we may have to pay
substantial royalties or grant cross licenses to our patents. </P>
<P
align=justify>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Redesigning
our potential drug compounds so that they do not infringe on other patents may
not be possible or could require substantial funds and time. </P>
<P align=justify>It is also unclear whether our trade secrets are adequately
protected. While we use reasonable efforts to protect our trade secrets, our
employees or consultants may unintentionally or willfully disclose our
information to competitors. Enforcing a claim that someone else illegally
obtained and is using our trade secrets, like patent litigation, is expensive
and time consuming, and the outcome is unpredictable. In addition, courts
outside the United States are sometimes less willing to protect trade secrets.
Our competitors may independently develop equivalent knowledge, methods and
know-how. </P>
<P align=justify>We may also support and collaborate in research conducted by
government organizations, hospitals, universities or other educational
institutions. These research partners may be unwilling to grant us any exclusive
rights to technology or products derived from these collaborations prior to
entering into the relationship.</P>
<P align=justify>If we do not obtain required licenses or rights, we could
encounter delays in our product development efforts while we attempt to design
around other patents or even be prohibited from developing, manufacturing or
selling potential drug compounds requiring these licenses. There is also a risk
that disputes may arise as to the rights to technology or potential drug
compounds developed in collaboration with other parties.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_27></A>
<P align=center>23</P>
<P align=justify><I>We incur substantial costs as a result of laws and
regulations and proposed changes in laws and regulations and we cannot predict
the impact of any future changes in law. </I></P>
<P align=justify>We face burdens relating to corporate governance and financial
reporting standards. Legislations or regulations such as Section 404 of the
Sarbanes-Oxley Act of 2002 impose strict corporate governance and financial
reporting standards and have led to substantial costs of compliance including
consulting, auditing and legal fees. Any new rules could make it more difficult
or more costly for us to obtain certain types of insurance, including directors&#146;
and officers&#146; liability insurance, and we may be forced to accept reduced policy
limits and coverage or incur substantially higher costs to obtain the same or
similar coverage. The impact of these events could also make it more difficult
for us to attract and retain qualified persons to serve on our board of
directors, our board committees or as executive officers. A failure to comply
with these new laws and regulations may impact market perception of our
financial condition and could materially harm our business. Additionally, it is
unclear what additional laws or regulations may develop, and we cannot predict
the ultimate impact of any future changes in law.</P>
<P align=justify><I>Our substantial debt and other financial obligations could
impair our financial condition and our ability to fulfill our debt obligations.
Any refinancing of this substantial debt could be at significantly higher
interest rates.</I></P>
<P align=justify>As of September 30, 2011, we had total liabilities of
$1,345,443 and accumulated deficit of $29,203,221. Our substantial indebtedness
and other current financial obligations and any that we may become a party to in
the future could:</P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>impair our ability to obtain financing in the future for working capital,
  capital expenditures, or general corporate purposes; </P>
  <LI>
  <P>have a material adverse effect on us if we fail to comply with financial
  and affirmative and restrictive covenants in debt agreements and an event of
  default occurs as a result of a failure that is not cured or waived; </P>
  <LI>
  <P>require us to dedicate a substantial portion of our cash flow for interest
  payments on our indebtedness and other financial obligations, thereby reducing
  the availability of our cash flow to fund working capital and capital
  expenditures; </P>
  <LI>
  <P>limit our flexibility in planning for, or reacting to, changes in our
  business and the industry in which we operate; and </P>
  <LI>
  <P>place us at a competitive disadvantage compared to our competitors that
  have proportionally less debt. </P></LI></UL>
<P align=justify>If we are unable to meet our debt service obligations and other
financial obligations, we could be forced to restructure or refinance our
indebtedness and other financial transactions, seek additional equity capital or
sell our assets. We might then be unable to obtain such financing or capital or
sell our assets on satisfactory terms, if at all. Any refinancing of our
indebtedness could be at significantly higher interest rates, and/or incur
significant transaction fees.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_28></A>
<P align=center>24</P>
<P align=justify><B><I>Risks Related to our Common Stock</I></B></P>
<P align=justify><I>A decline in the price of our common stock could affect our
ability to raise further working capital and adversely impact our operations and
would severely dilute existing or future investors if we were to raise funds at
lower prices. </I></P>
<P align=justify>A prolonged decline in the price of our common stock could
result in a reduction in our ability to raise capital. Because our operations
have been financed through the sale of equity securities, a decline in the price
of our common stock could be especially detrimental to our continued operations.
Any reduction in our ability to raise equity capital in the future would force
us to reallocate funds from other planned uses and would have a significant
negative effect on our business plans and operations, including our ability to
develop new products and continue our current operations. If the stock price
declines, there can be no assurance that we can raise additional capital or
generate funds from operations sufficient to meet our obligations. We believe
the following factors could cause the market price of our common stock to
continue to fluctuate widely and could cause our common stock to trade at a
price below the price at which you purchase your shares of common stock: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>actual or anticipated variations in our quarterly operating results; </P>
  <LI>
  <P>announcements of new services, products, acquisitions or strategic
  relationships by us or our competitors; </P>
  <LI>
  <P>changes in accounting treatments or principles; </P>
  <LI>
  <P>changes in earnings estimates by securities analysts and in analyst
  recommendations; and </P>
  <LI>
  <P>general political, economic, regulatory and market conditions. </P></LI></UL>
<P align=justify>The market price for our common stock may also be affected by
our ability to meet or exceed expectations of analysts or investors. Any failure
to meet these expectations, even if minor, could materially adversely affect the
market price of our common stock. </P>
<P align=justify><I>If we issue additional shares of common stock in the future,
it will result in the dilution of our existing stockholders. </I></P>
<P align=justify>Our articles of incorporation authorize the issuance of
150,000,000 shares of common stock. Our board of directors has the authority to
issue additional shares of common stock up to the authorized capital stated in
the articles of incorporation. Our board of directors may choose to issue some
or all of such shares of common stock to acquire one or more businesses or to
provide additional financing in the future. The issuance of any such shares of
common stock will result in a reduction of the book value or market price of the
outstanding shares of our common stock. If we do issue any such additional
shares of common stock, such issuance also will cause a reduction in the
proportionate ownership and voting power of all other stockholders. Further, any
such issuance may result in a change of control of our corporation. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_29></A>
<P align=center>25</P>
<P align=justify><I>Trading of our common stock may be volatile and sporadic,
which could depress the market price of our common stock and make it difficult
for our stockholders to resell their shares.</I></P>
<P align=justify>There is currently a limited market for our common stock and
the volume of our common stock traded on any day may vary significantly from one
period to another. Our common stock is quoted on the OTC Bulletin Board. Trading
in stock quoted on the OTC Bulletin Board is often thin and characterized by
wide fluctuations in trading prices, due to many factors that may have little to
do with our operations or business prospects. The availability of buyers and
sellers represented by this volatility could lead to a market price for our
common stock that is unrelated to operating performance. Moreover, the OTC
Bulletin Board is not a stock exchange, and trading of securities quoted on the
OTC Bulletin Board is often more sporadic than the trading of securities listed
on a stock exchange like NASDAQ. There is no assurance that a sufficient market
will develop in the stock, in which case it could be difficult for our
stockholders to resell their stock.</P>
<P align=justify><I>Our stock is classed as a &#147;penny stock&#148;. Trading of our
stock may be restricted by the Securities and Exchange Commission&#146;s penny stock
regulations which may limit a stockholder&#146;s ability to buy and sell our stock.
</I></P>
<P align=justify>Our stock is a penny stock. The Securities and Exchange
Commission has adopted Rule 15g-9 which generally defines &#147;penny stock&#148; to be
any equity security that has a market price (as defined) less than $5.00 per
share or an exercise price of less than $5.00 per share, subject to certain
exceptions. Our securities are covered by the penny stock rules, which impose
additional sales practice requirements on broker-dealers who sell to persons
other than established customers and &#147;accredited investors&#148;. The term
&#147;accredited investor&#148; refers generally to institutions with assets in excess of
$5,000,000 or individuals with a net worth in excess of $1,000,000 (excluding
the value of the primary residence of such individuals) or annual income
exceeding $200,000 or $300,000 jointly with their spouse. The penny stock rules
require a broker-dealer, prior to a transaction in a penny stock not otherwise
exempt from the rules, to deliver a standardized risk disclosure document in a
form prepared by the Securities and Exchange Commission which provides
information about penny stocks and the nature and level of risks in the penny
stock market. The broker-dealer also must provide the customer with current bid
and offer quotations for the penny stock, the compensation of the broker-dealer
and its salesperson in the transaction and monthly account statements showing
the market value of each penny stock held in the customer&#146;s account. The bid and
offer quotations, and the broker-dealer and salesperson compensation
information, must be given to the customer orally or in writing prior to
effecting the transaction and must be given to the customer in writing before or
with the customer&#146;s confirmation. In addition, the penny stock rules require
that prior to a transaction in a penny stock not otherwise exempt from these
rules; the broker-dealer must make a special written determination that the
penny stock is a suitable investment for the purchaser and receive the
purchaser&#146;s written agreement to the transaction. These disclosure requirements
may have the effect of reducing the level of trading activity in the secondary
market for the stock that is subject to these penny stock rules. Consequently,
these penny stock rules may affect the ability of broker-dealers to trade our
securities. We believe that the penny stock rules discourage investor interest
in and limit the marketability of our common stock.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_30></A>
<P align=center>26</P>
<P align=justify><I>The Financial Industry Regulatory Authority sales practice
requirements may also limit a stockholder&#146;s ability to buy and sell our
stock.</I></P>
<P align=justify>In addition to the &#147;penny stock&#148; rules described above, the
Financial Industry Regulatory Authority or FINRA has adopted rules that require
that in recommending an investment to a customer, a broker-dealer must have
reasonable grounds for believing that the investment is suitable for that
customer. Prior to recommending speculative low-priced securities to their
non-institutional customers, broker-dealers must make reasonable efforts to
obtain information about the customer&#146;s financial status, tax status, investment
objectives and other information. Under interpretations of these rules, FINRA
believes that there is a high probability that speculative low-priced securities
will not be suitable for at least some customers. The FINRA requirements make it
more difficult for broker-dealers to recommend that their customers buy our
common stock, which may limit your ability to buy and sell our stock and have an
adverse effect on the market for shares of our common stock.</P>
<P align=justify><B>ITEM 1B. UNRESOLVED STAFF COMMENTS </B></P>
<P align=justify>Not Applicable.</P>
<P align=justify><B>ITEM 2. PROPERTIES</B></P>
<P align=justify>We currently contract with Eurogenet Labs SA, a private Greek
company with a research laboratory located at 27 Marathonos Ave., 15351 Athens,
Greece for our research activities. This facility comprises approximately 10,000
square feet. This facility is leased on a month to month basis for $125,000 per
month and which amount is included in research and development expenses in our
financial statements.</P>
<P align=justify><B>ITEM 3. LEGAL PROCEEDINGS</B></P>
<P align=justify>We know of no material, existing or pending legal proceedings
to which we are a party or of which any of our properties is the subject. In
addition, we do not know of any such proceedings contemplated by any
governmental authorities. We know of no proceedings in which any of our
directors, officers or affiliates, or any registered or beneficial stockholder
is a party adverse to our company or has a material interest adverse to our
company. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_31></A>
<P align=center>27</P>
<P align=justify><B>ITEM 4. (REMOVED AND RESERVED)</B></P>
<P align=center><B>PART II</B></P>
<P align=justify><B>ITEM 5. MARKET FOR REGISTRANT&#146;S COMMON EQUITY, RELATED
STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</B></P>
<P align=justify><B><I>Market information</I></B></P>
<P align=justify>Our common stock is quoted on the OTC Bulletin Board under the
symbol &#147;AVXL.OB&#148;.</P>
<P align=justify>The following table shows the quarterly range of high and low
bid information for our common stock over the fiscal quarters for the last two
fiscal years as quoted on the OTC Bulletin Board. We obtained the following high
and low bid information from the OTC Bulletin Board. These over-the-counter
market quotations reflect inter-dealer prices without retail mark-up, mark-down
or commission, and may not represent actual transactions. Investors should not
rely on historical prices of our common stock as an indication of its future
price performance. On December 16, 2011, the closing price of our common stock
as reported by the OTC Bulletin Board was $1.21 per share. </P>
<DIV align=center>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="50%" border=1>

  <TR vAlign=top>
    <TD align=left ><B>Quarter Ended</B> </TD>
    <TD align=center width="30%"><B>High</B> </TD>
    <TD align=center width="30%"><B>Low</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left >September 30, 2011 </TD>
    <TD align=center width="30%">$2.50 </TD>
    <TD align=center width="30%">$0.00 </TD></TR>
  <TR vAlign=top>
    <TD align=left >June 30, 2011 </TD>
    <TD align=center width="30%">$3.65 </TD>
    <TD align=center width="30%">$1.01 </TD></TR>
  <TR vAlign=top>
    <TD align=left >March 31, 2011 </TD>
    <TD align=center width="30%">$4.45 </TD>
    <TD align=center width="30%">$0.00 </TD></TR>
  <TR vAlign=top>
    <TD align=left >December 31, 2010 </TD>
    <TD align=center width="30%">$4.25 </TD>
    <TD align=center width="30%">$3.05 </TD></TR>
  <TR vAlign=top>
    <TD align=left >September 30, 2010 </TD>
    <TD align=center width="30%">$4.15 </TD>
    <TD align=center width="30%">$3.00 </TD></TR>
  <TR vAlign=top>
    <TD align=left >June 30, 2010 </TD>
    <TD align=center width="30%">$3.61 </TD>
    <TD align=center width="30%">$2.30 </TD></TR>
  <TR vAlign=top>
    <TD align=left >March 31, 2010 </TD>
    <TD align=center width="30%">$3.30 </TD>
    <TD align=center width="30%">$1.94 </TD></TR>
  <TR vAlign=top>
    <TD align=left >December 31, 2009 </TD>
    <TD align=center width="30%">$2.83 </TD>
    <TD align=center width="30%">$1.80 </TD></TR></TABLE></DIV>
<P align=justify><B><I>Transfer Agent</I></B></P>
<P align=justify>Shares of our common stock are issued in registered form. The
Nevada Agency and Trust Company, 50 West Liberty Street, Reno, Nevada
(Telephone: (775) 322-0626; Facsimile: (775) 322-5623) is the registrar and
transfer agent for shares of our common stock.</P>
<P align=justify><B><I>Holders of Common Stock</I></B></P>
<P align=justify>As of December 19, 2011, there were 84 holders of record of our
common stock. As of such date, 27,187,174 shares of our common stock were issued
and outstanding.</P>
<P align=justify><B><I>Dividends</I></B></P>
<P align=justify>We have not paid any cash dividends on our common stock and
have no present intention of paying any dividends on the shares of our common
stock. Our current policy is to retain earnings, if any, for use in our
operations and in the development of our business. Our future dividend policy
will be determined from time to time by our board of directors.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_32></A>
<P align=center>28 </P>
<P align=justify><B><I>Securities Authorized for Issuance under Equity
Compensation Plans or Individual Compensation Arrangements </I></B></P>
<P align=justify>The following table summarizes certain information regarding
our equity compensation plan or individual compensation arrangements as at
September 30, 2011:</P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>
    <TR vAlign=bottom>
      <TD colspan="4" align=center>&nbsp;<B>Equity Compensation Plan Information</B>&nbsp;
      </TD>
    </TR>
    <TR vAlign=top>
      <TD align=center><BR> <BR> <BR> <BR> <BR> <BR> <B>Plan Category</B> </TD>
      <TD align=center width="25%"><BR> <B>Number of securities</B> <BR> <B>to
        be issued upon</B> <BR> <B>exercise of outstanding</B> <BR> <B>options,
        warrants and</B> <BR> <B>rights</B> <BR> <B>(a)</B> </TD>
      <TD align=center width="25%"><BR> <BR> <B>Weighted-average</B> <BR> <B>exercise
        price of</B> <BR> <B>outstanding options,</B> <BR> <B>warrants and rights</B>
        <BR> <B>(b)</B> </TD>
      <TD align=center width="25%"><B>Number of securities</B> <BR> <B>remaining
        available</B> <BR> <B>for future issuance</B> <BR> <B>under equity</B>
        <BR> <B>compensation plans</B> <BR> <B>(excluding securities</B> <BR>
        <B>reflected in column (a)</B> </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Equity compensation plans approved by security holders </TD>
      <TD align=right width="25%">2,375,000 </TD>
      <TD align=right width="25%">3.18 </TD>
      <TD align=right width="25%">1,625,000 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Equity compensation plans not approved by security holders
      </TD>
      <TD align=right width="25%">nil </TD>
      <TD align=right width="25%">- </TD>
      <TD align=right width="25%">nil </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left><B>Total</B> </TD>
      <TD align=right width="25%"><B>2,375,000</B> </TD>
      <TD align=right width="25%"><B>3.18</B> </TD>
      <TD align=right width="25%"><B>1,625,000</B> </TD>
    </TR>
  </TABLE>
</DIV>
<P align=justify><I>Stock Option Plan </I></P>
<P align=justify>On April 17, 2007, our directors adopted the 2007 Stock Option
Plan. On May 25, 2007, our stockholders ratified and approved the 2007 Stock
Option Plan at the annual meeting of stockholders. As of September 30, 2011,
2,375,000 options have been granted to employees, directors, officers and
consultants of our company.</P>
<P align=justify>The purpose of the 2007 Stock Option Plan is to retain the
services of valued key employees and consultants of our company and such other
persons as will be select in accordance with the 2007 Stock Option Plan, and to
encourage such persons to acquire a greater proprietary interest in our company,
thereby strengthening their incentive to achieve the objectives of the
shareholders of our company, and to serve as an aid and inducement in the hiring
of new employees and to provide an equity incentive to consultants.</P>
<P align=justify>The exercise price of shares subject to any option must be at
least 100% of the fair market value of the shares on the date of grant. The
maximum term of any stock option is 10 years from the date the option is
granted. </P>
<P align=justify>On February 2, 2011 we amended and restated our 2007 stock
option plan to increase the number of shares authorized to be issued under the
plan to 4,000,000 </P>
<P align=justify><B><I>Recent Sales of Unregistered Securities </I></B></P>
<P align=justify>Since the beginning of our fiscal year ended September 30,
2011, we have not sold any equity securities that were not registered under the
Securities Act of 1933 that were not previously reported in a quarterly report
on Form 10-Q or in a current report on Form 8-K. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_33></A>
<P align=center>29</P>
<P align=justify><B><I>Purchases of Equity Securities by Our Company and
Affiliated Purchasers</I></B></P>
<P align=justify>None.</P>
<P align=justify><B>ITEM 6 SELECTED FINANCIAL DATA</B></P>
<P align=justify>Not applicable.</P>
<P align=justify><B>ITEM 7 MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATION </B></P>
<P align=justify>The following discussion should be read in conjunction with our
audited consolidated financial statements and notes thereto for the fiscal year
ended September 30, 2011, included elsewhere in this annual report. The
following Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operations contains &#147;forward-looking statements&#148;. Forward-looking
statements are generally written in the future tense and/or are preceded by
words such as &#147;may,&#148; &#147;should,&#148; &#147;forecast,&#148; &#147;could,&#148; &#147;expect,&#148; &#147;suggest,&#148;
&#147;believe,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;plan,&#148; or other similar words. The
forward-looking statements contained in this annual report involve a number of
risks and uncertainties, many of which are outside of our control. Factors that
could cause actual results to differ materially from projected results include,
but are not limited to, those discussed in &#147;Risk Factors&#148; elsewhere in this
annual report. Readers are expressly advised to review and consider those Risk
Factors, which include risks associated with (1) our ability to successfully
conduct clinical and preclinical trials for our product candidates, (2) our
ability to obtain required regulatory approvals to develop and market our
product candidates, (3) our ability to raise additional capital on favorable
terms, (4) our ability to execute our development plan on time and on budget,
(5) our ability to obtain commercial partners, (6) our ability, whether alone or
with commercial partners, to successfully commercialize any of our product
candidates that may be approved for sale, and (7) our ability to identify and
obtain additional product candidates. Although we believe that the assumptions
underlying the forward-looking statements contained in this annual report are
reasonable, any of the assumptions could be inaccurate, and therefore there can
be no assurance that such statements will be accurate. In light of the
significant uncertainties inherent in the forward-looking statements included
herein, the inclusion of such information should not be regarded as a
representation by us or any other person that the results or conditions
described in such statements or our objectives and plans will be achieved.
Furthermore, past performance in operations and share price is not necessarily
indicative of future performance. Except as required by applicable laws
including the securities laws of the United States and Canada, we disclaim any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.</P>
<P align=justify><B><I>Our Business</I></B></P>
<P align=justify>We are a biopharmaceutical company engaged in the discovery and
development of novel drug targets to treat serious diseases for which there are
urgent unmet medical needs. The ANAVEX portfolio involves novel compounds
(ligands) directed to sigma receptors in preclinical and clinical stages that
target neurodegenerative diseases and cancer. Our lead drug candidate, ANAVEX
2-73, targeting Alzheimer&#146;s disease (AD), entered first Human Clinical Trials
(HCT) in the first quarter of 2011. This study was conducted in Germany in
collaboration with ABX-CRO Advanced Pharmaceutical Services. On November 14, 2011, we
announced the successful completion of a Phase 1 single ascending dose (SAD)
clinical trial of ANAVEX 2-73. We plan to continue clinical work for ANAVEX 2-73
and on other CNS compounds, including those targeting epilepsy, depression and
neuropathic pain, provided sufficient capital is available. Additionally, we
intend to further develop compounds in earlier preclinical phases, which target
various types of cancer and continue to develop and expand our
SIGMACEPTOR<SUP>TM</SUP> Discovery platform. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_34></A>
<P align=center>30</P>
<P align=justify><B><I>Results of Operations</I></B></P>
<P align=justify><I>Revenue</I></P>
<P align=justify>We have not earned any revenues since our inception on January
23, 2004. We are still in the development stage and do not anticipate earning
any revenues until we can establish an alliance with other companies to develop,
co-develop, license, acquire or market our products. </P>
<P align=justify><I>Expenses </I></P>
<P align=justify>Our expenses for the fiscal year ended September 30, 2011 and
2010 were as follows:</P>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="70%" border=0>
    <TR vAlign=top>
      <TD align=left >&nbsp; </TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD colspan="4" align=center><B>Year Ended September 30,</B> </TD>
      <TD align=right width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp; </TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=center width="17%"><B>2011</B> </TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="17%"><B>2010</B> </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff >Accounting and audit fees </TD>
      <TD align=left width="1%"  bgColor=#e6efff>$</TD>
      <TD align=right width="17%" bgColor=#e6efff>&nbsp;158,225 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>$</TD>
      <TD align=right width="17%" bgColor=#e6efff>&nbsp;151,010 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Amortization and depreciation </TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="17%">1,657 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="17%">910 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff >Bank charges and interest </TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="17%" bgColor=#e6efff>8,701 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="17%" bgColor=#e6efff>6,867 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Consulting fees </TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="17%">2,757,835 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="17%">2,082,888 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff >Insurance </TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="17%" bgColor=#e6efff>48,152 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="17%" bgColor=#e6efff>- </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Investor relations </TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="17%">133,805 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="17%">186,221 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff >Legal fees </TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="17%" bgColor=#e6efff>140,613 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="17%" bgColor=#e6efff>173,369 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Management fees </TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="17%">- </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="17%">- </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff >Office and miscellaneous </TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="17%" bgColor=#e6efff>30,068 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="17%" bgColor=#e6efff>39,722 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Registration and filing fees </TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="17%">58,878 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="17%">27,675 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff >Rent and administration </TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="17%" bgColor=#e6efff>63,110 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="17%" bgColor=#e6efff>12,810 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Research and development </TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="17%">2,597,279 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="17%">2,728,836 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff >Travel </TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="17%" bgColor=#e6efff>182,259 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="17%" bgColor=#e6efff>236,268 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Website design and maintenance </TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="17%">- </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="17%">1,692 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff ><B>Total expenses</B> </TD>
      <TD align=left width="1%"  bgColor=#e6efff>$</TD>
      <TD align=right width="17%" bgColor=#e6efff>&nbsp;6,180,582 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>$</TD>
      <TD align=right width="17%" bgColor=#e6efff>&nbsp;5,648,268 </TD>
      <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD>
    </TR>
  </TABLE>
</DIV>
<P align=justify><U>Year ended September 30, 2011 and 2010</U> </P>
<P align=justify>Expenses for the fiscal year ended September 30, 2011 increased
by $532,314 over the same period in 2010. Accounting and audit fees have
increased by $7,215 from $151,010 for the fiscal year ended September 30, 2010
to $158,225 for the fiscal year ended September 30, 2011 primarily as a result
of our company having to address complex accounting matters resulting from our
various agreements, thereby requiring increased attention by our external
auditors. Consulting fees have increased by $674,947 from $2,082,888 for the
fiscal year ended September 30, 2010 to $2,757,835 for the fiscal year ended
September 30, 2011 as a result of higher stock-based compensation charges
related to the re-pricing of stock options during the year. Investor relations expenses have decreased by $52,416
from $186,221 for the fiscal year ended September 30, 2010 to $133,805 for the
fiscal year ended September 30, 2011 as a result of decreased fundraising and
corporate awareness activities. Legal fees have decreased by $32,756 from
$173,369 for the fiscal year ended September 30, 2010 to $140,613 for the fiscal
year ended September 30, 2011 primarily related to decreased private placement
activities and drafting and review of agreements related to clinical trials and
other activities during the fiscal year ended September 30, 2011. Registration
and filing fees have increased by $31,203 from $27,675 for the fiscal year ended
September 30, 2010 to $58,878 for the fiscal year ended September 30, 2011 as a
result of increased corporate activities and enhanced filing requirements. Rent
and administration fees have increased by $50,300 from $12,810 for the fiscal
year ended September 30, 2010 to $63,110 for the fiscal year ended September 30,
2011 as a result of office lease expenses in North America. Research and
development expenses have decreased by $131,557 from $2,728,836 for the fiscal
year ended September 30, 2010 to $2,597,279 for the fiscal year ended September
30, 2011 as a result of decreased preclinical activities relating to preparation
for clinical trials for Anavex 2-73. Travel expenses have decreased by $54,009
from $236,268 for the fiscal year ended September 30, 2010 to $182,259 for the
fiscal year ended September 30, 2011 as a result of decreased travel related to
clinical trial and fundraising and corporate awareness activities.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_35></A>
<P align=center>31</P>
<P align=justify>Interest and financing fees decreased by $194,713 from $284,959
to $90,246 largely as a result of converting promissory notes to shares during
the year and thus avoiding further long-term debt interest charges. Similarly,
accretion of debt discount decreased by $1,767,578 from $1,836,997 to $69,419 as
a result of modifying the terms of the convertible notes in the year ended
September 30, 2010 such that embedded conversion features were no longer
required to be bifurcated as a derivative liability. Debt conversion expense
increased to $504,160 from $Nil as a result of inducing conversion of promissory
notes during the year by reducing a contracted conversion price.</P>
<P align=justify><B><I>Liquidity and Capital Resources </I></B></P>
<P align=justify><I>Working Capital</I></P>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="70%" border=0>
    <TR vAlign=top>
    <TD align=left >&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="21%"><B>September 30, 2011</B> </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="21%"><B>September 30, 2010</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Cash </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="21%" bgColor=#e6efff>134,702</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="21%" bgColor=#e6efff>264,669 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left >Current Assets </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="21%">200,605 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="21%">325,758 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Current Liabilities </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="21%"
    bgColor=#e6efff>1,345,443 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="21%"
    bgColor=#e6efff>3,290,071 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left >Working Capital (Deficit)$ </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="21%">(1,144, 838</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="21%">(2,964,313</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >) </TD></TR></TABLE></DIV>
<P align=justify>As of September 30, 2011, we had $134,702 in cash, a decrease
of $129,967 from September 30, 2010. The principal components of this decrease
in cash relate to the cash used in operating activities of $3,801,479, offset by
the cash provided by financing activities of $3,671,512, including proceeds from
the issuance of common shares of $3,021,512 and proceeds from the issuance of
promissory notes of $750,000. As of September 30, 2011, we had a working capital
deficit of $1,144,838, a decrease in deficit of $1,819,475 from September 30,
2010. The principal component of this decrease in working capital deficit was
the decrease in promissory notes payable of $1,624,389 that were converted to common
equity during the year ended September 30, 2011.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_36></A>
<P align=center>32</P>
<P align=justify>We anticipate that we will require up to $10,000,000 for the 12
month period ending September 30, 2012to implement our plan of operation of
researching and developing our patents, the related compounds and any further
intellectual property we may acquire. The majority of our capital resources
requirement is needed to continue clinical trials of Anavex 2-73 and continued
research and development of our Sigmaceptor&#153; platform. If we are not able to
secure additional financing, we will not be able to implement and fund this
work.</P>
<P align=justify><I>Going Concern</I></P>
<P align=justify>At September 30, 2011, we had an accumulated deficit of
$29,203,221 since our inception and incurred a net loss of $7,307,147 for the
fiscal year ended September 30, 2011. We expect to incur further losses in the
development of our business, all of which casts substantial doubt about our
ability to continue as a going concern. Our ability to continue as a going
concern is dependent upon our ability to generate future profitable operations
and/or to obtain the necessary financing to meet our obligations and repay our
liabilities arising from normal business operations when they come due. Our
independent auditors included an explanatory paragraph regarding substantial
doubt about our ability to continue as a going concern in their report on our
annual financial statements for the fiscal year ended September 30, 2011. </P>
<P align=justify><I>Future Financing</I></P>
<P align=justify>We will require additional financing to fund our planned
operations, including further strengthening our patents, securing patents for
other compounds and any further intellectual property that we may acquire and
commencing clinical development. We currently do not have committed sources of
additional financing and may not be able to obtain additional financing,
particularly, if the volatile conditions in the stock and financial markets, and
especially the market for early development stage pharmaceutical and
biotechnology research and development company stocks persist. </P>
<P align=justify>There can be no assurance that additional financing will be
available to us when needed or, if available, that it can be obtained on
commercially reasonable terms. If we are not able to obtain the additional
financing on a timely basis, if and when it is needed, we will be forced to
delay or scale down some or all of our research and development activities or
perhaps even cease the operation of our business. </P>
<P align=justify>Since inception we have funded our operations primarily through
equity and debt financings and we expect that we will continue to fund our
operations through the equity and debt financing. If we raise additional
financing by issuing equity securities, our existing stockholders&#146; ownership
will be diluted. Obtaining commercial loans, assuming those loans would be
available, will increase our liabilities and future cash commitments. </P>
<P align=justify>There is no assurance that we will be able to maintain
operations at a level sufficient for investors to obtain a return on their
investment in our common stock. Further, we may continue to be unprofitable.
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_37></A>
<P align=center>33</P>
<P align=justify><B><I>Off-Balance Sheet Arrangements</I></B></P>
<P align=justify>We have no off-balance sheet arrangements that have or are
reasonably likely to have a current or future effect on our financial condition,
changes in financial condition, revenues or expenses, results of operations,
liquidity, capital expenditures or capital resources that is material to our
stockholders.</P>
<P align=justify><B><I>Application of Critical Accounting Policies</I></B></P>
<P align=justify>Our financial statements and accompanying notes are prepared in
accordance with generally accepted accounting principles in the United States.
Preparing financial statements requires management to make estimates and
assumptions that affect the reported amounts of assets, liabilities, revenue and
expenses. These estimates and assumptions are affected by management&#146;s
application of accounting policies. We believe that understanding the basis and
nature of the estimates and assumptions involved with the following aspects of
our financial statements is critical to an understanding of our financials.</P>
<P align=justify>We base our assumptions and estimates on historical experience
and other sources that we believe to be reasonable at the time. Actual results
may vary from our estimates due to changes in circumstances, weather, politics,
global economics, mechanical problems, general business conditions and other
factors. Our significant estimates are related to the valuation of warrants and
options.</P>
<P align=justify>There are accounting policies that we believe are significant
to the presentation of our financial statements. The most significant of these
accounting policies relates to the accounting for our research and development
expenses and stock-based compensation expense. </P>
<P align=justify><I>Research and Development Expenses</I></P>
<P align=justify>Research and developments costs are expensed as incurred. These
expenses are comprised of the costs of our proprietary research and development
efforts, including salaries, facilities costs, overhead costs and other related
expenses as well as costs incurred in connection with third-party collaboration
efforts. Milestone payments made by us to third parties are expensed when the
specific milestone has been achieved. </P>
<P align=justify>In addition, we incur expenses in respect of the acquisition of
intellectual property relating to patents and trademarks. The probability of
success and length of time to developing commercial applications of the drugs
subject to the acquired patents and trademarks is difficult to determine and
numerous risks and uncertainties exist with respect to the timely completion of
the development projects. There is no assurance the acquired patents and
trademarks will ever be successfully commercialized. Due to these risks and
uncertainties, we expense the acquisition of patents and trademarks. </P>
<P align=justify><I>Stock-based Compensation</I></P>
<P align=justify>We account for all stock-based payments and awards under the
fair value based method.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_38></A>
<P align=center>34</P>
<P align=justify>Stock-based payments to non-employees are measured at the fair
value of the consideration received, or the fair value of the equity instruments
issued, or liabilities incurred, whichever is more reliably measurable. The fair
value of stock-based payments to non-employees is periodically re-measured until
the counterparty performance is complete, and any change therein is recognized
over the vesting period of the award and in the same manner as if we had paid
cash instead of paying with or using equity based instruments. The cost of the
stock-based payments to non-employees that are fully vested and non-forfeitable
as at the grant date is measured and recognized at that date, unless there is a
contractual term for services in which case such compensation would be amortized
over the contractual term. </P>
<P align=justify>We account for the granting of share purchase options to
employees using the fair value method whereby all awards to employees will be
recorded at fair value on the date of the grant. The fair value of all share
purchase options are expensed over their vesting period with a corresponding
increase to additional capital surplus. Upon exercise of share purchase options,
the consideration paid by the option holder, together with the amount previously
recognized in additional capital surplus, is recorded as an increase to share
capital.</P>
<P align=justify>We use the Black-Scholes option valuation model to calculate
the fair value of share purchase options at the date of the grant. Option
pricing models require the input of highly subjective assumptions, including the
expected price volatility. Changes in assumptions can materially affect the fair
value estimate and therefore the Black-Scholes model does not necessarily
provide a reliable single measure of the fair value of our share purchase
options. </P>
<P align=justify><I>Derivative Liabilities</I></P>
<P align=justify>Our convertible promissory notes include embedded conversion
options which, prior to their amendments, were required to be accounted for as
separate derivative liabilities. These liabilities were required to be measured
at fair value. These instruments were adjusted to reflect fair value at each
period end. Any increase or decrease in the fair value was recorded in results
of operations as change in fair value of derivative liabilities. In determining
the appropriate fair value, we used the binomial pricing model. </P>
<P align=justify>The debt discount arising from bifurcating the derivative
liability from the host debt instrument was accreted to income during the
period. </P>
<P align=justify><B><I>Recent Accounting Pronouncements</I></B></P>
<P align=justify>In October 2009, the FASB issued ASU No. 2009-13,
&#147;<I>Multiple-Deliverable Revenue Arrangements</I>,&#148; or ASU 2009-13, which amends
existing revenue recognition accounting pronouncements that are currently within
the scope of ASC 605. This guidance eliminates the requirement to establish the
fair value of undelivered products and services and instead provides for
separate revenue recognition based upon management&#146;s estimate of the selling
price for an undelivered item when there is no other means to determine the fair
value of that undelivered item. ASU 2009-13 is effective prospectively for
revenue arrangements entered into or materially modified in fiscal years
beginning on or after June 15, 2010. The adoption of this guidance did not have
a material impact on our consolidated financial statements.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_39></A>
<P align=center>35</P>
<P align=justify>In January 2010, the FASB issued Accounting Standards Update
2010-06, <I>Fair Value Measurements and Disclosures (Topic 820): Improving
Disclosures about Fair Value Measurements</I>. The ASU amends Subtopic 820-10
with new disclosure requirements and clarification of existing disclosure
requirements. New disclosures required include the amount of significant
transfers in and out of levels 1 and 2 fair value measurements and the reasons
for the transfers. In addition, the reconciliation for level 3 activity will be
required on a gross rather than net basis. The ASU provides additional guidance
related to the level of disaggregation in determining classes of assets and
liabilities and disclosures about inputs and valuation techniques. The
amendments are effective for annual or interim reporting periods beginning after
December 15, 2009, except for the requirement to provide the reconciliation for
level 3 activities on a gross basis, which is effective for fiscal years
beginning after December 15, 2010. We are currently assessing the impact of ASU
2010-6 and do not expect the adoption of this guidance to have a material impact
on our consolidated financial statements. </P>
<P align=justify><B>ITEM 7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISK </B></P>
<P align=justify>Not Applicable<BR></P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_40></A>
<P align=center>36</P>
<P align=justify><B>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</B></P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-1></A>
<P align=justify>&nbsp;</P>
<P align=center><B>ANAVEX LIFE SCIENCES CORP. </B></P>
<P align=center>(A Development Stage Company) </P>
<P align=center>CONSOLIDATED FINANCIAL STATEMENTS </P>
<P align=center>September 30, 2011 and 2010 </P>
<P align=center>(<U>Stated in US Dollars</U>) </P>
<P align=center>&nbsp;</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-2></A>&nbsp;<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left ><IMG
      src="bdo.gif" width="114" height="60"
      border=0></TD>
    <TD align=left width="33%">Tel: 604 688 5421 <BR>Fax: 604 688 5132
      <BR><B>www.bdo.ca </B><BR></TD>
    <TD align=left width="33%">BDO Canada LLP <BR>600 Cathedral Place <BR>925
      West Georgia Street <BR>Vancouver BC V6C 3L2 Canada </TD></TR></TABLE>
<P align=center><b>REPORT OF  INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </b> </P>
<p>To  the Directors and Stockholders, <br>
  Anavex  Life Sciences Corp.<br>
  (a  Development Stage Company)</p>
<p align="justify">We have audited the accompanying consolidated  balance sheets of Anavex Life Sciences Corp. (the &ldquo;Company&rdquo;) as of September  30, 2011 and 2010, and the related consolidated statements of operations, cash  flows and changes in capital deficit for the years then ended and for the  period from January 23, 2004 (date of inception) to September 30, 2011. These  financial statements are the responsibility of the Company&rsquo;s management. Our  responsibility is to express an opinion on these financial statements based on  our audits.</p>
<p align="justify"> We conducted our audits in accordance with the standards of the Public  Company Accounting Oversight Board (United States). Those standards require  that we plan and perform the audit to obtain reasonable assurance about whether  the financial statements are free of material misstatement. The Company is not  required to have, nor were we engaged to perform, an audit of its internal  control over financial reporting. Our audit included consideration of internal  control over financial reporting as a basis for designing audit procedures that  are appropriate in the circumstances, but not for the purpose of expressing an  opinion on the effectiveness of the Company&rsquo;s internal control over financial  reporting. Accordingly, we express no such opinion. An audit also includes  examining, on a test basis, evidence supporting the amounts and disclosures in  the financial statements. An audit also includes assessing the accounting  principles used and significant estimates made by management, as well as  evaluating the overall presentation of the financial statements. We believe  that our audits provide a reasonable basis for our opinion.</p>
<p align="justify">In our opinion, the consolidated financial statements referred to above  present fairly, in all material respects, the financial position of Anavex Life  Sciences Corp. at September 30, 2011 and 2010, and the results of its  operations and its cash flows for the years then ended and for the period from  January 23, 2004 (date of inception) to September 30, 2011, in conformity with  accounting principles generally accepted in the United States.</p>
<p align="justify">The  accompanying financial statements have been prepared assuming that the Company  will continue as a going concern. As discussed in Note 1 to the financial statements,  the Company had an accumulated deficit of $29,203,221 at September 30, 2011 and  incurred a net loss of $7,307,147 for the year then ended. These conditions  raise substantial doubt about the Company&rsquo;s ability to continue as a going  concern. Management&rsquo;s plans in regard to these matters are also described in  Note 1. The financial statements do not include any adjustments that might  result from the outcome of this uncertainty.</p>
<P align=justify>/s/ BDO Canada LLP</P>
<P align=justify>Chartered Accountants </P>
<P align=justify>Vancouver, Canada </P>
<P align=justify>December 16, 2011 </P>
<P align=justify>&nbsp;</P>
<P align=justify><FONT size=1>BDO Canada LLP, a Canadian limited liability partnership, is a member of BDO International Limited, a UK company limited by guarantee, and forms part of the international BDO network of independent member firms.</FONT></P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-3></A>
<P align=center><B>ANAVEX LIFESCIENCES CORP.</B><BR>(A Development Stage
Company)<BR>CONSOLIDATED BALANCE SHEETS<BR>September 30, 2011 and September 30,
2010<BR>
  <U>(Stated in US Dollars)</U></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>ASSETS</U></B> </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%">September 30, </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">September 30, </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="12%">2011
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="12%">2010
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp; </TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp; </TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Current </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Cash </TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>&nbsp;134,702
</TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>&nbsp;264,669
</TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>VAT recoverable </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">809 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">37,820 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Deferred financing charge - Note 5 </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>55,464 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Prepaid expenses </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">9,630 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">23,269 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>200,605 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>325,758 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Equipment </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">2,434 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">4,091 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>&nbsp;203,039 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>&nbsp;329,849 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp; </TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp; </TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#e6efff><B><U>LIABILITIES</U></B> </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp; </TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp; </TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Current </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Accounts payable and accrued liabilities - Note 7 </TD>
    <TD vAlign=bottom align=left width="1%" >$</TD>
    <TD vAlign=bottom align=right width="12%">&nbsp;410,024 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >$</TD>
    <TD vAlign=bottom align=right width="12%">&nbsp;797,763 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Derivative liability - Note 4 </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>67,500 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Promissory notes payable - Note 5 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">867,919 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">2,492,308 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>1,345,443 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>3,290,071 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp; </TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp; </TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=center><B><U>CAPITAL DEFICIT</U></B> </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Capital stock - Note 6 </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Authorized: <BR>150,000,000 common shares,
      par value $0.001 per share <BR>Issued and outstanding: <BR>26,571,574
      common shares (September 30, 2010 - 23,516,952) </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>26,572 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>23,517 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Additional paid-in capital </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">28,034,245 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">18,912,335 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Deficit accumulated during the development
      stage </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>(29,203,221</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>(21,896,074</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>) </TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">(1,142,404</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">(2,960,222</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >) </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>&nbsp;203,039 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>&nbsp;329,849 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD></TR></TABLE>
<P align=center>SEE ACCOMPANYING NOTES </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-4></A>
<P align=center><B>ANAVEX LIFESCIENCES CORP.</B><BR>(A Development Stage
Company)<BR>CONSOLIDATED STATEMENTS OF OPERATIONS<BR>for the years ended
September 30, 2011 and 2010 and<BR>for the period from January 23, 2004 (Date of
Inception) to September 30, 2011<BR>
  <U>(Stated in US Dollars)</U></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left nowrap>&nbsp; </TD>
    <TD width="1%" align=left nowrap >&nbsp;</TD>
    <TD colspan="4" align=center nowrap>Years Ended </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="12%" align=center nowrap>January 23, 2004 </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left nowrap>&nbsp; </TD>
    <TD width="1%" align=left nowrap >&nbsp;</TD>
    <TD colspan="4" align=center nowrap>September 30, </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="12%" align=center nowrap>(Date of Inception) to </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left nowrap>&nbsp; </TD>
    <TD width="1%" align=left nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="12%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">2011    </TD>
    <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="12%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">2010    </TD>
    <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD
      width="12%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">September 30, 2011 </TD>
    <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Expenses </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Accounting and audit fees </TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>&nbsp;158,225 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>&nbsp;151,010 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>&nbsp;522,353 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Amortization and depreciation </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">1,657 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">910 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">3,197 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Bank charges and interest </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>8,701 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>6,867 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>36,344 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Consulting fees - Note 7 </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">2,757,835 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">2,082,888 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">10,588,725 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Insurance </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>48,152 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>48,152 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Investor relations </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">133,805 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">186,221 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">723,569 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Legal fees </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>140,613 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>173,369 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>527,102 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Management fees </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">14,625 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Office and miscellaneous </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>30,068 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>39,722 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>138,537 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Registration and filing fees </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">58,878 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">27,675 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">127,604 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Rent and administration </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>63,110 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>12,810 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>224,670 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Research and development </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">2,597,279 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">2,728,836 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">9,905,089 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Travel </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>182,259 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>236,268 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>674,318 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Website design and maintenance </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">1,692 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">28,417 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Loss before other income (expenses) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">(6,180,582</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">(5,648,268</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">(23,562,702</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
  </TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Other income (expenses) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Interest and financing fees </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>(90,246</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>(284,959</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>(487,680</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Accretion of debt discount - Note 5 </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">(69,419</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">(1,836,997</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">(2,076,580</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Change in fair value of derivative liability
      - Note 4 </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>100,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>(630,774</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>(530,774</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Debt conversion expense - Note 5 </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">(504,160</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">(504,160</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Loss on settlement of accounts payable - Note
      6 </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>(334,053</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>(444,000</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>(778,053</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Loss on extinguishment of debt - Note 5 </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">(198,738</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">(686,207</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Foreign exchange gain (loss) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>(29,949</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>61,961 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>(26,261</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp; </TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp; </TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp; </TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Net loss for the period </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>&nbsp;(7,307,147</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>&nbsp;(8,783,037</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>&nbsp;(28,652,417</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp; </TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp; </TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp; </TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Basic and diluted loss per share </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>&nbsp;(0.29</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>&nbsp;(0.41</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp; </TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp; </TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp; </TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Weighted average number of shares outstanding
    </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>25,169,065 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>21,440,558 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<P align=center>SEE ACCOMPANYING NOTES </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-5></A>
<P align=center><B>ANAVEX LIFE SCIENCES CORP.</B><BR>(A Development Stage
Company)<BR>CONSOLIDATED STATEMENTS OF CASH FLOWS<BR>for the years ended
September 30, 2011 and 2010 and<BR>for the period from January 23, 2004 (Date of
Inception) to September 30, 2011<BR>
  <U>(Stated in US Dollars)</U></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left nowrap>&nbsp; </TD>
    <TD width="1%" align=left nowrap >&nbsp;</TD>
    <TD width="12%" align=center nowrap>&nbsp; </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="12%" align=center nowrap>&nbsp; </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="12%" align=center nowrap>January 23, 2004 </TD>
    <TD width="2%" align=left nowrap >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left nowrap>&nbsp; </TD>
    <TD width="1%" align=left nowrap >&nbsp;</TD>
    <TD colspan="4" align=center nowrap>Years ended September 30, </TD>
    <TD width="2%" align=center nowrap >&nbsp;</TD>
    <TD width="1%" align=center nowrap >&nbsp;</TD>
    <TD width="12%" align=center nowrap>(Date of Inception) to </TD>
    <TD width="2%" align=left nowrap >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left nowrap>&nbsp; </TD>
    <TD width="1%" align=left nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="12%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">2011    </TD>
    <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="12%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">2010    </TD>
    <TD width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD
      width="12%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">September 30, 2011 </TD>
    <TD width="2%" align=left nowrap style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp; </TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp; </TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp; </TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Cash Flows used in Operating Activities </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Net loss for the period </TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="12%"
    bgColor=#e6efff>&nbsp;(7,307,147</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="12%"
    bgColor=#e6efff>&nbsp;(8,783,037</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="12%"
    bgColor=#e6efff>&nbsp;(28,652,417</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Adjustments to reconcile net loss to net cash used in operations:
    </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Amortization and depreciation </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>1,657 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>910 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>3,197 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Accretion of debt discount </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">69,419 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">1,836,997 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">2,076,580 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Stock-based compensation </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>1,273,162 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>770,055 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>4,540,339 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Amortization of deferred financing charge </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">44,536 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">55,777 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">100,313 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Change in fair value of derivative liability
    </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>(100,000</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>630,774 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>530,774 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Consulting expense recorded in exchange for shares to be issued
    </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">236,337 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Common shares issued for consulting expenses
    </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>390,510 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Promissory note issued for severance </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">71,500 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Common shares issued for severance </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>340,600 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Common shares issued for research and development expenses
    </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">800,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Management fees contributed </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>14,625 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Debt conversion expense </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">504,160 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">504,160 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Loss on settlement of accounts payable </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>334,053 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>444,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>778,053 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Loss on extinguishment of debt </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">198,738 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">686,207 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Rent contributed </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>3,750 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Changes in non-cash working capital balances related to operations:
    </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>VAT recoverable </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>37,011 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>(37,820</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>(809</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Prepaid expenses </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">13,639 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">(23,088</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">(9,630</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Accounts payable and accrued liabilities </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>1,129,293 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>511,844 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>3,491,496 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Net cash used in operating activities </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">(3,801,479</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">(4,593,588</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">(14,094,415</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
  </TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Cash Flows provided by Financing Activities </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Issuance of common shares, net of share issue
      costs </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>3,021,512 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>3,095,573 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>9,250,583 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Financing fee </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">(100,000</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">(100,000</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Proceeds from promissory notes </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>750,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>1,415,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>4,817,500 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Repayment of promissory note </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">- </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">(100,000</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Due to related parties </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>33,665 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Shareholder advances </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">333,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Net cash provided by financing activities </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>3,671,512 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>4,510,573 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>14,234,748 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp; </TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp; </TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp; </TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Cash Flows used in Investing Activities </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Acquisition of equipment </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">(3,310</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">(5,631</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Net cash used in investing activities </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>(3,310</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>(5,631</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp; </TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp; </TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp; </TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Increase (decrease) in cash during the period </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>(129,967</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>(86,325</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>134,702 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Cash, beginning of period </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">264,669 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right

    width="12%">350,994 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">- </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Cash, end of period </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;134,702 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;264,669 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;134,702 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<P align=justify>Supplemental Cash Flow Information - Note 10</P>
<P align=center>SEE ACCOMPANYING NOTES </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-6></A>
<P align=center><B>ANAVEX</B><B> </B><B>LIFE SCIENCES</B><B> CORP.</B><BR>(A
Development Stage Company)<BR>CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL
DEFICIT<BR>for the period from January 23, 2004 (Date of Inception) to September
30, 2011<BR><U>(Stated in US Dollars)</U></P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 8pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
    <TR vAlign=top>
      <TD align=center nowrap>&nbsp; </TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Deficit </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=left nowrap>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center nowrap>&nbsp; </TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD colspan="10" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">
        Common Stock </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Accumulated </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=left nowrap>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center nowrap>&nbsp; </TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Shares </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Par Value </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Additional </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Common </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>During the </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=left nowrap>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center nowrap>&nbsp; </TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Paid-in </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Shares to be </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Development </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=left nowrap>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center nowrap>&nbsp; </TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
      width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp; </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
      width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp; </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
      width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Capital </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
      width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Issued </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Stage      </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Total      </TD>
      <TD
    width="2%" align=left nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    </TR>
    <TR>
      <TD>&nbsp; </TD>
      <TD align=right width="1%">&nbsp;</TD>
      <TD align=right width="8%">&nbsp; </TD>
      <TD align=right width="2%">&nbsp;</TD>
      <TD align=right width="1%">&nbsp;</TD>
      <TD align=right width="8%">&nbsp; </TD>
      <TD align=right width="2%">&nbsp;</TD>
      <TD align=right width="1%">&nbsp;</TD>
      <TD align=right width="8%">&nbsp; </TD>
      <TD align=right width="2%">&nbsp;</TD>
      <TD align=right width="1%">&nbsp;</TD>
      <TD align=right width="8%">&nbsp; </TD>
      <TD align=right width="2%">&nbsp;</TD>
      <TD align=right width="1%">&nbsp;</TD>
      <TD align=right width="8%">&nbsp; </TD>
      <TD align=right width="2%">&nbsp;</TD>
      <TD align=right width="1%">&nbsp;</TD>

      <TD align=right width="8%">&nbsp; </TD>
      <TD align=right width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Capital stock issued for cash on January
        23, 2004 - at $0.0033 </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>12,000,000 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;12,000 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;28,000 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;40,000 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Net loss from January 23, 2004 to September 30, 2004 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">(14,395</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">) </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">(14,395</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">) </TD>
    </TR>
    <TR>
      <TD bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Balance, September 30, 2004 </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">12,000,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">12,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">28,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">(14,395</TD>
      <TD vAlign=bottom align=left width="2%">) </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">25,605 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Capital stock issued for cash on December
        31, 2004 - at $0.0033 </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>7,200,000 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>7,200 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>16,800 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>24,000 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Management fees contributed </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">13,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">13,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Rent contributed </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>3,000 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>3,000 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Net loss for the year </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">(91,625</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">) </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">(91,625</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">) </TD>
    </TR>
    <TR>
      <TD bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Balance, September 30, 2005 </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">19,200,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">19,200 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">60,800 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">(106,020</TD>
      <TD vAlign=bottom align=left width="2%">) </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">(26,020</TD>
      <TD vAlign=bottom align=left width="2%">) </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Management fees contributed </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>1,625 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>1,625 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Rent contributed </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">750 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">750 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Debt forgiven by directors </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>33,666 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>33,666 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Net loss for the year </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">(25,532</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">) </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">(25,532</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">) </TD>
    </TR>
    <TR>
      <TD bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Balance, September 30, 2006 </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">19,200,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">19,200 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">96,841 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">(131,552</TD>
      <TD vAlign=bottom align=left width="2%">) </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">(15,511</TD>
      <TD vAlign=bottom align=left width="2%">) </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Capital stock issued for research and development
        services on September 24, 2007 - at $3.60 </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>222,222 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>222 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>799,778 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>800,000 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Capital stock issued for settlement of loan payable on September
        25, 2007 - at $3.60 </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">92,500 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">93 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">332,907 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">333,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Net loss for the year </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>(1,579,993</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>) </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>(1,579,993</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>) </TD>
    </TR>
    <TR>
      <TD>&nbsp; </TD>
      <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Balance, September 30, 2007 </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>19,514,722 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>19,515 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>1,229,526 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(1,711,545</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(462,504</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
    </TR>
  </TABLE>
</DIV>
<P align=center>SEE ACCOMPANYING NOTES </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-7></A>
<P align=center><B>ANAVEX</B><B> </B><B>LIFE SCIENCES</B><B> CORP.</B><BR>(A
Development Stage Company)<BR>CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL
DEFICIT<BR>for the period from January 23, 2004 (Date of Inception) to September
30, 2011<BR><U>(Stated in US Dollars)</U></P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 8pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
    <TR vAlign=top>
      <TD align=left nowrap>&nbsp; </TD>
      <TD width="1%" align=left nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Deficit </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=left nowrap>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left nowrap>&nbsp; </TD>
      <TD
    width="1%" align=left nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD colspan="10" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">
        Common Stock </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Accumulated </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=left nowrap>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left nowrap>&nbsp; </TD>
      <TD width="1%" align=left nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Shares </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Par Value </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Additional </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Common </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>During the </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=left nowrap>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left nowrap>&nbsp; </TD>
      <TD width="1%" align=left nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Paid-in </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Shares to be </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Development </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=left nowrap>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left nowrap>&nbsp; </TD>
      <TD
    width="1%" align=left nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
      width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp; </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
      width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp; </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
      width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Capital </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
      width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Issued </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Stage      </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Total      </TD>
      <TD
    width="2%" align=left nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    </TR>
    <TR>
      <TD>&nbsp; </TD>
      <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Balance, September 30, 2007 - brought forward
      </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>19,514,722 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>19,515 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>1,229,526 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(1,711,545</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(462,504</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Capital stock issued for cash on December 10, 2007 - at $3.50
      </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">150,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">150 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">524,850 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">525,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Capital stock issued for consulting services
        on December 18, 2007 - at $3.86 </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>50,000 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>50 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>192,950 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>193,000 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Capital stock issued in settlement of debt on December 18,
        2007 - at $4.50 </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">10,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">10 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">44,990 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">45,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Stock-based compensation for shares issued
        at a discount </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>65,000 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>65,000 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Capital stock issued for severance on May 15, 2008 - at $5.24
      </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">65,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">65 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">340,535 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">340,600 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Common shares to be issued for consulting
        services </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>252,599 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>252,599 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Common stock issued for consulting services on August 19,
        2008 - at $5.07 </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">25,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">25 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">126,725 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">(126,750</TD>
      <TD vAlign=bottom align=left width="2%">) </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Capital stock issued for cash on August 19,
        2008 - at $4.25 </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>142,698 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>142 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>606,325 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>606,467 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Stock-based compensation </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">1,493,937 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">1,493,937 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Net loss for the year </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>(5,351,269</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>) </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>(5,351,269</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>) </TD>
    </TR>
    <TR>
      <TD>&nbsp; </TD>
      <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Balance, September 30, 2008 </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>19,957,420 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>19,957 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>4,624,838 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>125,849 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(7,062,814</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(2,292,170</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
    </TR>
  </TABLE>
</DIV>
<P align=center>SEE ACCOMPANYING NOTES </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-8></A>
<P align=center><B>ANAVEX</B><B> LIFE </B><B>SCIENCES</B><B> CORP.</B><BR>(A
Development Stage Company)<BR>CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL
DEFICIT<BR>for the period from January 23, 2004 (Date of Inception) to September
30, 2011<BR><U>(Stated in US Dollars)</U></P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 8pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
    <TR vAlign=top>
      <TD align=left nowrap>&nbsp; </TD>
      <TD width="1%" align=left nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Deficit </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=left nowrap>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left nowrap>&nbsp; </TD>
      <TD
    width="1%" align=left nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD colspan="10" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">
        Common Stock </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Accumulated </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=left nowrap>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left nowrap>&nbsp; </TD>
      <TD width="1%" align=left nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Shares </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Par Value </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Additional </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Common </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>During the </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=left nowrap>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left nowrap>&nbsp; </TD>
      <TD width="1%" align=left nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Paid-in </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Shares to be </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Development </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=left nowrap>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left nowrap>&nbsp; </TD>
      <TD
    width="1%" align=left nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
      width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp; </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
      width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp; </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
      width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Capital </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
      width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Issued </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Stage      </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Total      </TD>
      <TD
    width="2%" align=left nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    </TR>
    <TR>
      <TD>&nbsp; </TD>
      <TD vAlign=bottom width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="8%">&nbsp; </TD>
      <TD vAlign=bottom width="2%">&nbsp;</TD>
      <TD vAlign=bottom width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="8%">&nbsp; </TD>
      <TD vAlign=bottom width="2%">&nbsp;</TD>
      <TD vAlign=bottom width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="8%">&nbsp; </TD>
      <TD vAlign=bottom width="2%">&nbsp;</TD>
      <TD vAlign=bottom width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="8%">&nbsp; </TD>
      <TD vAlign=bottom width="2%">&nbsp;</TD>
      <TD vAlign=bottom width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="8%">&nbsp; </TD>
      <TD vAlign=bottom width="2%">&nbsp;</TD>
      <TD vAlign=bottom width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="8%">&nbsp; </TD>
      <TD vAlign=bottom width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Balance, September 30, 2008 - brought forward
      </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>19,957,420 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>19,957 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>4,624,838 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>125,849 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(7,062,814</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(2,292,170</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Stock-based compensation - Note 10 </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">812,336 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">812,336 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Capital stock issued for consulting services
        on November 20, 2008 - $2.63 </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>25,000 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>25 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>65,725 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(65,750</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Capital stock issued for consulting services on February
        20, 2009 - $2.50 </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">25,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">25 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">62,475 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">(62,500</TD>
      <TD vAlign=bottom align=left width="2%">) </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Capital stock issued for cash on March 6,
        2009 - at $2.25 </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>89,148 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>89 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>200,494 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>200,583 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Capital stock issued for consulting services on March 20,
        2009 - at $2.00 </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">2,500 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">3 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">4,997 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">5,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Capital stock issued for cash on March 20,
        2009 - at $2.25 </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>10,800 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>11 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>24,289 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>24,300 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Capital stock issued for cash on June 11, 2009 - at $2.25
      </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">36,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">36 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">80,964 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">81,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Capital stock issued for services on June
        11, 2009 - at $2.25 </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>29,227 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>29 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>65,731 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>65,760 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Capital stock issued for cash on June 19, 2009 - at $2.25
      </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">495,556 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">496 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">1,114,504 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">1,115,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Capital stock issued for finders' fees on
        June 26, 2009 - at $2.51 </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>22,222 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>22 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>55,755 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>55,777 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Shares to be issued for consulting services - Note 8 </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">236,337 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">236,337 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Capital stock issued for cash on August 19,
        2009 - at $2.25 </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>128,888 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>129 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>289,869 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>289,998 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Less: Finders fees </TD>
      <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">(72,850</TD>
      <TD vAlign=bottom align=left width="2%">) </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">(72,850</TD>
      <TD vAlign=bottom align=left width="2%">) </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Beneficial conversion features on convertible
        debt issuances </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>333,056 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>333,056 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Extinguishment of debt - Note 4 </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">487,469 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">487,469 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Cancellation of common shares - Note 6 </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(75,000</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(75</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>234,011 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(233,936</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Share subscriptions received </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">300,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">300,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Net loss for the year </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>(5,499,419</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>) </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>(5,499,419</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" bgColor=#e6efff>) </TD>
    </TR>
    <TR>
      <TD>&nbsp; </TD>
      <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Balance, September 30, 2009 </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>20,746,761 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>20,747 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>8,383,663 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>300,000 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(12,562,233</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(3,857,823</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
    </TR>
  </TABLE>
</DIV>
<P align=center>SEE ACCOMPANYING NOTES </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-9></A>
<P align=center><B>ANAVEX</B><B> </B><B>LIFE SCIENCES</B><B> CORP.</B><BR>(A
Development Stage Company)<BR>CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL
DEFICIT<BR>for the period from January 23, 2004 (Date of Inception) to September
30, 2011<BR><U>(Stated in US Dollars)</U></P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 8pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
    <TR vAlign=top>
      <TD align=left nowrap>&nbsp; </TD>
      <TD width="1%" align=left nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Deficit </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=left nowrap>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left nowrap>&nbsp; </TD>
      <TD
    width="1%" align=left nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD colspan="10" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">
        Common Stock </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Accumulated </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=left nowrap>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left nowrap>&nbsp; </TD>
      <TD width="1%" align=left nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Shares </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Par Value </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Additional </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Common </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>During the </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=left nowrap>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left nowrap>&nbsp; </TD>
      <TD width="1%" align=left nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Paid-in </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Shares to be </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>Development </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="8%" align=center nowrap>&nbsp; </TD>
      <TD width="2%" align=left nowrap>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left nowrap>&nbsp; </TD>
      <TD
    width="1%" align=left nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
      width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp; </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
      width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp; </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
      width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Capital </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
      width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Issued </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Stage      </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD width="8%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Total      </TD>
      <TD
    width="2%" align=left nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    </TR>
    <TR>
      <TD>&nbsp; </TD>
      <TD vAlign=bottom width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="8%">&nbsp; </TD>
      <TD vAlign=bottom width="2%">&nbsp;</TD>
      <TD vAlign=bottom width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="8%">&nbsp; </TD>
      <TD vAlign=bottom width="2%">&nbsp;</TD>
      <TD vAlign=bottom width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="8%">&nbsp; </TD>
      <TD vAlign=bottom width="2%">&nbsp;</TD>
      <TD vAlign=bottom width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="8%">&nbsp; </TD>
      <TD vAlign=bottom width="2%">&nbsp;</TD>
      <TD vAlign=bottom width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="8%">&nbsp; </TD>
      <TD vAlign=bottom width="2%">&nbsp;</TD>
      <TD vAlign=bottom width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="8%">&nbsp; </TD>
      <TD vAlign=bottom width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Balance, September 30, 2009 - brought forward
      </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>20,746,761 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>20,747 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>8,383,663 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>300,000 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(12,562,233</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(3,857,823</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Cumulative effect of accounting changes </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">(333,056</TD>
      <TD vAlign=bottom align=left width="2%">) </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">(550,804</TD>
      <TD vAlign=bottom align=left width="2%">) </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">(883,860</TD>
      <TD vAlign=bottom align=left width="2%">) </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Capital stock issued for cash on October
        2, 2009 - at $2.25 </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>266,666 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>267 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>599,733 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(300,000</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>300,000 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Capital stock issued in settlement of promissory note on
        February 2, 2010 - at $2.02 </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">49,505 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">49 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">99,951 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">100,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Capital stock issued for cash on April 9,
        2010 - at $2.60 </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>92,499 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>93 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>240,405 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>240,498 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Capital stock issued in settlement of debt on April 30, 2010
        - at $2.85 </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">9,825 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">9 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">27,991 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">28,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Finders' fees paid in cash </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(24,050</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(24,050</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Capital stock issued for cash on June 29, 2010 - at $2.50
      </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">941,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">941 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">2,351,559 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">2,352,500 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Finders' fees paid in cash </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(206,500</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(206,500</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Capital stock issued in settlement of debt on July 5, 2010
        - at $2.50 </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">400,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">400 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">999,600 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">1,000,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Capital stock issued for cash on September
        3, 2010 - at $2.75 </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>163,000 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>163 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>448,087 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>448,250 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Capital stock issued for finders' fees on September 3, 2010
        - at $2.75 </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">9,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">9 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">(9</TD>
      <TD vAlign=bottom align=left width="2%">) </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Finders' fees paid in cash </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(15,125</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(15,125</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Shares issud on conversion of promissory note on September
        30, 2010 - at $2.25 </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">328,058 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">328 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">737,802 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">738,130 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Shares issud on conversion of promissory
        note on September 30, 2010 - at $2.35 </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>510,638 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>511 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>1,199,489 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>1,200,000 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Reclassification of dervative liability on modification of
        note terms </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">3,144,520 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">3,144,520 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Settlement of accounts payable - Note 6 </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>444,000 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>444,000 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Stock-based compensation </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">770,055 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">770,055 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Equity component of convertible promissory
        note </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>44,220 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>44,220 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Net loss for the year </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">(8,783,037</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">) </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">(8,783,037</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">) </TD>
    </TR>
    <TR>
      <TD bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom align=right width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Balance, September 30, 2010 </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">23,516,952 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">23,517 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">18,912,335 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">(21,896,074</TD>
      <TD vAlign=bottom align=left width="2%">) </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="8%">(2,960,222</TD>
      <TD vAlign=bottom align=left width="2%">) </TD>
    </TR>
  </TABLE>
</DIV>
<P align=center>SEE ACCOMPANYING NOTES </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-10></A>
<P align=center><B>ANAVEX</B><B> LIFE </B><B>SCIENCES</B><B> CORP.</B><BR>(A
Development Stage Company)<BR>CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL
DEFICIT<BR>for the period from January 23, 2004 (Date of Inception) to September
30, 2011<BR><U>(Stated in US Dollars)</U></P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 8pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
    <TR vAlign=top>
      <TD align=left>&nbsp; </TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=center width="7%">&nbsp; </TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="1%">&nbsp;</TD>
      <TD align=center width="7%">&nbsp; </TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="1%">&nbsp;</TD>
      <TD align=center width="7%">&nbsp; </TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="1%">&nbsp;</TD>
      <TD align=center width="7%">&nbsp; </TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="1%">&nbsp;</TD>
      <TD align=center width="7%">Deficit </TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="1%">&nbsp;</TD>
      <TD align=center width="7%">&nbsp; </TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>&nbsp; </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
      <TD colspan="10" align=center style="BORDER-BOTTOM: #000000 1px solid">
        Common Stock </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="2%">&nbsp;</TD>
      <TD align=center width="1%">&nbsp;</TD>
      <TD align=center width="7%">Accumulated </TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="1%">&nbsp;</TD>
      <TD align=center width="7%">&nbsp; </TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>&nbsp; </TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=center width="7%">Shares </TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="1%">&nbsp;</TD>
      <TD align=center width="7%">Par Value </TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="1%">&nbsp;</TD>
      <TD align=center width="7%">Additional </TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="1%">&nbsp;</TD>
      <TD align=center width="7%">Common </TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="1%">&nbsp;</TD>
      <TD align=center width="7%">During the </TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="1%">&nbsp;</TD>
      <TD align=center width="7%">&nbsp; </TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>&nbsp; </TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=center width="7%">&nbsp; </TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="1%">&nbsp;</TD>
      <TD align=center width="7%">&nbsp; </TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="1%">&nbsp;</TD>
      <TD align=center width="7%">Paid-in </TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="1%">&nbsp;</TD>
      <TD align=center width="7%">Shares to be </TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="1%">&nbsp;</TD>
      <TD align=center width="7%">Development </TD>
      <TD align=center width="2%">&nbsp;</TD>
      <TD align=center width="1%">&nbsp;</TD>
      <TD align=center width="7%">&nbsp; </TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>&nbsp; </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="7%">&nbsp; </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="7%">&nbsp; </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="7%">Capital </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="7%">Issued </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="7%">Stage
      </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="7%">Total
      </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="2%">&nbsp;</TD>
    </TR>
    <TR>
      <TD>&nbsp; </TD>
      <TD vAlign=bottom width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="7%">&nbsp; </TD>
      <TD vAlign=bottom width="2%">&nbsp;</TD>
      <TD vAlign=bottom width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="7%">&nbsp; </TD>
      <TD vAlign=bottom width="2%">&nbsp;</TD>
      <TD vAlign=bottom width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="7%">&nbsp; </TD>
      <TD vAlign=bottom width="2%">&nbsp;</TD>
      <TD vAlign=bottom width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="7%">&nbsp; </TD>
      <TD vAlign=bottom width="2%">&nbsp;</TD>
      <TD vAlign=bottom width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="7%">&nbsp; </TD>
      <TD vAlign=bottom width="2%">&nbsp;</TD>
      <TD vAlign=bottom width="1%">&nbsp;</TD>
      <TD vAlign=bottom width="7%">&nbsp; </TD>
      <TD vAlign=bottom width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD bgColor=#e6efff>Balance, September 30, 2010 - brought forward </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>23,516,952 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>23,517 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>18,912,335 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>(21,896,074</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>(2,960,222</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
    </TR>
    <TR vAlign=top>
      <TD>Capital stock issued for cash on November 18, 2010 - at $2.75 </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">393,846 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">393 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">1,082,682 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">1,083,075 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Less: Share issue costs </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>(65,363</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>(65,363</TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Capital stock issued for finders' fees on November 18, 2010
        - at $2.75 </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">3,636 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">4 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">(4</TD>
      <TD vAlign=bottom align=left width="2%">) </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Shares issued on the conversion of promissory
        note on November 18, 2010 - at $2.25 - Note 5 </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>853,075 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>853 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>1,918,565 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>1,919,418 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Debt conversion expense - Note 5 </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">504,160 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">504,160 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Shares issued on the conversion of a promissory
        note on November 18, 2010 - at $4.12 - Note 5 </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>145,063 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>145 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>597,515 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>597,660 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Capital stock issued in settlement of debt on November 18,
        2010 - at $4.12 </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">181,818 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">182 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">748,908 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">749,090 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Capital stock issued for cash on November
        25, 2010 - at $3.35 </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>29,851 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>30 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>99,970 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>100,000 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Capital stock issued for finders' fees on on November 25,
        2010 - at $3.35 </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">2,985 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">3 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">(3</TD>
      <TD vAlign=bottom align=left width="2%">) </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Capital stock issued for cash on February
        1, 2011 - at $3.75 </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>61,014 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>61 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>228,739 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>228,800 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Capital stock issued for cash on May 3, 2011 - at $3.00 </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">33,334 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">34 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">99,966 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">- </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">100,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Capital stock issued on exercise of warrants
        for cash on June 19, 2011 - at $2.25 </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>700,000 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>700 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>1,574,300 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>1,575,000 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Equity units issued in settlement of an account payable on
        September 28, 2011 - Note 6 </TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">650,000 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">650 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">1,059,313 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="7%"></TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="7%"></TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%">1,059,963 </TD>
      <TD vAlign=bottom align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Stock-based compensation - Note 9 </TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>1,273,162 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>- </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="7%" bgColor=#e6efff>1,273,162 </TD>
      <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Net loss for the period </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="7%">- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="7%">- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="7%">- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="7%">- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="7%">(7,307,147</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">) </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="7%">(7,307,147</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%">) </TD>
    </TR>
    <TR>
      <TD bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom width="7%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom width="7%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom width="7%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom width="7%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom width="7%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom width="7%" bgColor=#e6efff>&nbsp; </TD>
      <TD vAlign=bottom width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Balance, September 30, 2011 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="7%">26,571,574 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%">$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="7%">&nbsp;26,572 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%">$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="7%">&nbsp;28,034,245 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="7%">- </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%">$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="7%">&nbsp;(29,203,221</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%">) </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%">$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="7%">&nbsp;(1,142,404</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%">) </TD>
    </TR>
  </TABLE>
</DIV>
<P align=center>SEE ACCOMPANYING NOTES </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-11></A>
<P align=center><B>ANAVEX LIFE SCIENCES CORP. </B><BR>(A Development Stage
Company) <BR>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <BR>September 30,
2011 and 2010 <BR>
  (<U>Stated in US Dollars</U>) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Note 1 </TD>
    <TD align=left width="90%"><U>Business Description, Basis of Presentation
      and Liquidity</U> </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD align=left width="90%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="90%"><U>Business</U> </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD align=left width="90%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%">
      <P align=justify>Anavex Life Sciences Corp. (&#147;the Company&#148;) is a
      biopharmaceutical company engaged in the discovery and development of
      novel drug targets to treat serious diseases for which there are urgent
      unmet medical needs. The Company&#146;s portfolio involves novel compounds
      (ligands) directed to sigma receptors in preclinical and clinical stages
      of development that target neurodegenerative diseases and cancer. The
      Company&#146;s lead drug candidate, ANAVEX 2-73, targeting Alzheimer&#146;s disease
      (AD), entered first Human Clinical Trials (HCT) in the first quarter of
      fiscal 2011. The Company plans to continue preclinical work on other
      compounds, including backup compounds to ANAVEX 2-73, provided sufficient
      capital is available. Additionally, the Company intends to further develop
      compounds in earlier preclinical phases, and continue to develop and
      expand its SIGMACEPTOR<SUP>TM </SUP>Discovery platform. </P></TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD align=left width="90%">
      <P align=justify></P></TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="90%">
      <P align=justify><U>Basis of Presentation and Liquidity</U> </P></TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD align=left width="90%">
      <P align=justify></P></TD></TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%">
      <P align=justify>These financial statements have been prepared in
      accordance with generally accepted accounting principles in the United
      States of America and the instructions to Form 10-K. </P></TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD align=left width="90%">
      <P align=justify></P></TD></TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%">
      <P align=justify>The financial statements have been prepared on a going
      concern basis, which assumes that the Company will continue to realize its
      assets and discharge its obligations and commitments in the normal course
      of operations. Realization values may be substantially different from
      carrying values as shown and these financial statements do not give effect
      to adjustments that would be necessary to the carrying values and
      classification of assets and liabilities should the Company be unable to
      continue as a going concern. At September 30, 2011, the Company had not
      yet generated any recurring revenue or achieved profitable operations; the
      Company had an accumulated deficit of $29,203,221 since its inception and
      incurred a net loss of $7,307,147 for the year then ended and expects to
      incur further losses in the development of its business, all of which
      casts substantial doubt about the Company&#146;s ability to continue as a going
      concern. The Company&#146;s ability to continue as a going concern is dependent
      upon its ability to generate future profitable operations and/or to obtain
      the necessary financing to meet its obligations and repay its liabilities
      arising from normal business operations when they come due. Management has
      no formal plan in place to address this concern but considers obtaining
      additional funds by equity financing and/or from issuing promissory notes.
      Management expects the Company&#146;s cash requirement over the twelve-month
      period ended September 30, 2012 to be approximately $10,000,000. While the
      Company is expending its best efforts to achieve the above plans, there is
      no assurance that any such activity will generate funds for operations.
      </P></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-12></A>
<P align=justify>Anavex Life Sciences Corp. <BR>(A Development Stage Company)
<BR>Notes to the Consolidated Financial Statements <BR>September 30, 2011 and
2010 <BR>
  (<U>Stated in US Dollars</U>) &#150; Page 2 </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%" ><U>Summary of Significant
      Accounting Policies</U> </TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD>
      <P align=justify><U>Use of Estimates</U></P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>The preparation of financial statements in accordance
      with United States generally accepted accounting principles requires
      management to make estimates and assumptions that affect the reported
      amounts of assets and liabilities at the date of the financial statements
      and the reported amounts of revenue and expenses in the reporting period.
      The Company regularly evaluates estimates and assumptions related to
      deferred income tax asset valuations, asset impairment, conversion
      features embedded in convertible notes payable, derivative valuations,
      stock based compensation and loss contingencies. The Company bases its
      estimates and assumptions on current facts, historical experience and
      various other factors that it believes to be reasonable under the
      circumstances, the results of which form the basis for making judgments
      about the carrying values of assets and liabilities and the accrual of
      costs and expenses that are not readily apparent from other sources. The
      actual results experienced by the Company may differ materially and
      adversely from the Company&#146;s estimates. To the extent there are material
      differences between the estimates and the actual results, future results
      of operations will be affected.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD>
      <P align=justify><U>Principles of Consolidation</U></P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>These consolidated financial statements include the
      accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiary,
      Anavex Life Sciences (France) SA, a company incorporated under the laws of
      France. All inter-company transactions and balances have been
      eliminated.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD>
      <P align=justify><U>Development Stage Company</U></P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>The Company is devoting substantially all of its present
      efforts to establish a new business and none of its planned principal
      operations have commenced. All losses accumulated since inception has been
      considered as part of the Company&#146;s development stage
activities.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">d) </TD>
    <TD>
      <P align=justify><U>Equipment</U></P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>Equipment is recorded at cost and is depreciated at 33%
      per annum on the straight-line basis.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">e) </TD>
    <TD>
      <P align=justify><U>Impairment of Long-Lived Assets</U></P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>The Company reviews the recoverability of its long-lived
      assets whenever events or changes in circumstances indicate that the
      carrying amount of such assets may not be recoverable. The estimated
      future cash flows are based upon, among other things, assumptions about
      future operating performance, and may differ from actual cash flows.
      Long-lived assets evaluated for impairment are grouped with other assets
      to the lowest level for which identifiable cash flows are largely
      independent of the cash flows of other groups of assets and liabilities.
      If the sum of the projected undiscounted cash flows (excluding interest)
      is less than the carrying value of the assets, the assets will be written
      down to the estimated fair value in the period in which the determination
      is made.</P></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-13></A>
<P align=justify>Anavex Life Sciences Corp. <BR>(A Development Stage Company)
<BR>Notes to the Consolidated Financial Statements <BR>September 30, 2011 and
2010 <BR>
  (<U>Stated in US Dollars</U>) &#150; Page 3 </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%" ><U>Summary of Significant
      Accounting Policies </U>&#150; (cont&#146;d) </TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">f) </TD>
    <TD>
      <P align=justify><U>Financial Instruments</U></P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>The carrying value of the Company&#146;s financial
      instruments, consisting of cash and accounts payable and accrued
      liabilities approximate their fair value due to the short-term maturity of
      such instruments. Based on borrowing rates currently available to the
      Company for similar terms and based on the short term duration of the debt
      instruments, the carrying value of the promissory notes payable
      approximate their fair value. Unless otherwise noted, it is management&#146;s
      opinion that the Company is not exposed to significant interest, currency
      or credit risks arising from these financial instruments.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">g) </TD>
    <TD>
      <P align=justify><U>Foreign Currency Translation</U></P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>The functional currency of the Company is the US dollar.
      Monetary items denominated in a foreign currency are translated into US
      dollars at exchange rates prevailing at the balance sheet date and
      non-monetary items are translated at exchange rates prevailing when the
      assets were acquired or obligations incurred. Foreign currency denominated
      expense items are translated at exchange rates prevailing at the
      transaction date. Unrealized gains or losses arising from the translations
      are credited or charged to income in the period in which they
  occur.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">h) </TD>
    <TD>
      <P align=justify><U>Research and Development Expenses</U></P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>Research and developments costs are expensed as incurred.
      These expenses are comprised of the costs of the Company&#146;s proprietary
      research and development efforts, including salaries, facilities costs,
      overhead costs and other related expenses as well as costs incurred in
      connection with third-party collaboration efforts. Milestone payments made
      by the Company to third parties are expensed when the specific milestone
      has been achieved.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>In addition, the Company incurs expenses in respect of
      the acquisition of intellectual property relating to patents and
      trademarks. The probability of success and length of time to developing
      commercial applications of the drugs subject to the acquired patents and
      trademarks is difficult to determine and numerous risks and uncertainties
      exist with respect to the timely completion of the development projects.
      There is no assurance the acquired patents and trademarks will ever be
      successfully commercialized. Due to these risks and uncertainties, the
      acquisition of patents and trademarks does not meet the definition of an
      asset and thus are expensed as incurred.</P></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-14></A>
<P align=justify>Anavex Life Sciences Corp. <BR>(A Development Stage Company)
<BR>Notes to the Consolidated Financial Statements <BR>September 30, 2011 and
2010 <BR>
  (<U>Stated in US Dollars</U>) &#150; Page 4 </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%" ><U>Summary of Significant
      Accounting Policies </U>&#150; (cont&#146;d) </TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">i) </TD>
    <TD>
      <P align=justify><U>Income Taxes</U></P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>The Company has adopted the asset and liability method of
      accounting for income taxes. Under the asset and liability method,
      deferred tax assets and liabilities are recognized for the future tax
      consequences attributable to temporary differences between the financial
      statements carrying amounts of existing assets and liabilities and their
      respective tax bases. Deferred tax assets and liabilities are measured
      using enacted tax rates expected to apply to taxable income in the years
      in which those temporary differences are expected to be recovered or
      settled.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>The Company has adopted the provisions of FASB ASC 740
      "Income Taxes" regarding accounting for uncertainty in income taxes. The
      Company initially recognizes tax positions in the financial statements
      when it is more likely than not the position will be sustained upon
      examination by the tax authorities. Such tax positions are initially and
      subsequently measured as the largest amount of tax benefit that is greater
      than 50% likely of being realized upon ultimate settlement with the tax
      authority assuming full knowledge of the position and all relevant facts.
      Application requires numerous estimates based on available information.
      The Company considers many factors when evaluating and estimating our tax
      positions and tax benefits, and our recognized tax positions and tax
      benefits may not accurately anticipate actual outcomes. As additional
      information is obtained, there may be a need to periodically adjust the
      recognized tax positions and tax benefits. These periodic adjustments may
      have a material impact on the consolidated statements of
  operations.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">j) </TD>
    <TD>
      <P align=justify><U>Basic and Diluted Loss per Share</U></P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>The basic loss per common share is computed by dividing
      net loss available to common stockholders by the weighted average number
      of common shares outstanding. Diluted loss per common share is computed
      similar to basic loss per common share except that the denominator is
      increased to include the number of additional common shares that would
      have been outstanding if the potential common shares had been issued and
      if the additional common shares were dilutive. For the year ended
      September 30, 2011, loss per share excludes 5,080,479(September 30, 2010 &#150;
      5,594,362) potentially dilutive common shares (related to convertible
      notes payable and outstanding options and warrants) as their effect was
      anti-dilutive.</P></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-15></A>
<P align=justify>Anavex Life Sciences Corp. <BR>(A Development Stage Company)
<BR>Notes to the Consolidated Financial Statements <BR>September 30, 2011 and
2010 <BR>(<U>Stated in US Dollars</U>) &#150; Page 5 <BR></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%" ><U>Significant Accounting
      Policies </U>&#150; (cont&#146;d) </TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">k) </TD>
    <TD>
      <P align=justify><U>Stock-based Compensation</U></P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>The Company accounts for all stock-based payments and
      awards under the fair value based method.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>Stock-based payments to non-employees are measured at the
      fair value of the consideration received, or the fair value of the equity
      instruments issued, or liabilities incurred, whichever is more reliably
      measurable. The fair value of stock-based payments to non-employees is
      periodically re-measured until the counterparty performance is complete,
      and any change therein is recognized over the vesting period of the award
      and in the same manner as if the Company had paid cash instead of paying
      with or using equity based instruments. Compensation costs for stock-based
      payments with graded vesting are recognized on a straight-line basis. The
      cost of the stock-based payments to non-employees that are fully vested
      and non-forfeitable as at the grant date is measured and recognized at
      that date, unless there is a contractual term for services in which case
      such compensation would be amortized over the contractual term.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>The Company accounts for the granting of share purchase
      options to employees using the fair value method whereby all awards to
      employees will be recorded at fair value on the date of the grant. The
      fair value of all share purchase options are expensed over their vesting
      period with a corresponding increase to additional paid-in
  capital.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>The Company uses the Black-Scholes option valuation model
      to calculate the fair value of share purchase options at the date of the
      grant. Option pricing models require the input of highly subjective
      assumptions, including the expected price volatility. Changes in these
      assumptions can materially affect the fair value estimates.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">l) </TD>
    <TD>
      <P align=justify><U>Website Costs</U></P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>Direct costs incurred during the application stage of
      development of the Company&#146;s website are capitalized and amortized over
      the estimated useful life. Fees incurred for web site hosting are expensed
      over the period of the benefit. Costs of operating a web site are expensed
      as incurred.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">m) </TD>
    <TD>
      <P align=justify><U>Comprehensive Income (Loss)</U></P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>Comprehensive income (loss) represents the net change in
      stockholders&#146; equity during a period from sources other than transactions
      with stockholders. The Company has not recorded any components of
      comprehensive income (loss) for the years ended September 30, 2011 and
      2010 and, as at September 30, 2011, the Company does not have a balance
      recorded in respect of accumulated comprehensive income
  (loss).</P></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-16></A>
<P align=justify>Anavex Life Sciences Corp. <BR>(A Development Stage Company)
<BR>Notes to the Consolidated Financial Statements <BR>September 30, 2011 and
2010 <BR>
  (<U>Stated in US Dollars</U>) &#150; Page 6 </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%" ><U>Significant Accounting
      Policies </U>&#150; (cont&#146;d) </TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">n) </TD>
    <TD>
      <P align=justify><U>Recent Accounting Pronouncements</U></P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>In October 2009, the FASB issued Accounting Standards
      Update (&#147;ASU&#148;) No. 2009-13, <I>Multiple- Deliverable Revenue
      Arrangements</I>. The new standard changes the requirements for
      establishing separate units of accounting in a multiple element
      arrangement and requires the allocation of arrangement consideration to
      each deliverable based on the relative selling price. The selling price
      for each deliverable is based on vendor-specific objective evidence
      (&#147;VSOE&#148;) if available, third-party evidence if VSOE is not available, or
      estimated selling price if neither VSOE or third-party evidence is
      available. ASU 2009-13 is effective for revenue arrangements entered into
      in fiscal years beginning on or after June 15, 2010. The adoption of this
      standard did not have a material effect on the Company&#146;s consolidated
      financial statements.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>In January 2010, the FASB issued ASU No. 2010-06,
      <I>Improving Disclosures about Fair Value Measurements</I>, which requires
      additional disclosures about the amounts of and reasons for significant
      transfers in and out of Level 1 and Level 2 fair value measurements. This
      standard also clarifies existing disclosure requirements related to the
      level of disaggregation of fair value measurements for each class of
      assets and liabilities and disclosures about inputs and valuation
      techniques used to measure fair value for both recurring and non-recurring
      Level 2 and Level 3 measurements. Since this new accounting standard only
      required additional disclosure, the adoption of the standard in the first
      quarter of 2010 did not impact the Company&#146;s consolidated financial
      statements. Additionally, effective for annual periods beginning after
      December 15, 2010 and interim periods within those fiscal years, this
      standard will require additional disclosure and require an entity to
      present disaggregated information about activity in Level 3 fair value
      measurements on a gross basis, rather than one net
  amount.</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Note 3 </TD>
    <TD align=left width="90%" ><U>Equipment</U>
</TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD align=left >&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="15%">&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="15%">September 30, 2011 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="15%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left >&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="15%">&nbsp; </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%">Accumulated </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left >&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="15%"><U>Cost</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%"><U>Depreciation</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%"><U>Net</U> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD >&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Computer equipment </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>&nbsp;5,631 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>&nbsp;3,197 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>&nbsp;2,434 </TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD align=left >&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="15%">&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="15%">September 30, 2010 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="15%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left >&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="15%">&nbsp; </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%">Accumulated </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left >&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="15%"><U>Cost</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%"><U>Depreciation</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%"><U>Net</U> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD >&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Computer equipment </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>&nbsp;5,631 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>&nbsp;1,540 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>&nbsp;4,091 </TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-17></A>
<P align=justify>Anavex Life Sciences Corp. <BR>(A Development Stage Company)
<BR>Notes to the Consolidated Financial Statements <BR>September 30, 2011 and
2010 <BR>
  (<U>Stated in US Dollars</U>) &#150; Page 7 </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Note 4 </TD>
    <TD align=left width="90%"><U>Derivative Liabilities</U> </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="90%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%">
      <P align=justify>Derivative liabilities, consisting of the embedded
      conversion features in the Company&#146;s convertible promissory notes, are
      accounted for as separate liabilities measured at their respective fair
      values, as follows: </P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=center width="17%"><U>September 30, 2011</U> </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="17%"><U>September 30, 2010</U> </TD>
    <TD align=left width="2%">&nbsp;</TD></TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD>&nbsp; </TD>
    <TD vAlign=bottom width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="17%">&nbsp; </TD>
    <TD vAlign=bottom width="2%">&nbsp;</TD>
    <TD vAlign=bottom width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="17%">&nbsp; </TD>
    <TD vAlign=bottom width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Balance, beginning of the year </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="17%" bgColor=#e6efff>&nbsp;- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="17%" bgColor=#e6efff>&nbsp;2,513,746
    </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD></TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD>&nbsp; </TD>
    <TD vAlign=bottom width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="17%">&nbsp; </TD>
    <TD vAlign=bottom width="2%">&nbsp;</TD>
    <TD vAlign=bottom width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="17%">&nbsp; </TD>
    <TD vAlign=bottom width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Fair value of embedded conversion feature
      of convertible promissory notes </TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%" bgColor=#e6efff>167,500 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>Change in fair value of derivative liability </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%">(100,000</TD>
    <TD vAlign=bottom align=left width="2%">) </TD>
    <TD vAlign=bottom align=left width="1%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="17%">630,774 </TD>
    <TD vAlign=bottom align=left width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Reclassification of derivative liability to
      additional paid- in capital on amendment to terms of promissory note
      payable - Note 5 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="17%" bgColor=#e6efff>- </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="17%" bgColor=#e6efff>(3,144,520</TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>) </TD></TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD>&nbsp; </TD>
    <TD vAlign=bottom width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="17%">&nbsp; </TD>
    <TD vAlign=bottom width="2%">&nbsp;</TD>
    <TD vAlign=bottom width="1%">&nbsp;</TD>
    <TD vAlign=bottom width="17%">&nbsp; </TD>
    <TD vAlign=bottom width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Balance, end of the year </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="17%" bgColor=#e6efff>&nbsp;67,500 </TD>
    <TD vAlign=bottom align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%" bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="17%" bgColor=#e6efff>&nbsp;- </TD>
<TD vAlign=bottom align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD></TR></TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>The fair values of the convertible
promissory notes embedded call options have been determined using the binomial
pricing model using the following weighted average assumptions: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=center
      width="17%">September 30, 2011 </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=center
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=center
      width="17%">September 30, 2010 </TD>
    <TD align=left width="2%">&nbsp;</TD></TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD>&nbsp; </TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp; </TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp; </TD>
    <TD width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Risk-free interest rate </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>0.13% </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>0.42% </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>Expected life of derivative liability </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="17%">0.56 years </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="17%">2 years </TD>
    <TD align=left width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Annualized volatility </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>93.45% </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>68.51% </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>Dividend rate </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="17%">0.00% </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="17%">0.00% </TD>
<TD align=left width="2%">&nbsp;</TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Note 5 </TD>
    <TD align=left width="90%"><U>Promissory Notes Payable</U>
</TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=center width="17%">September 30, </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD align=center width="1%">&nbsp;</TD>
    <TD align=center width="17%">September 30, </TD>
    <TD align=left width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="17%">2011
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="17%">2010
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="2%">&nbsp;</TD></TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD>&nbsp; </TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp; </TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp; </TD>
    <TD width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Convertible non-interest bearing promissory
      notes payable </TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="17%" bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="17%" bgColor=#e6efff>&nbsp;1,919,418 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>Convertible interest bearing promissory notes payable </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="17%">750,000 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="17%">- </TD>
    <TD align=left width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Interest bearing promissory notes payable
    </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>216,000 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>572,890 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>Less: fair value of derivative liabilities on date of
      issuance </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="17%">(167,500</TD>
    <TD align=left width="2%">) </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="17%">(2,489,422</TD>
    <TD align=left width="2%">) </TD></TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Less: equity component of convertible note
    </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>(44,220</TD>
    <TD align=left width="2%" bgColor=#e6efff>) </TD></TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>Add: accumulated accretion </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="17%">69,419 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="17%">2,533,642 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>867,919 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>2,492,308 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>Less: current portion </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="17%">(867,919</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%">) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="17%">(2,492,308</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%">)
</TD></TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="17%"
    bgColor=#e6efff>&nbsp;- </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="17%"
    bgColor=#e6efff>&nbsp;- </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-18></A>
<P align=justify>Anavex Life Sciences Corp. <BR>(A Development Stage Company)
<BR>Notes to the Consolidated Financial Statements <BR>September 30, 2011 and
2010 <BR>
  (<U>Stated in US Dollars</U>) &#150; Page 8 </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Note 5 </TD>
    <TD align=left width="90%" >
      <P align=justify><U>Promissory Notes Payable &#150; (cont&#146;d)</U> </P></TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="90%" >
      <P align=justify> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="90%" >
      <P align=justify><I><U>Convertible non-interest bearing promissory
      notes</U></I> </P></TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="90%" >
      <P align=justify> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" >
      <P align=justify>The convertible non-interest bearing promissory notes
      were due on demand and were convertible into units at $2.25 per unit with
      respect to $100,000 and at $2.50 per unit with respect to $1,819,418. Each
      unit was comprised of one common share and one common share purchase
      warrant exercisable at $3.00 per share for a period of two years from the
      conversion date. </P></TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="90%" >
      <P align=justify> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" >
      <P align=justify>The embedded conversion features included in these
      promissory notes were recorded as separate derivative liability along with
      a corresponding debt discount and were determined to have a cumulative
      fair value of $1,698,631 at their respective issuance dates. During the
      year ended September 30, 2010, the Company recorded an accretion expense
      of $1,202,816 in respect of the debt discount on these notes. </P></TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="90%" >
      <P align=justify> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" >
      <P align=justify>During the year ended September 30, 2010, the Company and
      the respective note-holders agreed to amend the notes by removing certain
      dilutive issuance clauses with the result that, as at September 30, 2010,
      the embedded conversion features were no longer required to be recorded as
      a separate derivative liability. In accordance with the guidance of ASC
      815-15-50-3, &#147;<I>Embedded Conversion Option that Is No Longer</I>
      <I>Bifurcated&#148;, </I>the Company re-measured the fair value of the
      derivative liability associated with the embedded conversion features in
      these notes on the date the notes were amended and determined it to be
      $3,144,520 which was then reclassified from liabilities to additional
      paid-in capital. </P></TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="90%" >
      <P align=justify> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" >
      <P align=justify>During the year ended September 30, 2011, a convertible
      non-interest bearing promissory note in the amount of $100,000 was
      converted to 44,444 units. Each unit consisted of one share of the
      Company&#146;s common stock and one share purchase warrant exercisable at $3.00
      until November 18, 2012. As well, during the year ended September 30,
      2011, the remaining two convertible non-interest bearing promissory notes
      in the amount of $1,819,418 were converted to 808,631 units. Each unit
      consisted of one share of the Company&#146;s common stock and one share
      purchase warrant exercisable at $3.00 until November 18, 2012. The Company
      agreed to convert these notes at $2.25 as an inducement to the note
      holders to convert at that time. As a result of the reduction in the
      conversion price, the Company issued 80,864 more units than it would have
      had it converted the notes at the original conversion price. The Company
      recorded the fair value of the additional units as a debt conversion
      expense of $504,160 using a fair value of $4.12 for the shares based on
      their quoted market price on the date of the conversion and $2.09 for each
      warrant based on their fair value using the Black-Scholes model with the
      following assumptions: stock price - $4.12; strike price - $3.00; expected
      life &#150; 2 years; expected volatility &#150; 78.33%; risk-free discount rate &#150;
      0.52%. </P></TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="90%" >
      <P align=justify> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="90%" >
      <P align=justify><I><U>Convertible interest bearing promissory
      notes</U></I> </P></TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="90%" >
      <P align=justify> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" >
      <P align=justify>The Company issued unsecured convertible interest bearing
      promissory notes totaling $750,000 during the year ended September 30,
      2011. Included in these notes is a promissory note in the amount of
      $250,000 that matures on April 20, 2012 and a note in the amount of
      $500,000 that matures on May 4, 2012. Each of these notes incurs interest
      at 8% per annum. These notes are convertible at any time at the option of
      the holder into units of the Company at $3.00 per unit with each unit
      consisting of one common share and one common share purchase warrant
      entitling the holder thereof to purchase an additional common share for
      $4.00 for a period of 2 years from the date of issuance. Otherwise, the
      notes will automatically be either converted or redeemed should the
      Company undertake equity financing of an amount of or greater than
      $2,000,000 within any consecutive 30 calendar days during the period the
      notes are outstanding. Additionally, by way of an anti-dilution clause,
      the conversion price on the notes will be adjusted if the Company issues
      common shares in excess of 10% of common shares outstanding on the dates
      the notes were issued. </P></TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="90%" >
      <P align=justify> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" >
      <P align=justify>In connection with the issuance of these notes, the
      Company paid a finder&#146;s fee totaling $100,000 which was deferred and is
      being amortized to income using the effective interest method over the
      terms of the notes. As at September 30, 2011, there remains $55,464
      unamortized in respect of this deferred financing charge.
  </P></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-19></A>
<P align=justify>Anavex Life Sciences Corp. <BR>(A Development Stage Company)
<BR>Notes to the Consolidated Financial Statements <BR>September 30, 2011 and
2010 <BR>
  (<U>Stated in US Dollars</U>) &#150; Page 9 </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Note 5 </TD>
    <TD align=left width="90%" ><U>Promissory Notes Payable &#150;
      (cont&#146;d)</U> </TD></TR></TABLE>
<P style="MARGIN-LEFT: 10%" align=justify><I><U>Convertible interest bearing
promissory notes &#150; (cont&#146;d)</U></I><I> </I></P>
<P style="MARGIN-LEFT: 10%" align=justify>Pursuant to the guidance of ASC
815-40, the Company determined that the embedded conversion feature of the notes
failed to meet the &#147;fixed for fixed&#148; criteria contained within the guidance.
Accordingly, the Company bifurcated the embedded conversion features as a
separate derivative liability having a fair value of $167,500 at inception. The
corresponding debt discount is being accreted over the term of the note. During
the year ended September 30, 2011, the Company recorded accretion expense of
$69,419 in respect of this debt discount. During the twelve months ended
September 30, 2010, the Company recorded accretion expense of $634,181 in
respect of convertible interest bearing notes that were converted to equity
units during the year then ended. </P>
<P style="MARGIN-LEFT: 10%" align=justify><I><U>Interest bearing promissory notes</U></I></P>
<P style="MARGIN-LEFT: 10%" align=justify>During the year ended September 30,
2010, the Company issued a promissory note having a principal balance of
$200,000 with terms that included interest at 8% per annum and maturing on May
4, 2011. On May 4, 2011, this note, including accrued interest of $16,000
thereon, was exchanged for a new 8% interest bearing promissory note having a
principal balance of $216,000 maturing May 4, 2012.</P>
<P style="MARGIN-LEFT: 10%" align=justify>During the year ended September 30,
2011, the Company exchanged interest bearing promissory notes totaling $398,922
including accrued interest thereon of $26,032 for 145,063 common shares. Each
common share had a fair value of $4.12 based on its quoted market price on the
day of conversion for a total fair value of $597,660. Therefore, as a result of
this conversion, the Company recorded a loss on debt extinguishment of $198,738.
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Note 6 </TD>
    <TD align=left width="90%" ><U>Capital Stock</U>
  </TD></TR></TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>On May 24, 2006, the board of
directors approved a six (6) for one (1) forward split of the authorized issued
and outstanding common stock. The Company&#146;s authorized capital increased from
25,000,000 shares of common stock to 150,000,000 shares of common stock.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On September 24, 2007, the Company
issued 222,222 common shares common shares at $3.60 per share for a total of
$800,000 for research and development expenses. The common shares were recorded
based upon the quoted market price of the Company&#146;s common stock on the
agreement date. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On September 25, 2007, the Company
settled a loan payable in the amount of $333,000 by issuing 92,500 common shares
at $3.60 per share, being the quoted market price of the Company&#146;s common stock
on the settlement date. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On December 10, 2007, the Company
issued 150,000 units at $3.50 per unit for proceeds of $525,000. Each unit
consisted of one common share and one common share purchase warrant entitling
the holder to purchase an additional common share at $5.00 per share until
December 10, 2009.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On December 18, 2007, the Company
issued 10,000 shares at $4.50 per share for a total of $45,000 pursuant to an
agreement to settle a debt and issued 50,000 shares at $3.86 per share for a
total of $193,000 pursuant to a consulting agreement. The Company recorded
compensation expense of $65,000 in respect of these issuances based on the
excess of the fair value of these shares over the balances at which they were
recorded by the Company. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On May 15, 2008, the Company issued
65,000 common shares at $5.24 per share for a total of $340,600 to its former
CEO in accordance with the terms of a severance agreement upon the termination
of his services. The common shares were recorded based upon the quoted market
price of the Company&#146;s common stock on the agreement date. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-20></A>
<P align=justify>Anavex Life Sciences Corp. <BR>(A Development Stage Company)
<BR>Notes to the Consolidated Financial Statements <BR>September 30, 2011 and
2010 <BR>
  (<U>Stated in US Dollars</U>) &#150; Page 10 </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Note 6 </TD>
    <TD align=left width="90%" ><U>Capital Stock &#150; (cont&#146;d)</U>
    </TD></TR></TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>On August 19, 2008, the Company issued
25,000 common shares at $5.07 per share for a total of $ 126,750 to a director
of the Company pursuant to an agreement to provide consulting services. The
common shares were recorded based upon the quoted market price of the Company&#146;s
common stock on the agreement date. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On August 19, 2008, the Company issued
142,698 units at $4.25 per unit for proceeds of $606,467 pursuant to private
placement agreements. Each unit consisted of one common share and one common
share purchase warrant entitling the holder to purchase an additional common
share at $5.00 per share until August 19, 2009.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On November 20, 2008, the Company
issued 25,000 common shares at $2.63 per share for a total of $65,750 to a
director of the Company pursuant to an agreement to provide consulting services.
The common shares were recorded based upon the quoted market price of the
Company&#146;s common stock on the issuance date.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On February 20, 2009, the Company
issued 25,000 common shares at $2.50 per share for a total of $62,500 to a
director of the Company pursuant to an agreement to provide consulting services.
The common shares were recorded based upon the quoted market price of the
Company&#146;s common stock on the issuance date. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On March 6, 2009, the Company issued
89,148 units at $2.25 per unit for proceeds of $200,583 pursuant to private
placement agreements. Each unit consisted of one common share and one common
share purchase warrant entitling the holder to purchase an additional common
share at $4.00 per share until March 6, 2010. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On March 20, 2009, the Company issued
10,800 units at $2.25 per unit for proceeds of $24,300 pursuant to private
placement agreements. Each unit consisted of one common share and one common
share purchase warrant entitling the holder to purchase an additional common
share at $4.00 per share until March 20, 2010. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On March 20, 2009, the Company issued
2,500 common shares at $2.00 per share for a total of $5,000 to a public
relations consultant pursuant to an agreement to provide consulting services.
The common shares were recorded based upon the quoted market price of the
Company&#146;s common stock on the issuance date. On May 14, 2009, the Company
entered into a revised consulting agreement with a director whereby the
consultant returned 75,000 common shares to the Company for cancellation. The
return of shares was recorded in the same amount at which they were originally
issued.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On June 11, 2009 the Company issued
36,000 units at $2.25 per unit for proceeds of $81,000 pursuant to private
placement agreements. Each unit consisted of one common share and one common
share purchase warrant entitling the holder to purchase an additional common
share at $4.00 per share until June 11, 2010. The Company paid finders&#146; fees in
the amount of $8,100 in relation to this private placement. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On June 11, 2009 the Company issued
29,227 common shares at $2.25 per share for service rendered by consultants. The
common shares were recorded based upon the fair value of the Company&#146;s common
stock on the issuance date of the shares. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On June 19, 2009, the Company issued
495,556 units at $2.25 per Unit for total proceeds of $1,115,000 pursuant to
private placement agreements. Each unit consisted on one common share and one
and one-half of a common share purchase warrant entitling the holder to purchase
additional common shares at $2.25 per share until June 19, 2011. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On June 26, 2009, the Company issued
22,222 common shares at $2.51 per share for finder&#146;s fees related to the
issuance of a $500,000 note payable. The common shares were recorded based upon
the quoted market price of the Company&#146;s common stock on the issue date. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-21></A>
<P align=justify>Anavex Life Sciences Corp. <BR>(A Development Stage Company)
<BR>Notes to the Consolidated Financial Statements <BR>September 30, 2011 and
2010 <BR>
  (<U>Stated in US Dollars</U>) &#150; Page 11 </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Note 6 </TD>
    <TD align=left width="90%" ><U>Capital Stock &#150; (cont&#146;d)</U>
    </TD></TR></TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>On August 19, 2009, the Company issued
128,888 units at $2.25 per Unit for total proceeds of $289,998. Of these
placements, 40,000 Units consisted of one common share and one share purchase
warrant entitling the holder to purchase an additional common share at $4.00 per
share until July 9, 2010 and 88,888 Units consisted on one common share and one
and one-eighth share purchase warrant entitling the holder to purchase an
additional common shares at $2.25 per share until August 4, 2011. The Company
paid finders&#146; fees totalling $19,000 in respect of these private placements.
</P>
<P style="MARGIN-LEFT: 10%" align=justify>On October 2, 2009 the Company issued
266,666 units at $2.25 per unit for proceeds of $600,000 pursuant to private
placement agreement. Each unit consisted of one common share and one and
one-eighth common share purchase warrant entitling the holder to purchase an
additional common share at $2.25 per share until October 2, 2011. The Company
had received $300,000 of this amount in the year ended September 30, 2010. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On February 2, 2010 the Company issued
49,505 common shares of the Company, at their fair value of $2.02 per share
pursuant to an agreement with a former officer to settle an outstanding amount
owed. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On April 9, 2010, the Company issued
92,499 units at $2.60 per unit for proceeds of $240,498 pursuant to private
placement agreement. Each unit consisted of one common share and one-half common
share purchase warrant entitling the holder to purchase an additional common
share at $3.50 per share until April 9, 2011. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On April 30, 2010, the Company issued
9,825 common shares of the Company, at $2.85 per share as consideration for
terminating a consulting agreement and for services rendered under the
agreement. The common shares were recorded based upon the quoted market price of
the Company&#146;s common stock on the date of the termination of the agreement. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On June 29, 2010, the Company issued
941,000 units at $2.50 per unit for total proceeds of $2,352,500 pursuant to
private placement agreements. Each unit consisted on one common share and
one-half of a common share purchase warrant entitling the holder to purchase
additional common shares at $3.50 per share until December 29, 2011. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On July 5, 2010, the Company issued
400,000 units in settlement of $1,000,000 owing to a creditor. Each unit
consisted of one common share and one-half common share purchase warrant
entitling the holder to purchase an additional common share at 3.50 per share
until January 5, 2012. The fair value of the units issued was determined to be
$1,444,000 on the date they were issued and thus the Company recorded a loss on
settlement of accounts payable of $444,000 with a corresponding credit to
additional paid-in capital of the same amount on date of issuance. The fair
value of the shares included in the units was determined with reference to their
quoted market price and the value of the warrants was determined using the
Black-Scholes model with the following assumptions: exercise price - $3.50,
stock price - $3.15, expected volatility &#150; 68.45%, expected life &#150; 1.5 years,
dividend yield &#150; 0.00%. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On September 3, 2010, the Company
issued 163,000 units at $2.75 per unit for proceeds of $448,250 pursuant to
private placement agreement. Each unit consisted of one common share and
one-half common share purchase warrant entitling the holder to purchase an
additional common share at $3.75 per share until March 3, 2012. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On September 3, 2010, the Company
issued 9,000 units at $2.75 per unit for finder&#146;s fees related to the private
placement of the same date. Each unit consisted of one common share and one-half
common share purchase warrant entitling the holder to purchase an additional
common share at $3.75 per share until March 3, 2012. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On September 30, 2010, the Company
issued 510,638 common shares at $2.35 per share pursuant to the terms of a
convertible note payable. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-22></A>
<P align=justify>Anavex Life Sciences Corp. <BR>(A Development Stage Company)
<BR>Notes to the Consolidated Financial Statements <BR>September 30, 2011 and
2010 <BR>
  (<U>Stated in US Dollars</U>) &#150; Page 12 </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Note 6 </TD>
    <TD align=left width="90%" ><U>Capital Stock &#150; (cont&#146;d)</U>
    </TD></TR></TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>On September 30, 2010, the Company
issued 82,310 units at $2.25 per unit pursuant to the terms of convertible notes
payable. Each unit consisted of one common share and one-half common share
purchase warrant entitling the holder to purchase an additional common share at
$3.50 per share until September 30, 2011. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On September 30, 2010, the Company
issued 245,748 units at $2.25 per unit pursuant to the terms of convertible
notes payable. Each unit consisted of one common share and one common share
purchase warrant entitling the holder to purchase an additional common share at
$3.00 per share until September 30, 2012. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On November 18, 2010, the Company
issued 393,846 units at $2.75 per unit for proceeds of $1,083,075 pursuant to a
private placement agreement. Each unit consisted of one common share and
one-half common share purchase warrant entitling the holder to purchase an
additional common share at $4.50 per share until May 18, 2012. The Company paid
a finder&#146;s fee totalling $65,363 in respect of this private placement. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On November 18, 2010, the Company
issued 3,636 units at $2.75 per unit for finder&#146;s fees related to the private
placement of the same date. Each unit consisted of one common share and one-half
common share purchase warrant entitling the holder to purchase an additional
common share at $4.50 per share until May 18, 2012. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On November 18, 2010, the Company
issued 853,075 units in the conversion of two notes payable originally
convertible at $2.50. The Company recorded debt conversion expense of $504,160,
related to the fair value of the additional units issued as a result of
converting at the lower conversion price. Each unit consisted of one common
share and one common share purchase warrant entitling the holder to purchase an
additional common share at $3.00 per share until November 18, 2012. The fair
value of the shares included in the units was determined with reference to their
quoted market price and the value of the warrants was determined using the
Black-Scholes model with the following assumptions: exercise price - $3.00,
stock price - $4.12, expected volatility &#150; 78.33%, expected life &#150; 2.0 years,
dividend yield &#150; 0.00%, risk-free rate &#150; 0.52%. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On November 18, 2010, the Company
issued 145,063 shares of common stock at their fair value of $4.12 per share
based on their quoted market price pursuant to settling non-convertible interest
bearing notes payable outstanding in the amount of $398,922, including accrued
interest of $26,032. The Company recorded a loss on settlement of debt of
$198,738 based on the difference between the carrying value of the debt settled
and the fair value of the shares issued.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On November 18, 2010, the Company
issued 181,818 shares of common stock at their fair value of $4.12 per share
based on the quoted value of units issued in a private placement on the same
date to one creditor in settlement of $500,000 of debt owing. The Company
recorded a loss on settlement of accounts payable of $249,090 based on the
difference of the carrying value of the account payable and the fair value of
the shares issued. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On November 25, 2010, the Company
issued 29,851 units at $3.35 per unit for proceeds of $100,000 pursuant to a
private placement agreement. Each unit consisted of one common share and
one-half common share purchase warrant entitling the holder to purchase an
additional common share at $4.50 per share until November 25, 2012. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On November 25, 2010, the Company
issued 2,985 units at $3.35 per unit for finder&#146;s fees related to the private
placement of the same date. Each unit consisted of one common share and one-half
common share purchase warrant entitling the holder to purchase an additional
common share at $4.50 per share until November 25, 2012. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On February 1, 2011, the Company
issued 61,014 units at $3.75 per unit for proceeds of $228,800 pursuant to a
private placement agreement. Each unit consisted of one common share and
one-half common share purchase warrant entitling the holder to purchase an
additional common share at $5.25 per share until August 1, 2012. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-23></A>
<P align=justify>Anavex Life Sciences Corp. <BR>(A Development Stage Company)
<BR>Notes to the Consolidated Financial Statements <BR>September 30, 2011 and
2010 <BR>
  (<U>Stated in US Dollars</U>) &#150; Page 13 </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Note 6 </TD>
    <TD align=left width="90%" ><U>Capital Stock &#150; (cont&#146;d)</U>
    </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="90%" >&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" >
      <P align=justify>On May 3, 2011, the Company issued 33,334 units at $3.00
      per unit for proceeds of $100,000 pursuant to a private placement
      agreement. Each unit consisted of one common share and one-half common
      share purchase warrant entitling the holder to purchase an additional
      common share at $4.00 per share until April 20, 2013. </P></TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="90%" >
      <P align=justify> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" >
      <P align=justify>On June 19, 2011, the Company issued 700,000 common
      shares at $2.25 per share for proceeds of $1,575,000 pursuant to the
      exercise of warrants. </P></TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="90%" >
      <P align=justify> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" >
      <P align=justify>On September 26, 2011, the Company issued 650,000 units
      in settlement of $975,000 of debt owing. Each unit consisted of one common
      share and one-half common share purchase warrant entitling the holder to
      purchase an additional common share at $2.00 per share until September 26,
      2012. The Company recorded a loss on settlement of account payable in the
      amount of $84,963 based on the fair value of shares being $975,000 at
      their issuance and the fair value of the warrants determined to be
      $84,963. The fair value of the shares included in the units was determined
      with reference to their quoted market price and the value of the warrants
      was determined using the Black-Scholes model with the following
      assumptions: exercise price - $2.00, stock price - $1.50, expected
      volatility &#150; 69%, expected life &#150; 1.0 years, dividend yield &#150; 0.00%,
      risk-free interest rate &#150; 0.10%. </P></TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="90%" >
      <P align=justify> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>Note 7 </TD>
    <TD align=left width="90%" >
      <P align=justify><U>Related Party Transactions</U> </P></TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="90%" >
      <P align=justify> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="90%" >
      <P align=justify>The following amounts have been donated to the Company by
      the directors: </P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp; </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp; </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">January 23, </TD>
    <TD align=center width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp; </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp; </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">2004 (Date of </TD>
    <TD align=center width="2%" ></TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD colspan="4" align=center>Years ended </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">Inception) to </TD>
    <TD align=center width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD colspan="4" align=center>September 30, </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">September 30, </TD>
    <TD align=center width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2010</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2009</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2010</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD>&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Management fees </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>14,625 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>Rent </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">3,750 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Debt forgiven by directors </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>33,666 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD>&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>52,041 </TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>During the year ended September 30,
2011, the Company was charged consulting fees totaling $674,917(2010: $725,310)
by directors, officers and a significant shareholder of the Company. </P>
<P style="MARGIN-LEFT: 10%" align=justify>As at September 30, 2011, included in
accounts payable and accrued liabilities is $20,833 (2010: $9,521) owing to
directors and officers of the Company. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-24></A>
<P align=justify>Anavex Life Sciences Corp. <BR>(A Development Stage Company)
<BR>Notes to the Consolidated Financial Statements <BR>September 30, 2011 and
2010 <BR>
  (<U>Stated in US Dollars</U>) &#150; Page 14 </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Note 8 </TD>
    <TD align=left width="90%" ><U>Income Taxes</U> </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="90%" >&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" >
      <P align=justify>The tax effects of the temporary differences that give
      rise to the Company's estimated deferred tax assets and liabilities are as
      follows: </P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2011</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2010</U> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>34%</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>34%</U> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD>&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Net operating loss carryforwards </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;5,548,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;3,848,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>Research and development tax credits </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">500,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">331,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Foreign exchange </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>15,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>17,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>Intangible asset costs </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">32,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">35,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Valuation allowance for deferred tax assets
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>(6,095,000</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>(4,231,000</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD>&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Net deferred tax assets </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;- </TD>
<TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD></TR></TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>The provision for income taxes differ
from the amount established using the statutory income tax rate as follows: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2011</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2010</U> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Income tax benefit at statutory rate </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;(2,532,000</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;(2,986,000</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>Stock-based compensation </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">433,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">263,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Foreign income taxed at foreign statutory
      rate </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>1,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>4,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>Debt extinguishment </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">181,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">150,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Debt accretion </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>24,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>625,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>Other permanent differences </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">29,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">125,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Change in valuation allowance </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>1,864,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>1,819,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD>&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Deferred income tax recovery </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;- </TD>
<TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD></TR></TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>As of September 30, 2011, the Company
had net operating loss carry-forwards of approximately $16,300,000 available to
offset future taxable income. The carry-forwards will begin expiring in 2027
unless utilized in earlier years. The Company is in arrears in filing its income
tax returns in the United States for years prior to 2008 and the Company has not
filed any income tax returns in France as they are not yet due.</P>
<P style="MARGIN-LEFT: 10%" align=justify>The Company evaluates its valuation
allowance requirements based on projected future operations. When circumstances
change and this causes a change in management&#146;s judgment about the
recoverability of deferred tax assets, the impact of the change on the valuation
allowance is reflected in current income. As management of the Company does not
currently believe that it is more likely than not that the Company will receive
the benefit of this asset, a valuation allowance equal to the deferred tax asset
has been established at both September 30, 2011 and September 30, 2010. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-25></A>
<P align=justify>Anavex Life Sciences Corp. <BR>(A Development Stage Company)
<BR>Notes to the Consolidated Financial Statements <BR>September 30, 2011 and
2010 <BR>
  (<U>Stated in US Dollars</U>) &#150; Page 15 </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Note 8 </TD>
    <TD align=left width="90%" ><U>Income Taxes &#150; (cont&#146;d)</U>
  </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="90%" >&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="90%" >Uncertain Tax Positions </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="90%" >&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" >
      <P align=justify>The Company files income tax returns in the U.S. federal
      jurisdiction, various state and foreign jurisdictions. The Company&#146;s tax
      returns are subject to tax examinations by U.S. federal and state tax
      authorities, or examinations by foreign tax authorities until respective
      statute of limitation. It is subject to tax examinations by tax
      authorities for all taxation years commencing on or after 2004. </P></TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="90%" >
      <P align=justify> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" >
      <P align=justify>Provision has not been made for U.S. or additional
      foreign taxes on undistributed earnings of foreign subsidiaries. Such
      earnings have been and will continue to be reinvested but could become
      subject to additional tax if they were remitted as dividends, or were
      loaned to the Company affiliate. It is not practicable to determine the
      amount of additional tax, if any, that might be payable on the
      undistributed foreign earnings. </P></TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="90%" >&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>Note 9 </TD>
    <TD align=left width="90%" ><U>Commitments</U>
</TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD>
      <P align=justify><U>Share Purchase Warrants</U></P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>A summary of the Company&#146;s share purchase warrants
      outstanding is presented below:</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD width="15%"  >&nbsp;</TD>
    <TD align=left >&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="17%">&nbsp; </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="17%">Weighted Average </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left >&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="17%">Number of Shares </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="17%">Exercise Price </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD></TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD >&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="17%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="17%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Balance, September 30, 2009
    </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>983,448 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="17%" bgColor=#e6efff>&nbsp;2.93 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left >Expired </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="17%">(325,948</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="17%">&nbsp;4.46 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Issued </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="17%"
    bgColor=#e6efff>1,389,651 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="17%"
    bgColor=#e6efff>&nbsp;3.16 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left >Balance, September 30, 2010 </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="17%">2,047,151 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="17%">&nbsp;2.87 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Expired </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>(148,749</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="17%" bgColor=#e6efff>&nbsp;2.64 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left >Exercised </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="17%">(700,000</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="17%">&nbsp;2.25 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Issued </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="17%"
    bgColor=#e6efff>1,457,077 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="17%"
    bgColor=#e6efff>&nbsp;3.07 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left >Balance, September 30, 2011 </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="17%">2,655,479 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="17%">&nbsp;3.16 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-26></A>
<P align=justify>Anavex Life Sciences Corp. <BR>(A Development Stage Company)
<BR>Notes to the Consolidated Financial Statements <BR>September 30, 2011 and
2010 <BR>
  (<U>Stated in US Dollars</U>) &#150; Page 16 </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Note 9 </TD>
    <TD align=left width="90%"><U>Commitments &#150; (cont&#146;d)</U>
</TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD>
      <P align=justify><U>Share Purchase Warrants &#150; (cont&#146;d)</U></P></TD></TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>At September 30, 2011, the Company has 2,655,479
      currently exercisable share purchase warrants outstanding as
    follows:</P></TD></TR></TABLE><BR>
<DIV align=center>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="70%" border=0>

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right>Number </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
    width="5%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="28%">Exercise Price </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="28%">Expiry Date </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=right bgColor=#e6efff>154,999 </TD>
    <TD align=right width="5%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=center width="28%" bgColor=#e6efff>&nbsp;2.25 </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="28%" bgColor=#e6efff>October 2, 2011 </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=right>470,500 </TD>
    <TD align=right width="5%">&nbsp;</TD>
    <TD align=left width="1%">$</TD>
    <TD align=center width="28%">&nbsp;3.50 </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="28%">December 29, 2011 </TD>
    <TD align=left width="1%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=right bgColor=#e6efff>200,000 </TD>
    <TD align=right width="5%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=center width="28%" bgColor=#e6efff>&nbsp;3.50 </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="28%" bgColor=#e6efff>January 5, 2012 </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=right>86,000 </TD>
    <TD align=right width="5%">&nbsp;</TD>
    <TD align=left width="1%">$</TD>
    <TD align=center width="28%">&nbsp;3.75 </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="28%">March 3, 2012 </TD>
    <TD align=left width="1%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=right bgColor=#e6efff>198,741 </TD>
    <TD align=right width="5%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=center width="28%" bgColor=#e6efff>&nbsp;4.50 </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="28%" bgColor=#e6efff>May 18, 2012 </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=right>30,508 </TD>
    <TD align=right width="5%">&nbsp;</TD>
    <TD align=left width="1%">$</TD>
    <TD align=center width="28%">&nbsp;5.25 </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="28%">August 1, 2012 </TD>
    <TD align=left width="1%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=right bgColor=#e6efff>325,000 </TD>
    <TD align=right width="5%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=center width="28%" bgColor=#e6efff>&nbsp;2.00 </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="28%" bgColor=#e6efff>September 26, 2012 </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=right>41,155 </TD>
    <TD align=right width="5%">&nbsp;</TD>
    <TD align=left width="1%">$</TD>
    <TD align=center width="28%">&nbsp;3.50 </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="28%">September 30, 2012 </TD>
    <TD align=left width="1%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=right bgColor=#e6efff>245,748 </TD>
    <TD align=right width="5%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=center width="28%" bgColor=#e6efff>&nbsp;3.00 </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="28%" bgColor=#e6efff>September 30, 2012 </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=right>853,075 </TD>
    <TD align=right width="5%">&nbsp;</TD>
    <TD align=left width="1%">$</TD>
    <TD align=center width="28%">&nbsp;3.00 </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="28%">November 18, 2012 </TD>
    <TD align=left width="1%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=right bgColor=#e6efff>16,419 </TD>
    <TD align=right width="5%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=center width="28%" bgColor=#e6efff>&nbsp;4.50 </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="28%" bgColor=#e6efff>November 25, 2012 </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right>33,334 </TD>
    <TD align=right width="5%">&nbsp;</TD>
    <TD align=left width="1%">$</TD>
    <TD align=center width="28%">&nbsp;4.00 </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="28%">April 20, 2013 </TD>
    <TD align=left width="1%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      bgColor=#e6efff>2,655,479 </TD>
    <TD align=right width="5%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=center width="28%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="28%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="1%"
bgColor=#e6efff>&nbsp;</TD></TR></TABLE></DIV><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>Subsequent to September 30, 2011, the 154,999 warrants
      exercisable at $2.25 until October 2, 2011 expired unexercised.</P></TD></TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD>
      <P align=justify><U>Stock&#150;based Compensation Plan</U></P></TD></TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>In April, 2007, the Company adopted a stock option plan
      which provides for the granting of stock options to selected directors,
      officers, employees or consultants in an aggregate amount of up to
      3,000,000 common shares of the Company and, in any case, the number of
      shares to be issued to any one individual pursuant to the exercise of
      options shall not exceed 10% of the issued and outstanding share capital.
      The granting of stock options, exercise prices and terms are determined by
      the Company's Board of Directors. If no vesting schedule is specified by
      the Board of Directors on the grant of options, then the options shall
      vest over a 4-year period with 25% the granted vesting each year
      commencing 1 year from the grant date. For stockholders who have greater
      than 10% of the outstanding common shares of the Company and who have
      granted options, the exercise price of their options shall not be less
      than 110% of the fair of the stock on grant date. Otherwise, options
      granted shall have an exercise price equal to their fair value on grant
      date.</P></TD></TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>On February 2, 2011, the Company amended and restated the
      2007 stock option plan to increase the number of shares authorized to
      4,000,000.</P></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-27></A>
<P align=justify>Anavex Life Sciences Corp. <BR>(A Development Stage Company)
<BR>Notes to the Consolidated Financial Statements <BR>September 30, 2011 and
2010 <BR>
  (<U>Stated in US Dollars</U>) &#150; Page 17 </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Note 9 </TD>
    <TD align=left width="90%" ><U>Commitments &#150; (cont&#146;d)</U>
  </TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD>
      <P align=justify><U>Stock&#150;based Compensation Plan &#150; (cont&#146;d)</U></P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>A summary of the status of Company&#146;s outstanding stock
      purchase options for the years ended September 30, 2011 and September 30, 2010 is presented
      below:</P></TD></TR></TABLE><BR>
<DIV align=center>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="70%" border=0>

  <TR vAlign=top>
    <TD align=left >&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="17%">&nbsp; </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="17%">Weighted </TD>
    <TD align=center width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="17%">&nbsp; </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="17%">Average </TD>
    <TD align=center width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="17%">Number of Shares </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="17%">Exercise Price </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Outstanding at September 30,
      2009 </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>3,195,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="17%" bgColor=#e6efff>&nbsp;3.37 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left >Cancelled </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="17%">(820,000</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="17%">&nbsp;2.50 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Granted </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="17%"
    bgColor=#e6efff>400,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="17%"
    bgColor=#e6efff>&nbsp;3.48 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left >Outstanding at September 30, 2010 </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="17%">2,775,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="17%">&nbsp;3.29 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Forfeited </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>(1,000,000</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="17%" bgColor=#e6efff>&nbsp;3.93 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left >Cancelled </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="17%">(50,000</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="17%">&nbsp;2.75 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Granted </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="17%"
    bgColor=#e6efff>650,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="17%"
    bgColor=#e6efff>&nbsp;4.06 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left >Outstanding at September 30, 2011 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="17%">2,375,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="17%">&nbsp;3.18 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Exercisable at September 30,
      2011 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="17%"
    bgColor=#e6efff>930,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="17%"
    bgColor=#e6efff>&nbsp;2.90 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left >Exercisable at September 30, 2010 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="17%">1,613,333 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="17%">&nbsp;3.52 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    >&nbsp;</TD></TR></TABLE></DIV>
<P style="MARGIN-LEFT: 10%" align=justify>At September 30, 2011, the following
stock options were outstanding: </P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
    <TR vAlign=top>
      <TD colspan="5" align=center style="BORDER-BOTTOM: #000000 1px solid">Number
        of Shares </TD>
      <TD align=center width="12%">&nbsp; </TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">&nbsp; </TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">&nbsp; </TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">&nbsp; </TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">&nbsp; </TD>
      <TD align=center width="2%" >&nbsp;</TD>
    </TR>
    <TR>
      <TD align=center>&nbsp; </TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="4%"  >&nbsp;</TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">&nbsp; </TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">&nbsp; </TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">&nbsp; </TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">&nbsp; </TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">&nbsp; </TD>
      <TD align=center width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD colspan="4" align=center>Total </TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">Number </TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">Exercise </TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">Expiry Date </TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">Aggregate </TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">Remaining </TD>
      <TD align=center width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center>&nbsp; </TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="4%"  >&nbsp;</TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">Vested </TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">Price </TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">&nbsp; </TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">Intrinsic </TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">Contractual </TD>
      <TD align=center width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center>&nbsp; </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="4%"
     >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="12%">&nbsp; </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="12%">&nbsp; </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="12%">&nbsp; </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="12%">Value </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="12%">Life
        (yrs) </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right></TD>
      <TD align=right width="1%" >&nbsp;</TD>
      <TD align=right width="4%"  >&nbsp;</TD>
      <TD align=right width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff>100,000 </TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="4%"  bgColor=#e6efff
    >(1</TD>
      <TD align=left width="2%"  bgColor=#e6efff>)&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>100,000 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>$</TD>
      <TD align=right width="12%" bgColor=#e6efff>&nbsp;3.75 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>November 1, 2012 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>- </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>1.09 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right></TD>
      <TD align=right width="1%" >&nbsp;</TD>
      <TD align=right width="4%"  >&nbsp;</TD>
      <TD align=right width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff>100,000 </TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="4%"  bgColor=#e6efff
    >(2</TD>
      <TD align=left width="2%"  bgColor=#e6efff>)&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>- </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>$</TD>
      <TD align=right width="12%" bgColor=#e6efff>&nbsp;3.86 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>December 1, 2012 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>- </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>1.17 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right></TD>
      <TD align=right width="1%" >&nbsp;</TD>
      <TD align=right width="4%"  >&nbsp;</TD>
      <TD align=right width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff>300,000 </TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="4%"  bgColor=#e6efff
    >(3</TD>
      <TD align=left width="2%"  bgColor=#e6efff>)&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>300,000 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>$</TD>
      <TD align=right width="12%" bgColor=#e6efff>&nbsp;3.10 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>June 3, 2013 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>- </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>1.68 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right></TD>
      <TD align=right width="1%" >&nbsp;</TD>
      <TD align=right width="4%"  >&nbsp;</TD>
      <TD align=right width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff>400,000 </TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="4%"  bgColor=#e6efff
    >(4</TD>
      <TD align=left width="2%"  bgColor=#e6efff>)&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>400,000 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>$</TD>
      <TD align=right width="12%" bgColor=#e6efff>&nbsp;2.50 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>September 15, 2013 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>- </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>1.96 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right></TD>
      <TD align=right width="1%" >&nbsp;</TD>
      <TD align=right width="4%"  >&nbsp;</TD>
      <TD align=right width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff>500,000 </TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="4%"  bgColor=#e6efff
    >(5</TD>
      <TD align=left width="2%"  bgColor=#e6efff>)&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>- </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>$</TD>
      <TD align=right width="12%" bgColor=#e6efff>&nbsp;2.50 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>October 19, 2013 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>- </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>2.05 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right></TD>
      <TD align=right width="1%" >&nbsp;</TD>
      <TD align=right width="4%"  >&nbsp;</TD>
      <TD align=right width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff>5,000 </TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="4%"  bgColor=#e6efff
    >(6</TD>
      <TD align=left width="2%"  bgColor=#e6efff>)&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>5,000 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>$</TD>
      <TD align=right width="12%" bgColor=#e6efff>&nbsp;2.50 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>March 2, 2014 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>- </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>2.42 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right></TD>
      <TD align=right width="1%" >&nbsp;</TD>
      <TD align=right width="4%"  >&nbsp;</TD>
      <TD align=right width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff>50,000 </TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="4%"  bgColor=#e6efff
    >(7</TD>
      <TD align=left width="2%"  bgColor=#e6efff>)&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>50,000 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>$</TD>
      <TD align=right width="12%" bgColor=#e6efff>&nbsp;3.50 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>June 29, 2015 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>- </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>3.75 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right></TD>
      <TD align=right width="1%" >&nbsp;</TD>
      <TD align=right width="4%"  >&nbsp;</TD>
      <TD align=right width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff>400,000 </TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="4%"  bgColor=#e6efff
    >(8</TD>
      <TD align=left width="2%"  bgColor=#e6efff>)&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>- </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>$</TD>
      <TD align=right width="12%" bgColor=#e6efff>&nbsp;4.28 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>February 1, 2016 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>- </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>4.34 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right></TD>
      <TD align=right width="1%" >&nbsp;</TD>
      <TD align=right width="4%"  >&nbsp;</TD>
      <TD align=right width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff>150,000 </TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="4%"  bgColor=#e6efff
    >(9</TD>
      <TD align=left width="2%"  bgColor=#e6efff>)&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>- </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>$</TD>
      <TD align=right width="12%" bgColor=#e6efff>&nbsp;3.72 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>February 24, 2016 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>- </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>4.41 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right></TD>
      <TD align=right width="1%" >&nbsp;</TD>
      <TD align=right width="4%"  >&nbsp;</TD>
      <TD align=right width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff>100,000 </TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="4%"  bgColor=#e6efff
    >(10</TD>
      <TD align=left width="2%"  bgColor=#e6efff>)&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>75,000 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>$</TD>
      <TD align=right width="12%" bgColor=#e6efff>&nbsp;3.67 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>March 30, 2016 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>- </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>4.50 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right></TD>
      <TD align=right width="1%" >&nbsp;</TD>
      <TD align=right width="4%"  >&nbsp;</TD>
      <TD align=right width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      bgColor=#e6efff>270,000 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="4%"
     bgColor=#e6efff >(11</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>)&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>$</TD>
      <TD align=right width="12%" bgColor=#e6efff>&nbsp;3.00 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>February 8, 2017 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>5.36 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right>2,375,000 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="4%"
     >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">930,000 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%">- </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=left width="12%">&nbsp; </TD>
      <TD align=left width="2%"
>&nbsp;</TD>
    </TR>
  </TABLE>
</DIV><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-28></A>
<P align=justify>Anavex Life Sciences Corp. <BR>(A Development Stage Company)
<BR>Notes to the Consolidated Financial Statements <BR>September 30, 2011 and
2010 <BR>
  (<U>Stated in US Dollars</U>) &#150; Page 18 </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Note 9 </TD>
    <TD align=left width="90%" ><U>Commitments &#150; (cont&#146;d)</U>
  </TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD colSpan=2>
      <P align=justify><U>Stock&#150;based Compensation Plan &#150; (cont&#146;d)</U></P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD colSpan=2>
      <P align=justify>The aggregate intrinsic value is calculated as the
      difference between the exercise price of the underlying awards and the
      quoted market price of the Company&#146;s stock for the options that were in-
      the-money at September 30, 2011.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%"><SUP>(1)</SUP> </TD>
    <TD>
      <P align=justify>As at September 30, 2011 and September 30, 2010, these
      options had fully vested. The Company did not recognize any stock-based
      compensation for these options in the year ended September 30, 2011 (2010:
      $nil).</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%"><SUP>(2)</SUP> </TD>
    <TD>
      <P align=justify>As at September 30, 2011 and September 30, 2010, these
      options have not vested. The options vest upon the Company listing its
      shares on the American Stock Exchange or any other nationally recognized
      stock exchange by December 1, 2012 or in the event of a change of control
      a listing on a nationally recognized stock exchange is not required. No
      stock-based compensation has been recorded in the financial statements as
      the performance condition has not yet been met.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%"><SUP>(3)</SUP> </TD>
    <TD>
      <P align=justify>As at September 30, 2011 and September 30, 2010, these
      options had fully vested. The Company did not recognize any stock-based
      compensation during the year ended September 30, 2011. As a result of
      re-pricing these options on March 26, 2010, the Company recognized
      stock-based compensation of $130,950 during the year ended September 30,
      2010.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%"><SUP>(4)</SUP> </TD>
    <TD>
      <P align=justify>As at September 30, 2011 and September 30, 2010, these
      options had fully vested. The Company did not recognize any stock-based
      compensation for these options during the year ended September 30, 2011
      (2010: $64,268). As a result of extending these options on September 16,
      2011, the Company recognized stock-based compensation of
  $138,411.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%"><SUP>(5)</SUP> </TD>
    <TD>
      <P align=justify>As at September 30, 2011 and September 30, 2010 none of
      these options have vested. The options vest as to 100,000 per compound
      entered into a phase II trial. The fair value of these options was
      calculated to be $740,000, which the Company has not yet recognized in the
      financial statements as the performance conditions have not yet been
      met.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%"><SUP>(6)</SUP> </TD>
    <TD>
      <P align=justify>As at September 30, 2011 and September 30, 2010, these
      options had fully vested. The Company did not recognize any stock-based
      compensation for these options in the year ended September 30, 2011 (2010:
      $nil).</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%"><SUP>(7)</SUP> </TD>
    <TD>
      <P align=justify>As at September 30, 2011 these options had fully vested
      (2010: 25,000). The Company recognized $62,500 as stock-based compensation
      for the year ended September 30, 2011 (2010: $187,500).</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%"><SUP>(8)</SUP> </TD>
    <TD>
      <P align=justify>These options were granted during the year ended
      September 30, 2011, none of these options have vested. The options vest as
      to 100,000 upon completion of the phase I trial, 100,000 upon approval of
      a phase II a trial, 100,000 upon completion of a phase II a trial and
      100,000 upon approval of a phase II trial for ANAVEX 2-73. The fair value
      of these options was calculated to be $860,000, which the Company has not
      yet recognized in the financial statements as the performance conditions
      have not yet been met.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%"><SUP>(9)</SUP> </TD>
    <TD>
      <P align=justify>These options were granted during the year ended
      September 30, 2011, none of these options have vested. The options vest on
      February 24, 2012. The fair value of these options was calculated to be
      $281,000, of which the Company recognized stock-based compensation in the
      amount of $243,084 for the year ended September 30, 2011.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%"><SUP>(10)</SUP> </TD>
    <TD>
      <P align=justify>These options were granted during the year ended
      September 30, 2011 , 75,000 of these options have vested. The remaining
      25,000 options vest on December 31, 2011. The fair value of these options
      was calculated to be $183,000, of which the Company has recognized
      $120,250 as stock based compensation in the year ended September 30,
      2011.</P></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-29></A>
<P align=justify>Anavex Life Sciences Corp. <BR>(A Development Stage Company)
<BR>Notes to the Consolidated Financial Statements <BR>September 30, 2011 and
2010 <BR>
  (<U>Stated in US Dollars</U>) &#150; Page 19 </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Note 9 </TD>
    <TD align=left width="90%" ><U>Commitments &#150; (cont&#146;d)</U>
  </TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD colSpan=2>
      <P align=justify><U>Stock&#150;based Compensation Plan &#150; (cont&#146;d)</U></P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%"><SUP>(11)</SUP> </TD>
    <TD>
      <P align=justify>As at September 30, 2011 and September 30, 2010, these
      options have not vested. The options vest upon one or more compounds:
      entering Phase II trial &#150; 90,000 options; entering Phase III trial &#150;
      90,000 options; and receiving FDA approval &#150; 90,000 options. No
      stock-based compensation has been recorded in the financial statements as
      none of the performance conditions have yet been met.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>During the year ended September 30, 2011, a total of
      1,000,000 options were forfeited for which the Company had recognized
      stock-based compensation of $708,917 (2010: $304,927) in respect of these
      options.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>During the year ended September 30, 2011, a total of
      50,000 options were cancelled for which the Company had recognized
      stock-based compensation of $9,910 for the year ended September 30,
      2010.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>During the year ended September 30, 2010, a total of
      700,000 options were cancelled for which the Company had recognized
      stock-based compensation totalling $72,500.</P></TD></TR></TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>The fair value of stock options
granted has been determined using the Black-Scholes option pricing model using
the following weighted average assumptions applied to stock options granted
during the years: </P>
<DIV align=center>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="60%" border=0>

  <TR vAlign=top>
    <TD align=left >&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="18%">2011
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="18%">2010
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Risk-free interest rate </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="18%" bgColor=#e6efff>0.96% - 2.21% </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="18%" bgColor=#e6efff>0.79% - 2.20% </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left >Expected life of options </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="18%">4.5 - 5.0 years </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="18%">5.0 years </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Annualized volatility </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="18%" bgColor=#e6efff>56.27% - 62.52% </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="18%" bgColor=#e6efff>88.54% - 95.45% </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left >Dividend rate </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="18%">0% </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="18%">0% </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR></TABLE></DIV>
<P style="MARGIN-LEFT: 10%" align=justify>At September 30, 2011, the following
summarizes the unvested stock options: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp; </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp; </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">Weighted </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp; </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">&nbsp; </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">Average </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%">Number of </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">Weighted Average </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%">Grant-Date </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="12%">Shares </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="12%">Exercise Price </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="12%">Fair
      Value </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD>&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Unvested options at September 30, 2009 </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>1,865,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;4.31 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;1.55 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>Cancelled </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">(820,000</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">&nbsp;2.50 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">&nbsp;1.57 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Granted </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>400,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;3.48 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;2.51 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>Vested </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">(283,333</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >) </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">&nbsp;2.90 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">&nbsp;1.82 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD bgColor=#e6efff>&nbsp; </TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>Unvested options at September 30, 2010 </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">1,161,667 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">&nbsp;2.98 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">&nbsp;1.80 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Granted </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>650,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;4.11 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&nbsp;2.06 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>Forfeited </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">(748,334</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">&nbsp;3.45 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">&nbsp;2.51 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Vested </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>(133,333</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>&nbsp;3.63 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>&nbsp;2.00 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>Unvested options at September 30, 2011 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="12%">930,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="12%">&nbsp;3.33 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="12%">&nbsp;1.38 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    >&nbsp;</TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-30></A>
<P align=justify>Anavex Life Sciences Corp. <BR>(A Development Stage Company)
<BR>Notes to the Consolidated Financial Statements <BR>September 30, 2011 and
2010 <BR>
  (<U>Stated in US Dollars</U>) &#150; Page 20 </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Note 9 </TD>
    <TD align=left width="90%" ><U>Commitments &#150; (cont&#146;d)</U>
  </TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD>
      <P align=justify><U>Stock&#150;based Compensation Plan &#150; (cont&#146;d)</U></P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>As at September 30, 2011, there was a total of $50,250 of
      unrecognized compensation cost associated with unvested share-based
      compensation awards that will become vested exclusive of achieving any
      performance milestones that is expected to be recognized in the year ended
      September 30, 2012. There has been no stock-based compensation recognized
      in the financial statements for the year ended September 30, 2011 (2010:
      $nil) for options that will vest upon the achievement of performance
      milestones because the Company has determined that satisfaction of the
      performance milestones was not probable. Compensation relating to stock
      options exercisable upon achieving performance milestones will be
      recognized in the period the milestones are achieved.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>Stock-based compensation amounts, including those
      relating to shares issued for services during the year ended September 30,
      2011 are classified in the Company&#146;s Statement of Operations as
      follows:</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD width="15%"  >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2011</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2010</U> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Consulting fees </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;1,273,162 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&nbsp;770,055 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD colSpan=2>
      <P align=justify><U>Patent and Collaboration Agreement</U></P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD colSpan=2>
      <P align=justify>On February 1, 2007, the Company signed a contract with
      an officer of the Company to acquire property for the development of a new
      drug compound including three patents and one patent application. Pursuant
      to the agreement, the Company agreed to the following:</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">i) </TD>
    <TD>
      <P align=justify>Invest a minimum of $200,000 every fiscal year into
      scientific research and;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">ii) </TD>
    <TD>
      <P align=justify>Hire the officer as a consultant to carry out the
      Company&#146;s Research and Development program at $US6, 000 per month
    and;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">iii) </TD>
    <TD>
      <P align=justify>Pay the officer 6% of the net income earned from the
      exploitation of the patent and patent application; and</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">iv) </TD>
    <TD>
      <P align=justify>Disburse a one-time payment to the officer an amount of
      $72,000 before December 31, 2007 as consideration for the transfer of the
      patents and the patent application. (paid)</P></TD></TR></TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>Effective January 1, 2008, the monthly
salary paid to the director was increased to 7,000 Euros.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-31></A>
<P align=justify>Anavex Life Sciences Corp. <BR>(A Development Stage Company)
<BR>Notes to the Consolidated Financial Statements <BR>September 30, 2011 and
2010 <BR>
  (<U>Stated in US Dollars</U>) &#150; Page 21 </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Note 10 </TD>
    <TD align=left width="90%" >
      <P align=justify><U>Supplemental Cash Flow Information</U> </P></TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%"  >
      <P align=justify>&nbsp;</P></TD></TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" >
      <P align=justify>Investing and financing activities that do not have a
      direct impact on current cash flows are excluded from the statements of
      cash flows. </P></TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" >
      <P align=justify>&nbsp;</P></TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="90%" >
      <P align=justify>During the year ended September 30, 2011:
  </P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD>
      <P align=justify>The Company issued 3,636 units at $2.75 per unit for
      finder&#146;s fees related to the private placement. Each unit consists of one
      common share and one-half common share purchase warrant entitling the
      holder to purchase an additional common share at $4.50 per share until May
      18, 2012.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD>
      <P align=justify>The Company issued 853,075 units in the conversion of two
      notes payable. The Company recorded debt conversion expense of $504,160,
      related to the fair value of the additional units issued based on the
      difference between the fair value of the units issued and the carrying
      value of the debt. Each unit consisted of one common share and one common
      share purchase warrant entitling the holder to purchase an additional
      common share at $3.00 per share until November 18, 2012.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD>
      <P align=justify>The Company issued 145,063 shares of common stock at
      their fair value of $4.12 per share to settle non-convertible interest
      bearing notes payable outstanding in the amount of $398,922, including
      accrued interest of $26,032. The Company recorded a loss on debt
      settlement of $198,738 as a result of this transaction.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">d) </TD>
    <TD>
      <P align=justify>The Company issued 181,818 shares of common stock at
      their fair value of $4.12 per share based on their quoted market price to
      one creditor in settlement of $500,000 of accounts payable. The Company
      recorded a loss on settlement of accounts payable of $249,090 as a result
      of the difference between the carrying value of the account payable and
      the fair value of the shares issued.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">e) </TD>
    <TD>
      <P align=justify>The Company issued 2,985 units at $3.35 per unit for
      finder&#146;s fees related to the private placement of the same date. Each unit
      consisted of one common share and one-half common share purchase warrant
      entitling the holder to purchase an additional common share at $4.50 per
      share until November 25, 2012.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD >&nbsp;</TD>
    <TD vAlign=top>f) </TD>
    <TD>On September 26, 2011, the Company issued 650,000 units
      having a fair value of $1,059,963 to settle an account payable totalling
      $975,000 and thus recorded a loss of $84,963 on the settlement of account
    payable.</TD>
  </TR>
  <TR>
    <TD >&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">g)</TD>
    <TD><P align=justify>The Company issued an 8% interest bearing promissory note having a  principal balance of $216,000 in exchange for a promissory note that had a principal  balance of $200,000 with accrued interest of $16,000 thereon.</P></TD></TR></TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-32></A>
<P align=justify>Anavex Life Sciences Corp. <BR>(A Development Stage Company)
<BR>Notes to the Consolidated Financial Statements <BR>September 30, 2011 and
2010 <BR>
  (<U>Stated in US Dollars</U>) &#150; Page 22 </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Note 10 </TD>
    <TD align=left width="90%" ><U>Supplemental Cash Flow
      Information &#150; (cont&#146;d)</U> </TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="90%" >During the year ended September
      30, 2010, the Company: </TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD>
      <P align=justify>issued 49,505 common shares at $2.20 per share in
      settlement of a promissory note to a former officer of the Company for a
      total of $100,000.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD>
      <P align=justify>issued 9,825 common shares at $2.85 per share for a total
      of $28,000 as consideration for amounts owing in respect of consulting
      services which was included in accounts payable as at September 30,
      2009.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD>
      <P align=justify>issued 400,000 units at $2.50 per unit for a total of
      $1,000,000 as consideration for amounts owing for services rendered in
      prior years. Each unit consisted of one common share and one-half common
      share purchase warrant entitling the holder to purchase an additional
      common share at 3.50 per share until January 5, 2012. The fair value of
      the units issued was determined to be $1,444,000 on the date they were
      issued and thus the Company recorded a loss on settlement of accounts
      payable of $444,000 with a corresponding credit to additional paid-in
      capital of the same amount on date of issuance.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">d) </TD>
    <TD>
      <P align=justify>issued 9,000 common shares at $2.75 per share for a total
      of $24,750 as consideration for finders&#146; fees associated with a private
      placement.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">e) </TD>
    <TD>
      <P align=justify>issued 328,058 common shares at $2.25 per share upon
      conversion of promissory notes in the amount of $738,130, including
      accrued interest of $70,130.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">f) </TD>
    <TD>
      <P align=justify>issued 510,638 common shares at $2.35 per share upon
      settlement of a promissory note in the amount of $1, 200,000 including
      accrued interest of $200,000.</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Note 11 </TD>
    <TD align=left width="90%" ><U>Subsequent Events</U> </TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="90%" >Subsequent to September 30, 2011,
      the Company: </TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD>
      <P align=justify>issued an interest bearing promissory note totaling
      $250,000. The note bears interest at 8% and matures January 30,
    2012.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD>
      <P align=justify>issued 615,600 units at $1.25 for a total of $769,500.
      Each unit consisted of one common share and one-half common share purchase
      warrant. Each whole warrant entitles the holder to purchase an additional
      share at $2.00 for a period of one year from the date of closing. The
      Company paid a cash finders&#146; fee in the amount of
  $57,000.</P></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_41></A>
<P align=center>37</P>
<P align=justify><B>ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
ACCOUNTING AND FINANCIAL MATTERS </B></P>
<P align=justify>None</P>
<P align=justify><B>ITEM 9A. CONTROLS AND PROCEDURES</B></P>
<P align=justify><B><I>Disclosure Controls and Procedures</I></B></P>
<P align=justify>As required by Rule 13a-15 under the Securities Exchange Act of
1934, our management, with the participation of our principal executive officer
and principal financial officer, evaluated our disclosure controls and
procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934)
as of the end of the period covered by this annual report.</P>
<P align=justify>Disclosure controls and procedures are controls and other
procedures that are designed to ensure that information required to be disclosed
in our reports filed or submitted under the Securities Exchange Act of 1934 is
recorded, processed, summarized and reported, within the time periods specified
in the Securities and Exchange Commission&#146;s rules and forms. Disclosure controls
and procedures include controls and procedures designed to ensure that
information required to be disclosed in our reports filed under the Securities
Exchange Act of 1934 is accumulated and communicated to our principal executive
officer and principal financial officer to allow timely decisions regarding
required disclosure. </P>
<P align=justify>Based on its evaluation, our management, with the participation
of our principal executive officer and principal financial officer concluded
that as of the end of the period covered by this annual report, our disclosure
controls and procedures were not effective. The ineffectiveness of our
disclosure controls and procedures was due to material weaknesses described
below. </P>
<P align=justify><B><I>Management&#146;s Annual Report on Internal Control over
Financial Reporting </I></B></P>
<P align=justify>Management is responsible for establishing and maintaining
adequate internal control over our financial reporting, as such term is defined
in Rule 13a-15(f) under the Securities Exchange Act of 1934. Our management
evaluated, under the supervision and with the participation of our principal
executive officer and principal financial officer, the effectiveness of our
internal control over financial reporting as of September 30, 2011. </P>
<P align=justify>Based on its evaluation under the framework in Internal
Control&#151;Integrated Framework, issued by the Committee of Sponsoring
Organizations of the Treadway Commission, our management, with the participation
of our principal executive officer and principal financial officer concluded
that our internal control over financial reporting was not effective as of
September 30, 2011. The ineffectiveness of our internal control over financial
reporting was due to the existence of significant deficiencies constituting
material weaknesses, as described in greater detail below. A material weakness
is a control deficiency, or combination of control deficiencies, such that there
is a reasonable possibility that a material misstatement of the annual or
interim financial statements will not be prevented or detected on a timely
basis. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_42></A>
<P align=center>38</P>
<P align=justify><I>Material Weaknesses Identified</I></P>
<P align=justify>Based on our management&#146;s evaluation required by Rule 13a-15 of
the Securities Exchange Act of 1934, certain significant deficiencies in
internal control became evident to management that our management believes
represent material weaknesses, including:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(i) </TD>
    <TD>
      <P align=justify>Insufficient segregation of duties in our finance and
      accounting functions due to limited personnel. During the fiscal year
      ended September 30, 2011, we had limited staff that performed nearly all
      aspects of our financial reporting process, including, but not limited to,
      access to the underlying accounting records and systems, the ability to
      post and record journal entries and responsibility for the preparation of
      the financial statements. This creates certain incompatible duties and a
      lack of review over the financial reporting process that would likely
      result in a failure to detect errors in spreadsheets, calculations, or
      assumptions used to compile the financial statements and related
      disclosures as filed with the Securities and Exchange Commission. These
      control deficiencies could result in a material misstatement to our
      interim or annual financial statements that would not be prevented or
      detected;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(ii) </TD>
    <TD>
      <P align=justify>There has been a lack of sufficient supervision and
      review by our management;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(iii) </TD>
    <TD>
      <P align=justify>Insufficient corporate governance policies. Although we
      have a code of ethics which provides broad guidelines for corporate
      governance, our corporate governance activities and processes have not
      always been formally documented; and</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(iv) </TD>
    <TD>
      <P align=justify>Our company&#146;s accounting staff has not had sufficient
      technical accounting knowledge relating to accounting for income taxes and
      complex US GAAP matters. Management was advised of certain material errors
      related to the calculation of stock-based compensation, certain of our
      financial instruments and incorrect postings of debt and equity issuance
      costs by our external auditors and corrected these items prior to the
      release of our company&#146;s September 30, 2011 financial
  statements.</P></TD></TR></TABLE>
<P align=justify><I>Plan for Remediation of Material Weaknesses</I></P>
<P align=justify>We intend to take appropriate and reasonable steps to make the
necessary improvements to remediate these deficiencies. We intend to consider
the results of our remediation efforts and related testing as part of our
year-end 2012 assessment of the effectiveness of our internal control over
financial reporting. </P>
<P align=justify>In our fiscal year ended September 30, 2012, we intend to hire
accounting staff that possess the requisite knowledge of accounting for complex
US GAAP matters. </P>
<P align=justify>Due to our size and nature, segregation of all conflicting
duties has not always been possible and may not be economically feasible.
However, we are in the process of implementing new processes and procedures that
will mitigate any material weaknesses identified,</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_43></A>
<P align=center>39</P>
<P align=justify>We believe that the foregoing steps will remediate the
deficiencies identified above, and we intend to continue to monitor the
effectiveness of these steps and make any changes that our management deems
appropriate. </P>
<P align=justify><I>Limitations on Effectiveness of Controls</I></P>
<P align=justify>Our principal executive officer and principal financial officer
do not expect that our disclosure controls and procedures or our internal
control over financial reporting will prevent all errors and all fraud. A
control system, no matter how well conceived and operated, can provide only
reasonable, not absolute, assurance that the objectives of the control system
are met. Further, the design of a control system must reflect the fact that
there are resource constraints, and the benefits of controls must be considered
relative to their costs. Because of the inherent limitations in all control
systems, no evaluation of controls can provide absolute assurance that all
control issues and instances of fraud, if any, within our company have been
detected. These inherent limitations include the realities that judgments in
decision-making can be faulty, and that breakdowns can occur because of a simple
error or mistake. Additional controls can be circumvented by the individual acts
of some persons, by collusion of two or more people, or by management override
of the controls. The design of any system of controls also is based in part upon
certain assumptions about the likelihood of future events, and there can be no
assurance that any design will succeed in achieving its stated goals under all
potential future conditions; over time, controls may become inadequate because
of changes in conditions, or the degree of compliance with the policies or
procedures may deteriorate. Because of the inherent limitations in a
cost-effective control system, misstatements due to error or fraud may occur and
not be detected. </P>
<P align=justify><B><I>Changes in Internal Control over Financial
Reporting</I></B></P>
<P align=justify>There were no changes in our internal control over financial
reporting during the fourth quarter ended September 30, 2011 that have
materially affected, or are reasonably likely to materially affect our internal
control over financial reporting. </P>
<P align=justify><B>ITEM 9B OTHER INFORMATION</B></P>
<P align=justify>None.</P>
<P align=center><B>PART III</B></P>
<P align=justify><B>ITEM 10 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE
GOVERNANCE</B></P>
<P align=justify><B><I>Directors and Executive Officers</I></B></P>
<P align=justify>Our directors are to be elected at our annual meeting and each
director elected is to hold office until his or her successor is elected and
qualified. Our board of directors may remove our officers at any time. </P>
<P align=justify>Our directors and executive officers, their age, positions
held, and duration of such, are as follows: </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_44></A>
<P align=center>40 </P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>
    <TR vAlign=top bgcolor="#EEEEEE">
      <TD align=center><BR>
        <B>Name</B> </TD>
      <TD width="45%" align=center ><BR>
        <B>Position Held with Our
      Company</B> </TD>
      <TD width="5%" align=center ><BR>
        <B>Age</B> </TD>
      <TD width="26%" align=center><B>Date First Elected</B> <BR>
        <B>or
      Appointed</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left>Harvey Lalach </TD>
    <TD align=left width="45%" >President, Chief Operating
      Officer, Secretary, Interim Chief Financial Officer and Director </TD>
    <TD align=center width="5%" >46 </TD>
    <TD align=center width="26%">April 25, 2006 </TD></TR>
  <TR vAlign=top>
    <TD align=left>Sean Lowry </TD>
    <TD align=left width="45%" >Director </TD>
    <TD align=center width="5%" >39 </TD>
    <TD align=center width="26%">February 24, 2011 </TD></TR>
  <TR vAlign=top>
    <TD align=left>Robert Chisholm </TD>
    <TD align=left width="45%" >Director </TD>
    <TD align=center width="5%" >49 </TD>
    <TD align=center width="26%">May 13, 2011 </TD></TR>
  <TR vAlign=top>
    <TD align=left>George Tidmarsh </TD>
    <TD align=left width="45%" >Executive Director </TD>
    <TD align=center width="5%" >51 </TD>
    <TD align=center width="26%">October 10, 2011 </TD></TR></TABLE></DIV>
<P align=justify><I>Business Experience</I></P>
<P align=justify>The following is a brief account of the education and business
experience of directors and executive officers during at least the past five
years, indicating their principal occupation during the period, and the name and
principal business of the organization by which they were employed.</P>
<P align=justify><U>Harvey Lalach</U> </P>
<P align=justify>For the past 25 years Mr. Lalach has been involved in various
aspects of the securities industry. From 1986 through to 1997 he was involved in
various roles in financial institutions starting at the Vancouver Stock Exchange
and later working in securities related roles for BMO Nesbitt Burns and TD Bank
and for the past 10 years Mr. Lalach has focused on the operation and
administration of numerous start-up US and Canadian public companies serving as
both director and officer in various capacities. Most recently Mr. Lalach served
as President and CEO for Assure Energy, Inc. (OTCBB: ASUR) and Quarry Oil &amp;
Gas Corp. (TSXV: QUC). Throughout his career, Mr. Lalach has gained extensive
experience in the management and governance of listed public companies. </P>
<P align=justify>We believe Mr. Lalach is qualified to serve on our board of
directors because of his knowledge of our company&#146;s history and current
operations, which he gained from serving as our officer and director since April
25, 2006, in addition to his business experiences described above. </P>
<P align=justify><U>Sean Lowry</U> </P>
<P align=justify>Since 2001, Mr. Lowry has been president of Wm. Lowry Consulting,
  a management consulting company. He has been a partner and portfolio manager
  in Gulfstream Ventures, a venture capital firm, since 2006. Mr. Lowry has served
  as an officer and director of several private companies as well as director
  of investor relations for Workbrain Inc. (TSX:WB) between 2004 and 2006. </P>
<P align=justify>We believe Mr. Lowry is qualified to serve on our board of directors
  because of his knowledge of our company&#146;s history and current operations,
  which he gained from serving as our director since February 24, 2011, in addition
  to his business experiences described above.</P>
<P align=justify><U>Robert Chisholm</U> </P>
<P align=justify>Mr. Chisholm is currently an officer and partner of Emprise
Capital Corp, a private company focused on advising portfolio companies on
managing finances, including development and implementation of comprehensive
budgeting processes, public market listings and oversight of contract
negotiations. Mr. Chisholm has been the Chief Financial Officer and a director
of Savary Capital Corp. since March 2011 and Windamere Ventures Ltd. (formerly
Advanced Vision Systems Corp.) since May 2010. Mr. Chisholm is also a
member of the Board of Directors for Rare Earth Industries Limited (formerly
Seymour Ventures Corp.) and Chief Financial Officer of TMT Resources Inc. Mr.
Chisholm served as CFO for PNI Digital Media (formerly PhotoChannel Networks
Inc.) between September 2001 and March 2009 and joined PNI's Board of Directors
in April 2009. Prior to 2001, Mr. Chisholm was CFO for SCS Solars Computing
Systems Inc. In addition, Mr. Chisholm&#146;s background includes previous
appointments as CFO and a director of Brookwater Ventures Inc. and Ocean Park
Ventures Corp. and CFO of Chantrell Ventures Corp. (formerly Tiger Pacific
Mining Corp.). Mr. Chisholm holds a professional accounting designation from the
Certified Management Accountants of Canada and received his BBA with a major in
accounting from Saint Francis Xavier University in Nova Scotia. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_45></A>
<P align=center>41</P>
<P align=justify>We believe Mr. Chisholm is qualified to serve on our board of
directors because of his knowledge of our company&#146;s history and current
operations, which he gained from serving as our director since May 13, 2011, in
addition to his business experiences described above. </P>
<P align=justify><U>George Tidmarsh</U></P>
<P align=justify>Dr. Tidmarsh is also a consultant for biopharmaceutical
companies and is currently working with Citizen&#146;s Oncology Foundation and Solana
Therapeutics among others. He has also founded several successful companies
including Horizon Therapeutics (now Horizon Pharma) (NASDAQ: HZNP). From 2005
through 2008 Dr. Tidmarsh served as Horizon&#146;s Chief Executive Officer,
successfully completing four Phase I and two large Phase III trials, including
the registration trials for Duexa. Prior to Horizon, Dr. Tidmarsh founded
Threshold Pharmaceuticals (NASDAQ: THLD) where he served as the company&#146;s
President and as a Director from 2001 to 2006. Most recently, Dr. Tidmarsh
served as Chief Scientific Officer at Spectrum Pharmaceuticals as a part of
their acquisition of Metronome Therapeutics, a novel cancer drug development
company that Dr. Tidmarsh founded in 2007. In addition, Dr. Tidmarsh&#146;s
background includes various positions at Coulter Pharmaceuticals, including
Chief Medical Officer, and SEQQUS where he played a key role in the approval of
Doxil. He has also held scientific and clinical positions at Gilead Sciences and
SyStemix. </P>
<P align=justify>Dr. Tidmarsh has published 25 peer-reviewed articles in leading
journals and authored 15 U.S. patents. He received his Bachelor of Science,
M.D., and Ph.D. from Stanford University, where he also completed Residency and
Fellowship training. In addition, Dr. Tidmarsh is currently an Associate
Professor of Pediatrics and Neonatology at Stanford University School of
Medicine. </P>
<P align=justify>We believe Mr. Tidmarsh is qualified to serve on our board of
directors because of his knowledge of our company&#146;s history and current
operations, which he gained from serving as our director since October 10, 2011,
in addition to his business experiences described above. </P>
<P align=justify><B><I>Family Relationships</I></B></P>
<P align=justify>There are no family relationships between any director or
executive officer.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_46></A>
<P align=center>42</P>
<P align=justify><B><I>Involvement in Certain Legal Proceedings</I></B></P>
<P align=justify>There are no material proceedings to which any director or
executive officer or any associate of any such director or officer is a party
adverse to our company or has a material interest adverse to our company. </P>
<P align=justify>No director or executive officer has been involved in any of
the following events during the past ten years: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">1. </TD>
    <TD>
      <P align=justify>any bankruptcy petition filed by or against any business
      of which such person was a general partner or executive officer either at
      the time of the bankruptcy or within two years prior to that
  time;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">2. </TD>
    <TD>
      <P align=justify>any conviction in a criminal proceeding or being subject
      to a pending criminal proceeding (excluding traffic violations and other
      minor offences);</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">3. </TD>
    <TD>
      <P align=justify>being subject to any order, judgment, or decree, not
      subsequently reversed, suspended or vacated, of any court of competent
      jurisdiction, permanently or temporarily enjoining, barring, suspending or
      otherwise limiting his involvement in any type of business, securities or
      banking activities;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">4. </TD>
    <TD>
      <P align=justify>being found by a court of competent jurisdiction (in a
      civil action), the Securities and Exchange Commission or the Commodity
      Futures Trading Commission to have violated a federal or state securities
      or commodities law, and the judgment has not been reversed, suspended, or
      vacated;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">5. </TD>
    <TD>
      <P align=justify>being the subject of, or a party to, any federal or state
      judicial or administrative order, judgment, decree, or finding, not
      subsequently reversed, suspended or vacated, relating to an alleged
      violation of: (i) any federal or state securities or commodities law or
      regulation; or (ii) any law or regulation respecting financial
      institutions or insurance companies including, but not limited to, a
      temporary or permanent injunction, order of disgorgement or restitution,
      civil money penalty or temporary or permanent cease- and- desist order, or
      removal or prohibition order; or (iii) any law or regulation prohibiting
      mail or wire fraud or fraud in connection with any business entity;
    or</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">6. </TD>
    <TD>
      <P align=justify>being the subject of, or a party to, any sanction or
      order, not subsequently reversed, suspended or vacated, of any
      self-regulatory organization (as defined in Section 3(a)(26) of the
      Securities Exchange Act of 1934), any registered entity (as defined in
      Section 1(a)(29) of the Commodity Exchange Act), or any equivalent
      exchange, association, entity or organization that has disciplinary
      authority over its members or persons associated with a
  member.</P></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_47></A>
<P align=center>43</P>
<P align=justify><B><I>Compliance with Section 16(a) of the Securities Exchange
Act of 1934 </I></B></P>
<P align=justify>Section 16(a) of the Securities Exchange Act of 1934 requires
our executive officers and directors and persons who own more than 10% of our
common stock to file with the Securities and Exchange Commission initial
statements of beneficial ownership, reports of changes in ownership and annual
reports concerning their ownership of our common stock and other equity
securities, on Forms 3, 4 and 5 respectively. Executive officers, directors and
greater than 10% shareholders are required by the Securities and Exchange
Commission regulations to furnish us with copies of all Section 16(a) reports
that they file. </P>
<P align=justify>Based solely on our review of the copies of such forms received
by us, or written representations from certain reporting persons, we believe
that during fiscal year ended September 30, 2011, all filing requirements
applicable to our officers, directors and greater than 10% percent beneficial
owners were complied with the exception of the following:</P>
<DIV align=center>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="90%" border=1>

  <TR vAlign=top>
    <TD align=center><BR><BR>Name </TD>
    <TD align=center width="25%"><BR>Number of <BR>Late Reports </TD>
    <TD align=center width="25%">Number of Transactions <BR>Not Reported on a
      Timely <BR>Basis </TD>
    <TD align=center width="25%"><BR>Failure to File <BR>Required Forms </TD></TR>
  <TR vAlign=top>
    <TD align=left>Harvey Lalach </TD>
    <TD align=center width="25%">2 </TD>
    <TD align=center width="25%">6 </TD>
    <TD align=center width="25%">Nil </TD></TR>
  <TR vAlign=top>
    <TD align=left>Robert Chisholm </TD>
    <TD align=center width="25%">1 </TD>
    <TD align=center width="25%">1 </TD>
    <TD align=center width="25%">Nil </TD></TR></TABLE></DIV>
<P align=justify><B><I>Code of Ethics</I></B></P>
<P align=justify>We have adopted a code of ethics that applies to our principal
executive officer, principal financial officer, principal accounting officer or
controller, or persons performing similar functions. We undertake herewith to
provide by mail to any person without charge, upon request, a copy of such code
of ethics if we receive the request in writing by mail to Anavex Life Sciences
Corp., 45 Tintern Lane, Portola Valley, California 84028, Attention: President.
</P>
<P align=justify><B><I>Audit Committee and Audit Committee Financial Experts
</I></B></P>
<P align=justify>We have an audit committee, comprised of three directors,
Harvey Lalach, Robert Chisholm, and Sean Lowry. During the fiscal year ended
September 30, 2011, our audit committee held one meeting. The audit committee
represents our board of directors in discharging its responsibility relating to
the accounting, reporting and financial practices of our company, and has
general responsibility for oversight of internal controls, accounting and audit
activities and legal compliance of our company. However, the audit committee&#146;s
function is one of oversight only and does not relieve our management of its
responsibilities for preparing financial statements which accurately and fairly
present our financial results and conditions or the responsibilities of the
independent registered public accounting firm relating to the audit or review of
financial statements.</P>
<P align=justify>Sean Lowry, and Robert Chisholm are each considered an &#147;audit
  committee financial expert&#148; as defined in Item 407(d)(5)(ii) of Regulation
  S-K. Sean Lowry is Chairman of the audit committee. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_48></A>
<P align=center>44</P>
<P align=justify><B><I>Nominating and Compensation Committees</I></B></P>
<P align=justify>We do not have standing nominating or compensation committees,
or committees performing similar functions. Our board of directors believes that
it is not necessary to have a standing compensation committee at this time
because the functions of such committee are adequately performed by our board of
directors. Our board of directors has not adopted a charter for the compensation
committee. </P>
<P align=justify>Our board of directors also is of the view that it is
appropriate for us not to have a standing nominating committee because our board
of directors has performed and is expected to perform adequately the functions
of a nominating committee. Our board of directors has not adopted a charter for
the nominating committee. There has not been any defined policy or procedure
requirements for stockholders to submit recommendations or nomination for
directors. Our board of directors does not believe that a defined policy with
regard to the consideration of candidates recommended by stockholders is
necessary at this time because we believe that, at this stage of our
development, a specific nominating policy would be premature and of little
assistance until our business operations are at a more advanced level. There are
no specific, minimum qualifications that our board of directors believes must be
met by a candidate recommended by our board of directors. The process of
identifying and evaluating nominees for director typically begins with our board
of directors soliciting professional firms with whom we have an existing
business relationship, such as law firms, accounting firms or financial advisory
firms, for suitable candidates to serve as directors. It is followed by our
board of directors&#146; review of the candidates&#146; resumes and interview of
candidates. Based on the information gathered, our board of directors then makes
a decision on whether to recommend the candidates as nominees for director. We
do not pay any fee to any third party or parties to identify or evaluate or
assist in identifying or evaluating potential nominee. </P>
<P align=justify><B>ITEM 11. EXECUTIVE COMPENSATION</B></P>
<P align=justify><B><I>Summary Compensation </I></B></P>
<P align=justify>The particulars of compensation paid to the following
persons:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>our principal executive officers;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>each of our two most highly compensated executive
      officers who were serving as executive officers at the end of the fiscal
      year ended September 30, 2011 who had total compensation exceeding
      $100,000; and</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(c) </TD>
    <TD>
      <P align=justify>up to two additional individuals for whom disclosure
      would have been provided under (b) but for the fact that the individual
      was not serving as our executive officer at the end of the most recently
      completed financial year, who we will collectively refer to as the named
      executive officers, for our fiscal years ended September 30, 2011 and
      2010, are set out in the following summary compensation
  table:</P></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_49></A>
<P align=center>45 </P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>
    <TR vAlign=bottom bgcolor="#EEEEEE">
      <TD colspan="10" align=center vAlign=bottom >&nbsp;&nbsp;<B>SUMMARY COMPENSATION
        TABLE</B>&nbsp;&nbsp;&nbsp; </TD>
    </TR>
    <TR vAlign=top bgcolor="#EEEEEE">
      <TD align=center vAlign=bottom nowrap ><BR>
        <BR> <BR> <B>Name</B> <BR> <B>and Principal</B>
      <BR> <B>Position</B> <BR> <BR></TD>
      <TD width="5%" align=center vAlign=bottom nowrap
      ><BR>
      <BR> <BR> <BR> <BR> <B>Year</B> <BR> <BR></TD>
      <TD width="9%" align=center vAlign=bottom nowrap><BR>
        <BR> <BR> <BR> <B>Salary
      </B><BR> <B>($)</B> <BR> <BR></TD>
      <TD
      width="9%" align=center vAlign=bottom nowrap><BR>
        <BR> <BR> <BR> <STRONG>Bonus</STRONG><BR>
      <B>($)</B> <BR> <BR></TD>
      <TD width="9%" align=center vAlign=bottom nowrap><BR>
        <BR> <BR> <B>Stock</B> <BR>
      <STRONG>Awards </STRONG><BR> <B>($)</B> <BR> <BR></TD>
      <TD width="9%" align=center vAlign=bottom nowrap><BR>
        <BR> <BR> <B>Option</B> <BR>
      <STRONG>Awards </STRONG><BR> <B>($)</B><SUP>(4)</SUP> <BR> <BR></TD>
      <TD width="9%" align=center vAlign=bottom nowrap><B>Non-</B> <BR>
        <B>Equity</B>
        <BR> <B>Incentive</B> <BR> <B>Plan</B> <BR> <STRONG>Compensa-</STRONG>
      <BR> <B>tion</B> <BR> <B>($)</B> <BR></TD>
      <TD width="9%" align=center vAlign=bottom nowrap><BR>
        <B>Nonqualified</B> <BR>
        <B>Deferred</B> <BR> <B>Compensation </B><BR> <B>Earnings</B> <BR> <B>($)</B>
      <BR> <BR></TD>
      <TD width="9%" align=center vAlign=bottom nowrap><BR>
        <B>All</B> <BR> <B>Other</B>
        <BR> <STRONG>Compensa-</STRONG> <BR> <B>tion</B> <BR> <B>($)</B> <BR>
      <BR></TD>
      <TD width="9%" align=center vAlign=bottom nowrap><BR>
        <BR> <BR> <BR> <B>Total</B>
      <BR> <B>($)</B> <BR> <BR></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Dr. Cameron Durrant<SUP>(1)</SUP> <BR> <I>Former Executive
        Chairman and</I> <I>Director</I> <BR></TD>
      <TD align=right width="5%" >2011 <BR>
        2010 <BR></TD>
      <TD align=right width="9%">300,000 <BR>
        $200,000 <BR></TD>
      <TD align=right width="9%">Nil <BR>
        Nil <BR></TD>
      <TD align=right width="9%">Nil <BR>
        Nil <BR></TD>
      <TD align=right width="9%">Nil <BR>
        $Nil <BR></TD>
      <TD align=right width="9%">Nil <BR>
        Nil <BR></TD>
      <TD align=right width="9%">Nil <BR>
        Nil <BR></TD>
      <TD align=right width="9%">Nil <BR>
        Nil <BR></TD>
      <TD align=right width="9%">$300,000 <BR>
        $200,000 <BR></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Harvey Lalach<SUP>(2)</SUP> <BR> <I>President, Chief Operating
        Officer,</I> <I>Secretary and Director and</I> <I>Former Chief Financial
        Officer</I> </TD>
      <TD align=right width="5%" >2011 <BR>
        2010 </TD>
      <TD align=right width="9%">$150,000 <BR>
        $150,000 </TD>
      <TD align=right width="9%">Nil <BR>
        Nil </TD>
      <TD align=right width="9%">Nil <BR>
        Nil </TD>
      <TD align=right width="9%">Nil <BR>
        $Nil </TD>
      <TD align=right width="9%">Nil <BR>
        Nil </TD>
      <TD align=right width="9%">Nil <BR>
        Nil </TD>
      <TD align=right width="9%">Nil <BR>
        Nil </TD>
      <TD align=right width="9%">150,000 <BR>
        $150,000 </TD>
    </TR>
  </TABLE>
</DIV><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%"><SUP>(1) </SUP></TD>
    <TD>
      <P align=justify>Dr. Cameron Durrant was appointed as our Executive
      Chairman on January 2, 2010. Prior to that date, Dr. Durrant served as an
      advisor to the company and as a director and received certain stock option
      awards for his services in that capacity. Dr. Durrant resigned as a
      director and officer of the Company on September 16, 2011.</P></TD></TR>
  <TR>
    <TD width="5%"><SUP>&nbsp;</SUP></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="5%"><SUP>(2) </SUP></TD>
    <TD>
      <P align=justify>Mr. Lalach was appointed President and Secretary on April
      25, 2006. On August 27, 2011, Mr. Lalach was appointed Chief Operating
      Officer and on May 13, 2011 he was appointed Interim Chief Financial
      Officer.</P></TD></TR>
  <TR>
    <TD width="5%"><SUP>&nbsp;</SUP></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="5%"><SUP>(3) </SUP></TD>
    <TD>
      <P align=justify>Details of our stock-based compensation arrangements,
      including the assumptions used in calculating the fair value of our share
      based awards, are disclosed in footnote 9 to our financial
    statements.</P></TD></TR></TABLE>
<P align=justify><B><I>Consulting Agreements </I></B></P>
<P align=justify><I>Cameron Durrant </I></P>
<P align=justify>On May 20, 2008, we entered into a consulting agreement with
Cameron Durrant to provide certain management and consulting services to our
company. Consideration for his services included:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>the issuance of 200,000 shares of common stock to be paid
      installments of 25,000 shares every quarter;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>the issuance of 400,000 stock options exercisable at
      $5.25 per share for a period of three years, subject to vesting
      provisions; and</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(c) </TD>
    <TD>
      <P align=justify>a payment of a finder&#146;s fee for any financing our company
      receives in the amount of 4% on the first $100,000,000 and 2% on the
      balance.</P></TD></TR></TABLE>
<P align=justify>On May 14, 2009, we signed an amended consulting agreement with
Cameron Durrant, whereby the consideration of 200,000 common shares to be paid
in installments of 25,000 common shares every quarter was replaced with a grant
of 400,000 options at an exercise price of $2.50 per share until May 12, 2014
and vest as follows: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>200,000 options upon the execution of the amended
      consulting agreement;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>50,000 options on August 14, 2009</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(c) </TD>
    <TD>
      <P align=justify>50,000 options on November 14,
2009</P></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_50></A>
<P align=center>46</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD vAlign=top width="5%">&nbsp;</TD>
    <TD vAlign=top width="5%">(d) </TD>
    <TD> <P style="MARGIN-LEFT: 0%" align=justify>50,000 on February 14, 2010</P></TD>
  </TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top width="5%">&nbsp;</TD>
    <TD vAlign=top width="5%">(e) </TD>
    <TD> <P align=justify>50,000 options on May 14, 2010</P></TD>
  </TR>
</TABLE>
<P align=justify>Dr. Durrant received 75,000 shares of common stock pursuant to
the consulting agreement dated May 20, 2008 and subsequently returned these
75,000 shares to our company for cancellation as a result of the award
modification. </P>
<P align=justify>On January 2, 2010 we signed a second amended consulting
agreement with Dr. Durrant, whereby we retained his services as our Executive
Chairman commencing as of January 2, 2010. In consideration of Dr. Durrant&#146;s
services, we agreed to pay him a monthly fee of $25,000, which equates to
$300,000 over the course of one year. The term of this agreement was for a
period of two years commencing on January 2, 2010 and expiring on January 1,
2012. Effective September 16, 2011, Dr. Durrant resigned from our board of
directors and as an officer of our company.</P>
<P align=justify><I>Harvey Lalach</I></P>
<P align=justify>We have a consulting agreement dated February 1, 2007 with
Harvey Lalach to provide management services to our company for consideration of
$7,000 per month. The contract had a two year term, and was extended for an
additional two year term expiring January 31, 2011. During the fiscal year ended
September 30, 2008, we agreed to increase the compensation of Mr. Lalach to
$12,500 per month. Effective February 1, 2011 we entered into a consulting
agreement with Mr. Lalach whereby Mr. Lalach agreed to continue to provide
management services to our company in return for compensation of $12,500 per
month for an additional two years.</P>
<P align=justify><I>Dr. George Tidmarsh</I></P>
<P align=justify>Effective October 10, 2011 we entered into a consulting
agreement with Dr. Tidmarsh to act as our executive director for the following
consideration: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>a monthly consulting fee of $10,000;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>500,000 Share purchase options exercisable at $1.50 per
      option share until October 10, 2016 (subject to certain vesting
      provisions);</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(c) </TD>
    <TD>
      <P align=justify>reimbursement of all reasonable
  expenditures.</P></TD></TR></TABLE>
<P align=justify>The consulting agreement is for a period of one year and may be
reviewed by either our company or Dr. Tidmarsh. </P>
<P align=justify><B><I>Outstanding Equity Awards at Fiscal Year-End </I></B></P>
<P align=justify>The following table sets forth for each named executive officer
and director certain information concerning the outstanding equity awards as of
September 30, 2011.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_51></A>
<P align=center>47 </P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>
    <TR vAlign=top bgcolor="#EEEEEE">
      <TD
      rowSpan=2 align=center vAlign=bottom nowrap><BR>
        <BR> <BR> <BR> <BR> <BR> <BR>
      <BR> <BR> <BR> <BR> <BR> <BR> <BR> <B>Name</B> </TD>
      <TD colspan="5" align=center vAlign=bottom nowrap> <B>Option Awards</B> </TD>
      <TD colspan="4" align=center vAlign=bottom nowrap> <B>Stock Awards</B> </TD>
    </TR>
    <TR vAlign=top>
      <TD
      width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE"><BR>
        <BR> <BR>
        <BR> <BR> <BR> <BR> <BR> <B>Number of</B> <BR> <B>Securities</B> <BR>
      <B>Underlying</B> <BR> <B>Unexercised</B> <BR> <B>Options</B> <BR> <B>Exercisable</B></TD>
      <TD
      width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE"><BR>
        <BR> <BR>
        <BR> <BR> <BR> <BR> <BR> <B>Number of</B> <BR> <B>Securities</B> <BR>
        <STRONG>Underlying </STRONG><BR> <STRONG>Unexercised </STRONG><BR> <B>Options</B>
      <BR> <STRONG>Unexercisable</STRONG> </TD>
      <TD
      width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE"><BR>
        <BR> <BR>
        <BR> <BR> <BR> <B>Equity Incentive</B> <BR> <B>Plan Awards:</B> <BR> <B>Number
        of</B> <BR> <B>Securities</B> <BR> <B>Underlying</B> <BR> <B>Unexercised</B>
      <BR> <B>Unearned</B> <BR> <B>Options</B> </TD>
      <TD
      width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE"><BR>
        <BR> <BR>
        <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <B>Option </B><BR> <B>Exercise
      </B><BR> <B>Price</B> </TD>
      <TD
      width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE"><BR>
        <BR> <BR>
        <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <STRONG>Option</STRONG> <BR> <STRONG>Expiration</STRONG>
      <BR> <B>Date</B> </TD>
      <TD width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE"><BR>
        <BR> <BR>
        <BR> <BR> <B>Number </B><BR> <B>of</B> <BR> <B>Shares </B><BR> <B>or Units</B>
        <BR> <B>of Stock </B><BR> <B>that</B> <BR> <B>Have </B><BR> <B>Not</B>
      <BR> <B>Vested </B></TD>
      <TD width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE"><BR>
        <BR> <B>Market</B>
        <BR> <B>Value</B> <BR> <B>of</B> <BR> <STRONG>Shares</STRONG> <BR> <B>or
        </B><BR> <STRONG>Units </STRONG><BR> <B>of</B> <BR> <STRONG>Stock </STRONG><BR>
        <B>that</B> <BR> <STRONG>Have</STRONG> <BR> <B>Not </B><BR> <STRONG>Vested
      </STRONG></TD>
      <TD width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE"><B>Equity</B>
        <BR>
        <B>Incentive</B> <BR> <B>Plan</B> <BR> <B>Awards :</B> <BR> <B>Number</B>
        <BR> <B>of</B> <BR> <STRONG>Unearned</STRONG> <BR> <STRONG>Shares,</STRONG>
        <BR> <B>Units or</B> <BR> <STRONG>Other</STRONG> <BR> <B>Rights</B> <BR>
      <B>that</B> <BR> <STRONG>Have Not</STRONG> <BR> <STRONG>Vested </STRONG></TD>
      <TD
      width="10%" align=center vAlign=bottom nowrap bgcolor="#EEEEEE"><BR>
        <BR> <BR>
        <BR> <BR> <BR> <B>Equity Incentive Plan</B> <BR> <B>Awards :</B> <BR>
        <B>Market or Payout Value of</B> <BR> <B>Unearned</B> <BR> <B>Shares,
        Units or Other</B> <BR> <B>Rights that</B> <BR> <B>Have Not</B> <BR> <B>Vested</B>
      </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Harvey <BR>
        Lalach <BR> <BR></TD>
      <TD align=right width="10%">150,000 <BR>
        50,000 <BR> <BR></TD>
      <TD align=right width="10%">Nil <BR>
        Nil <BR> <BR></TD>
      <TD align=right width="10%">Nil <BR>
        Nil <BR> <BR></TD>
      <TD align=right width="10%">$3.10 <BR>
        $3.50 <BR> <BR></TD>
      <TD align=right width="10%">June 3, 2013 <BR>
        June&nbsp;29,2015 </TD>
      <TD align=right width="10%">Nil <BR> <BR> <BR></TD>
      <TD align=right width="10%">Nil <BR> <BR> <BR></TD>
      <TD align=right width="10%">Nil <BR> <BR> <BR></TD>
      <TD align=right width="10%">Nil <BR> <BR> <BR></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Alison <BR>
        Ayers <BR> <BR> <BR>
        Cameron <BR>
        Durrant <BR></TD>
      <TD align=right width="10%">150,000 <BR>
        50,000 <BR> <BR> <BR>
        400,000 <BR>
        400,000 <BR>
        150,000 <BR>
        25,000 </TD>
      <TD align=right width="10%">Nil <BR>
        Nil <BR> <BR> <BR>
        Nil <BR>
        Nil <BR>
        Nil <BR>
        25,000 </TD>
      <TD align=right width="10%">Nil <BR>
        Nil <BR> <BR> <BR>
        Nil <BR>
        Nil <BR>
        Nil <BR>
        Nil </TD>
      <TD align=right width="10%">$3.10 <BR>
        $3.50 <BR> <BR> <BR>
        $5.25 <BR>
        $2.50 <BR>
        $3.10 <BR>
        $3.50 </TD>
      <TD align=right width="10%">June 3, 2013 <BR>
        June 29, 2015 <BR> <BR> <BR>
        May 20, 2011 <BR>
        May 12, 2012 <BR>
        Dec 12, 2012 <BR>
        June 29, 2015 </TD>
      <TD align=right width="10%">Nil <BR> <BR> <BR> <BR>
        Nil <BR> <BR> <BR></TD>
      <TD align=right width="10%">Nil <BR> <BR> <BR> <BR>
        Nil <BR> <BR></TD>
      <TD align=right width="10%">Nil <BR> <BR> <BR> <BR>
        Nil <BR> <BR></TD>
      <TD align=right width="10%">Nil <BR> <BR> <BR> <BR>
        Nil <BR> <BR></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Sean Lowry <BR> <BR> <BR>
        Robert <BR>
        Chisholm </TD>
      <TD align=right width="10%">150,000 <BR> <BR>
        Nil <BR></TD>
      <TD align=right width="10%">Nil <BR> <BR>
        Nil <BR></TD>
      <TD align=right width="10%">Nil <BR> <BR>
        Nil <BR></TD>
      <TD align=right width="10%">$3,72 <BR> <BR>
        - <BR></TD>
      <TD align=right width="10%">Feb 24, 2016 <BR> <BR>
        - <BR></TD>
      <TD align=right width="10%">Nil <BR> <BR>
        Nil <BR></TD>
      <TD align=right width="10%">Nil <BR> <BR>
        Nil <BR></TD>
      <TD align=right width="10%">Nil <BR> <BR>
        Nil <BR></TD>
      <TD align=right width="10%">Nil <BR> <BR>
        Nil <BR></TD>
    </TR>
  </TABLE>
</DIV>
<P align=justify>We have not adopted any other equity compensation plan other
than our 2007 Stock Option Plan.</P>
<P align=justify><B><I>Compensation of Directors </I></B></P>
<P align=justify>The table below shows the compensation of our directors who
were not our named executive officers for the fiscal year ended September 30,
2011:</P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=center><BR><BR><BR><BR><B>Name</B> </TD>
    <TD align=center width="12%"><BR><BR><B>Fees Earned or</B> <BR><B>Paid in
      Cash</B> <BR><B>($)</B> </TD>
    <TD align=center width="12%"><BR><BR><B>Stock</B> <BR><B>Awards</B>
      <BR><B>($)</B> </TD>
    <TD align=center width="12%"><BR><BR><B>Option</B>
      <BR><B>Awards</B><SUP>(1)</SUP> <BR><B>($)</B> </TD>
    <TD align=center width="12%"><BR><B>Non-Equity</B> <BR><B>Incentive
      Plan</B> <BR><B>Compensation</B> <BR><B>($)</B> </TD>
    <TD align=center width="12%"><B>Nonqualified</B> <BR><B>Deferred</B>
      <BR><B>Compensation</B> <BR><B>Earnings</B> <BR><B>($)</B> </TD>
    <TD align=center width="12%"><BR><BR><B>All other</B>
      <BR><B>Compensation</B> <BR><B>($)</B> </TD>
    <TD align=center width="12%"><BR><BR><BR><B>Total</B> <BR><B>($)</B>
</TD></TR>
  <TR vAlign=top>
    <TD align=left>Alison <SUP>(2)</SUP> <BR>Ayers </TD>
    <TD align=left width="12%">Nil <BR></TD>
    <TD align=left width="12%">Nil <BR></TD>
    <TD align=left width="12%">Nil <BR></TD>
    <TD align=left width="12%">Nil <BR></TD>
    <TD align=left width="12%">Nil <BR></TD>
    <TD align=left width="12%">Nil <BR></TD>
    <TD align=left width="12%">Nil <BR></TD></TR>
  <TR vAlign=top>
    <TD align=left>Sean Lowry <BR></TD>
    <TD align=left width="12%">40,000 <BR></TD>
    <TD align=left width="12%">NIL <BR></TD>
    <TD align=left width="12%">406,500 <BR></TD>
    <TD align=left width="12%">Nil <BR></TD>
    <TD align=left width="12%">Nil <BR></TD>
    <TD align=left width="12%">Nil <BR></TD>
    <TD align=left width="12%">446,500 <BR></TD></TR>
  <TR vAlign=top>
    <TD align=left>Robert <BR>Chisholm </TD>
    <TD align=left width="12%">Nil <BR></TD>
    <TD align=left width="12%">Nil <BR></TD>
    <TD align=left width="12%">Nil <BR></TD>
    <TD align=left width="12%">Nil <BR></TD>
    <TD align=left width="12%">Nil <BR></TD>
    <TD align=left width="12%">Nil <BR></TD>
    <TD align=left width="12%">Nil <BR></TD></TR></TABLE></DIV><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_52></A>
<P align=center>48</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%"><SUP>(1)</SUP> </TD>
    <TD>
      <P align=justify>Details of our stock-based compensation arrangements,
      including the assumptions used in calculating the fair value of our share
      based awards, are disclosed in footnote 2 to our financial statements. The
      amount indicated for the value of the option award reflects the fair value
      of the award on its grant date.</P></TD></TR>
  <TR>
    <TD vAlign=top width="5%"><SUP>(2)</SUP> </TD>
    <TD>
      <P align=justify>Alison Ayers resigned as a director of our company on
      October 21, 2011.</P></TD></TR></TABLE>
<P align=justify>We reimburse our directors for expenses incurred in connection
with attending board meetings. We have not paid any director&#146;s fees or other
cash compensation for services rendered as a director since our inception to
September 30, 2011. </P>
<P align=justify>During the fiscal year ended September 30, 2011, there were no
standard or other arrangements pursuant to which any of our directors were
compensated for services provided in their capacity as directors. </P>
<P align=justify>We currently have no formal plan for compensating our directors
for their services in their capacity as directors, although we may elect to
issue stock options to such persons in the future. Directors are entitled to
reimbursement for reasonable travel and other out-of-pocket expenses incurred in
connection with attendance at meetings of our board of directors. Our board of
directors may award special remuneration to any director undertaking any special
services on our behalf other than services ordinarily required of a
director.</P>
<P align=justify><I>Retirement or Similar Benefit Plans</I></P>
<P align=justify>There are no arrangements or plans in which we provide
retirement or similar benefits for our directors or executive officers.</P>
<P align=justify><I>Resignation, Retirement, Other Termination, or Change in
Control Arrangements</I></P>
<P align=justify>We have no contract, agreement, plan or arrangement, whether
written or unwritten, that provides for payments to our directors or executive
officers at, following, or in connection with the resignation, retirement or
other termination of our directors or executive officers, or a change in control
of our company or a change in our directors&#146; or executive officers&#146;
responsibilities following a change in control. </P>
<P align=justify><B>ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT AND RELATED STOCKHOLDER MATTERS </B></P>
<P align=justify>The following table sets forth, as of December 19, 2011,
certain information with respect to the beneficial ownership of our common stock
by each stockholder known by us to be the beneficial owner of more than 5% of
our common stock, by each of our current directors and executive officers. Each
person has sole voting and investment power with respect to the shares of common
stock, except as otherwise indicated. Beneficial ownership consists of a direct
interest in the shares of common stock, except as otherwise indicated. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_53></A>
<P align=center>49 </P>
<P align=justify><B><I>Security ownership of certain beneficial
owners</I></B></P>
<P align=justify>In the following tables, we have determined the number and
  percentage of shares beneficially owned in accordance with Rule 13d-3 of the <I>Securities Exchange Act of 1934</I> based on information provided to us by
  our controlling stockholder, named executive officers, current executive officers and directors, and this information does not
  necessarily indicate beneficial ownership for any other purpose. In determining
  the number of shares of our common stock beneficially owned by a person and the
  percentage ownership of that person, we include any shares as to which the
  person has sole or shared voting power or investment power, as well as any
  shares subject to warrants or options held by that person that are currently
  exercisable or exercisable within 60 days. </P>
<DIV>
  <TABLE width="90%" border=1 align="center" cellPadding=3 cellSpacing=0
borderColor=#000000
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; ">
    <TR vAlign=top>
    <TD vAlign=bottom align=center><B>Title of class</B> </TD>
    <TD vAlign=bottom align=center width="40%" ><B>Name and
      address of</B> <BR><B>beneficial owner</B> </TD>
    <TD vAlign=bottom align=center width="20%" ><B>Amount and
      nature of</B> <BR><B>beneficial ownership</B> </TD>
    <TD vAlign=bottom align=center width="20%"><B>Percent of</B> <BR><B>class
      </B><B><SUP>1</SUP></B> </TD></TR>
  <TR vAlign=top>
    <TD align=center>Common Stock </TD>
    <TD align=left width="40%" ><B>Athanasios Skarpelos</B>
      <BR>2, Place du Port <BR>Geneva, Switzerland <BR>CH 1204 </TD>
    <TD align=center width="20%" >6,725,832 </TD>
    <TD align=center width="20%">24.73% </TD></TR></TABLE></DIV>
<P align=justify><B><I>Security Ownership of Management</I></B></P>
<DIV>
  <TABLE width="90%" border=1 align="center" cellPadding=3 cellSpacing=0
borderColor=#000000
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; ">
    <TR vAlign=top>
    <TD vAlign=bottom align=center><BR><B>Title of class</B> </TD>
    <TD vAlign=bottom align=center width="40%" ><B>Name and
      address of</B> <BR><B>beneficial owner</B> </TD>
    <TD vAlign=bottom align=center width="20%" ><B>Amount and
      nature of</B> <BR><B>beneficial ownership</B> <BR></TD>
    <TD vAlign=bottom align=center width="21%"><B>Percent of</B> <BR><B>class
      </B><B><SUP>1</SUP></B> </TD></TR>
  <TR vAlign=top>
    <TD align=center>Common Stock </TD>
    <TD align=left width="40%" ><B>Harvey Lalach</B> <BR>4837
      Canyon Ridge Crescent <BR>Kelowna, British Columbia <BR>Canada </TD>
    <TD align=right width="20%" >768,572&nbsp;&nbsp;&nbsp; Direct
      <SUP>2</SUP> </TD>
    <TD align=center width="21%">2.8% </TD></TR>
  <TR vAlign=top>
    <TD align=center>Common Stock </TD>
    <TD align=left width="40%" ><B>Sean Lowry</B> <BR>300-1172
      Bay Street <BR>Toronto, Ontario M5S 1L9 </TD>
    <TD align=right width="20%" >150,000&nbsp;&nbsp;&nbsp;
      Direct<SUP>3</SUP> </TD>
    <TD align=center width="21%">0.5% </TD></TR>
  <TR vAlign=top>
    <TD align=center>Common Stock </TD>
    <TD align=left width="40%" ><B>Robert Chisholm</B> <BR>c/o
      1600 &#150; 609 Granville <BR>Street Vancouver, BC V7Y <BR>1C3 </TD>
    <TD align=right width="20%" >0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      Direct </TD>
    <TD align=center width="21%">0% </TD></TR>
  <TR vAlign=top>
    <TD align=center>Common Stock </TD>
    <TD align=left width="40%" ><B>George Tidmarsh</B> <BR>951
      Gateway Blvd., Suite 3A <BR>South, San Francisco, CA, <BR>USA 94060 </TD>
    <TD align=right width="20%" >0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      Direct </TD>
    <TD align=center width="21%">0% </TD></TR>
  <TR vAlign=top>
    <TD align=center>Common Stock </TD>
    <TD align=left width="40%" ><B>Cameron Durrant</B> <BR>#90
      Fairmount Road West <BR>Califon, NJ 07830-3330 </TD>
    <TD align=right width="20%"
      >400,000&nbsp;&nbsp;&nbsp;&nbsp;Direct<SUP>4</SUP> </TD>
    <TD align=center width="21%">1.4% </TD></TR>
  <TR vAlign=top>
    <TD align=center></TD>
    <TD align=left width="40%" ><B>Directors &amp; Executive</B>
      <BR><B>Officers as a group (4</B> <BR><B>persons)</B> </TD>
    <TD align=right width="20%"
      ><B>918,572</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Direct </TD>
    <TD align=center width="21%">3.3% </TD></TR></TABLE></DIV>
<P align=justify><SUP>1</SUP> Percentage of ownership is based on
27,187,174shares of our common stock issued and outstanding as of December19,
2011. Except as otherwise indicated, we believe that the beneficial owners of
the common stock listed above, based on information furnished by such owners,
have sole investment and voting power with respect to such shares, subject to
community property laws where applicable. Beneficial ownership is determined in
accordance with the rules of the Securities and Exchange Commission and
generally includes voting or investment power with respect to securities. Shares
of common stock subject to options or warrants currently exercisable, or
exercisable within 60 days, are deemed outstanding for purposes of computing the
percentage ownership of the person holding such option or warrants, but are not
deemed outstanding for purposes of computing the percentage ownership of any
other person.<BR><SUP>2 </SUP>Includes 568,572 shares of common stock and
200,000 stock options exercisable within 60 days. <BR><SUP>3</SUP>Includes
150,000 stock options exercisable within 60 days. <BR><SUP>4 </SUP>Dr. Durrant
resigned as executive chairman on September 16, 2011 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_54></A>
<P align=center>50</P>
<P align=justify><B><I>Changes in Control</I></B></P>
<P align=justify>We are unaware of any contract or other arrangement the
operation of which may at a subsequent date result in a change of control of our
company.</P>
<P align=justify><B>ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND
DIRECTOR INDEPENDENCE </B></P>
<P align=justify><B><I>Transactions with related persons</I></B></P>
<P align=justify>There has been no transaction, since October 1, 2009, or
currently proposed transaction, in which we were or are to be a participant and
the amount involved exceeds the lesser of $120,000 or one percent of the average
of our total assets at year end for the last two completed fiscal years, and in
which any of the following persons had or will have a direct or indirect
material interest. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(i) </TD>
    <TD>
      <P align=justify>any director or executive officer of our
  company;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(ii) </TD>
    <TD>
      <P align=justify>any beneficial owner of shares carrying more than 5% of
      the voting rights attached to our outstanding shares of common stock;
      and</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(iii) </TD>
    <TD>
      <P align=justify>any member of the immediate family (including spouse,
      parents, children, siblings and in-laws) of any of the foregoing
      persons.</P></TD></TR></TABLE>
<P align=justify><B><I>Compensation of Executive Officers and Directors</I></B>
</P>
<P align=justify>For information regarding compensation of our executive
officers and directors, please see &#147;Item 11. Executive Compensation.&#148; </P>
<P align=justify><B><I>Director Independence</I></B></P>
<P align=justify>Under NASDAQ Rule 5605(a)(2), a director is not considered to
be independent if he or she is also an executive officer or employee of the
company or accepted any compensation from the company in excess of $120,000
during any period of twelve consecutive months within the three years preceding
the determination of independence.</P>
<P align=justify>We determined that Harvey Lalach and Dr. George Tidmarsh are
  not independent as that term is defined by NASDAQ 5605(a)(2) because Mr. Lalach
  is our President, Chief Operating Officer and interim Chief Financial Officer
  and Dr. Tidmarsh is an executive director. We determined that Robert Chisholm
  and Sean Lowry are independent as that term is defined by NASDAQ Rule 5605(a)(2).
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_55></A>
<P align=center>51 </P>
<P align=justify><B>ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES </B></P>
<P align=justify><B><I>Fees Paid to Our Independent Registered Public Accounting
Firm </I></B></P>
<P align=justify>The following table sets forth the aggregate fees billed or
expected to be billed to our company for professional services rendered by our
independent registered public accounting firms, for the fiscal years ended
September 30, 2011 and 2010: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left><B>Fees</B> </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><B>2011</B> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><B>2010</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR bgcolor="#EEEEEE">
    <TD>&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Audit fees </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>87,570 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>86,656 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Audit related fees </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">Nil </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">Nil </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Tax fees </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>7,349 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>6,537 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;All other fees </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">NIL </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">Nil </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff><B>Total Fees</B> </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>94,919 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff><B>$</B></TD>
    <TD align=right width="12%" bgColor=#e6efff><B>93,193</B> </TD>
<TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD></TR></TABLE>
<P align=justify><B><I>Audit Fees</I></B><I>.</I> Consist of fees billed for
professional services rendered for the audits of our financial statements,
reviews of our interim financial statements included in quarterly reports,
services performed in connection with filings with the Securities and Exchange
Commission and other services that are normally provided by BDO Dunwoody LLP for
the fiscal years ended September 30, 2011 and 2010, in connection with statutory
and regulatory filings or engagements.</P>
<P align=justify><B><I>Policy on Pre-Approval by Audit Committee of Services
Performed by Independent Registered Public Accounting Firm</I></B><B><I><FONT
color=#808080> </FONT></I></B></P>
<P align=justify>Our audit committee pre-approves all services provided by our
independent registered public accounting firm. All of the above services and
fees were reviewed and approved by our audit committee before the respective
services were rendered. </P>
<P align=justify>Our audit committee has considered the nature and amount of
fees billed by BDO Dunwoody LLP and believes that the provision of services for
activities unrelated to the audit was compatible with maintaining BDO Dunwoody
LLP&#146;s independence. </P>
<P align=center><B>PART IV</B></P>
<P align=justify><B>ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</B></P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left><B>Exhibit</B> <BR><B>Number</B> </TD>
    <TD align=left width="90%" ><BR><B>Description</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left><B>(3)</B> </TD>
    <TD align=left width="90%" ><B>Articles of Incorporation and
      Bylaws</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left>3.1 </TD>
    <TD align=left width="90%" >
      <P align=justify>Articles of Incorporation (incorporated by reference to
      an exhibit to our Registration Statement on Form SB-2 filed on January 13,
      2005) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>3.2 </TD>
    <TD align=left width="90%" >
      <P align=justify>Bylaws (incorporated by reference to an exhibit to our
      Registration Statement on Form SB-2 filed on January 13, 2005) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>3.3 </TD>
    <TD align=left width="90%" >
      <P align=justify>Articles of Merger filed with the Secretary of State of
      Nevada on January 10, 2007 and which is effective January 25, 2007
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on January 25, 2007) </P></TD></TR></TABLE></DIV><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_56></A>
<P align=center>52 </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left><B>Exhibit</B> <BR><B>Number</B> </TD>
    <TD align=left width="90%" >
      <P align=justify><BR><B>Description</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left><B>(4)</B> </TD>
    <TD align=left width="90%" >
      <P align=justify><B>Instruments defining rights of security holders,
      including indentures</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>4.1 </TD>
    <TD align=left width="90%" >
      <P align=justify>Specimen Stock Certificate (incorporated by reference to
      an exhibit to our Registration Statement on Form SB-2 filed on January 13,
      2005) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>4.2 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Convertible Loan Agreement (incorporated by
      reference to an exhibit to our Form 8-K filed on April 3, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>4.3 </TD>
    <TD align=left width="90%" >
      <P align=justify>8% Convertible Loan Agreement dated June 3, 2009
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>4.4 </TD>
    <TD align=left width="90%" >
      <P align=justify>&nbsp;8% Convertible Loan Agreement dated June 19, 2009
      (incorporated by reference to </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="90%" >
      <P align=justify>&nbsp;an exhibit to our Current Report on Form 8-K filed
      on June 26, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left><B>(10)</B> </TD>
    <TD align=left width="90%" >
      <P align=justify><B>Material Contracts</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.1 </TD>
    <TD align=left width="90%" >
      <P align=justify>Agreement between Anavex Life Sciences Corp. and Dr.
      Alexandre Vamvakides dated January 31, 2007 (incorporated by reference to
      an exhibit to our Current Report on Form 8-K filed on February 7, 2007)
      </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.2 </TD>
    <TD align=left width="90%" >
      <P align=justify>Abstract of Disclosure of Greek Patent Number 1002616
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on February 7, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.3 </TD>
    <TD align=left width="90%" >
      <P align=justify>Abstract of Disclosure of Greek Patent Number 1004208
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on February 7, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.4 </TD>
    <TD align=left width="90%" >
      <P align=justify>Abstract of Disclosure of Greek Patent Number 1004868
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on February 7, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.5 </TD>
    <TD align=left width="90%" >
      <P align=justify>Written description of Greek Patent Application Number
      20070100020 (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on February 7, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.6 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Stock Option Agreement (incorporated by reference
      to an exhibit to our Current Report on Form 8-K filed on February 22,
      2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.7 </TD>
    <TD align=left width="90%" >
      <P align=justify>Shares for Services and Subscription Agreement dated
      September 11, 2007 between our company and Eurogenet Labs S.A.
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on September 27, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.8 </TD>
    <TD align=left width="90%" >
      <P align=justify>2007 Stock Option Plan (incorporated by reference to an
      exhibit to our Current Report on Form 8-K filed on September 28, 2007)
    </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.9 </TD>
    <TD align=left width="90%" >
      <P align=justify>Consulting Agreement with Cameron Durrant dated May 20,
      2008 (incorporated by reference to an exhibit to our Quarterly Report on
      Form 10-QSB filed on August 18, 2008 </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.10 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Convertible Loan Agreement (incorporated by
      reference to an exhibit to our Current Report on Form 8-K filed on April
      3, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.11 </TD>
    <TD align=left width="90%" >
      <P align=justify>Consulting Agreement with Tariq Arshad dated March 2,
      2009 (incorporated by reference to an exhibit to our Current Report on
      Form 8-K filed on April 3, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.13 </TD>
    <TD align=left width="90%" >
      <P align=justify>Consulting Agreement with Dr. Mark Smith dated January
      13, 2009 (incorporated by reference to an exhibit to our Current Report on
      Form 8-K filed on April 3, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.14 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (incorporated by reference
      to an exhibit to our Current Report on Form 8-K filed on April 3, 2009)
      </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.15 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate (incorporated by reference to
      an exhibit to our Current Report on Form 8-K filed on April 3, 2009)
    </P></TD></TR></TABLE></DIV><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_57></A>
<P align=center>53 </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left><B>Exhibit</B> <BR><B>Number</B> </TD>
    <TD align=left width="90%" ><BR><B>Description</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left>10.16 </TD>
    <TD align=left width="90%" >
      <P align=justify>Amended Consulting Agreement with Cameron Durrant dated
      May 14, 2009 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.17 </TD>
    <TD align=left width="90%" >
      <P align=justify>CEO Consulting Agreement with Dr. Herve de Kergrohen
      dated June 12, 2009 (incorporated by reference to an exhibit to our
      Current Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.18 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Private Placement subscription agreement dated
      June 15, 2009 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.19 </TD>
    <TD align=left width="90%" >
      <P align=justify>Shares for Services Agreement with Andreas Eleuthariadis
      dated June 10, 2009 (incorporated by reference to an exhibit to our
      Current Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.20 </TD>
    <TD align=left width="90%" >
      <P align=justify>Shares for Services Agreement with Vasileios Kourafalos
      dated June 10, 2009 (incorporated by reference to an exhibit to our
      Current Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.21 </TD>
    <TD align=left width="90%" >
      <P align=justify>Shares for Services Agreement with George Kalkanis dated
      June 10, 2009 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.22 </TD>
    <TD align=left width="90%" >
      <P align=justify>Stock Option Agreement with Alexandre Vamvakides dated
      June 11, 2009 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.23 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Private Placement Subscription Agreement
      Convertible Loan (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on June 26, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.24 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Private Placement Subscription Agreement for
      Units (incorporated by reference to an exhibit to our Current Report on
      Form 8-K filed on June 26, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.25 </TD>
    <TD align=left width="90%" >
      <P align=justify>Consultant Services Agreement with NAD Ltd. dated July 1,
      2009 (incorporated by reference to an exhibit to our Current Report on
      Form 8-K filed on November 24, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.26 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (incorporated by reference
      to an exhibit to our Current Report on Form 8-K filed on November 24,
      2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.27 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate (incorporated by reference to
      an exhibit to our Current Report on Form 8-K filed on August 12, 2009)
    </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.28 </TD>
    <TD align=left width="90%" >
      <P align=justify>Stock Option Agreement with Alexander Vamvakides dated
      October 19, 2009 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on November 24, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.29 </TD>
    <TD align=left width="90%" >
      <P align=justify>Promissory note issued to Stonehedge Limited on January
      1, 2010 (incorporated by reference to an exhibit to our Quarterly Report
      on Form 10-Q filed on March 31, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.30 </TD>
    <TD align=left width="90%" >
      <P align=justify>Second Amended Consulting Agreement with Dr. Cameron
      Durrant dated January 2, 2010 (incorporated by reference to an exhibit to
      our Current Report on Form 8-K filed on April 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.31 </TD>
    <TD align=left width="90%" >
      <P align=justify>Contract Lease Agreement with Euro Genet Labs SA dated
      February 1, 2010 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on April 9, 2010)
</P></TD></TR></TABLE></DIV><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_58></A>
<P align=center>54 </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left>
      <P align=justify><B>Exhibit</B> <BR><B>Number</B> </P></TD>
    <TD align=left width="90%" >
      <P align=justify><BR><B>Description</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.32 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (incorporated by reference
      to an exhibit to our Current Report on Form 8-K filed on April 9, 2010)
      </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.33 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate (incorporated by reference to
      an exhibit to our Current Report on Form 8-K filed on April 9, 2010)
    </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.34 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Convertible Loan Agreement (incorporated by
      reference to an exhibit to our Current Report on Form 8-K filed on April
      9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.35 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement for US subscribers
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on July 6, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.36 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement for non-US subscribers
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on July 6, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.37 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate for US warrant holders
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on July 6, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.38 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate for non-US warrant holders
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on July 6, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.39 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Shares for Services Agreement dated July 5, 2010 with
      Eurogenet Labs SA (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on July 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.40 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate for non-US warrant holders
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on July 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.41 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Agreement for Services with Genesis Biopharma Group LLC
      dated August 10, 2010 (incorporated by reference to an exhibit of our
      Current Report on Form 8-K filed on August 18, 2010) <I>(portions of the
      exhibit have been omitted pursuant to a request for</I> <I>confidential
      treatment)</I> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.42 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Agreement for Services with ABX-CRO Advanced
      Pharmaceutical Services dated August 10, 2010 (incorporated by reference
      to an exhibit of our Current Report on Form 8-K filed on August 18, 2010)
      <I>(portions of the exhibit have been omitted</I> <I>pursuant to a request
      for confidential treatment)</I> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.43 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (US Purchasers)
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on September 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.44 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (Canadian and Offshore
      Purchasers) (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on September 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.45 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate (US warrant
      holders)(incorporated by reference to an exhibit to our Current Report on
      Form 8-K filed on September 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.46 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate (Canadian and Offshore
      warrant holders) (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on September 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.47 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Consulting Agreement dated August 2, 2010 with Tom
      Skarpelos (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on September 27, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.48 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Independent Contractor Agreement dated September 1, 2010
      with David Tousley (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on September 27, 2010)
</P></TD></TR></TABLE></DIV><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_59></A>
<P align=center>55 </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left><B>Exhibit</B> <BR><B>Number</B> </TD>
    <TD align=left width="90%" >
      <P align=justify><BR><B>Description</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.49 </TD>
    <TD align=left width="90%" >
      <P align=justify>Sublease Contract with Genesis Research LLC dated
      September 15, 2010 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on September 27, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.50 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (US Purchasers)
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on November 22, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.51 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (non-US Purchasers)
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on November 22, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.52 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate (US Warrant Holders) (US
      Purchasers) (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on November 22, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.53 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate (non-US Warrant Holders) (US
      Purchasers) (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on November 22, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.54 </TD>
    <TD align=left width="90%" >
      <P align=justify>Shares for Service and Subscription Agreement dated
      November 1, 2010 with Eurogenet Labs SA (incorporated by reference to an
      exhibit to our Current Report on Form 8-K filed on November 22, 2010)
    </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.55 </TD>
    <TD align=left width="90%" >
      <P align=justify>Subscription Agreement with Stonehedge Limited dated
      November 17, 2010 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on November 22, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.56 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (incorporated by reference
      to an exhibit to our Current Report on Form 8-K filed on November 30,
      2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.57 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate Form of Subscription
      Agreement (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on November 30, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.58 </TD>
    <TD align=left width="90%" >
      <P align=justify>Shares for Services Agreement Form of Subscription
      Agreement (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on November 30, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.59 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (non-US Purchasers)
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on February 7, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.60 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate (non-US Warrant Holders)
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on February 7, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.61 </TD>
    <TD align=left width="90%" >
      <P align=justify>Termination Agreement dated February 2, 2011 with Genesis
      BioPharma Group, LLC (incorporated by reference to an exhibit to our
      Current Report on Form 8-K filed on February 7, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.62 </TD>
    <TD align=left width="90%" >
      <P align=justify>Independent Contractor Agreement with Harvey Lalach dated
      February 1, 2011 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on February 7, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.63 </TD>
    <TD align=left width="90%" >
      <P align=justify>Independent Contractor Agreement with Dr. Angelos
      Stergiou dated February 1, 2011 (incorporated by reference to an exhibit
      to our Current Report on Form 8-K filed on February 7, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.64 </TD>
    <TD align=left width="90%" >
      <P align=justify>Amended and Restated 2007 Stock Option Plan (incorporated
      by reference to an exhibit to our Current Report on Form 8-K filed on
      February 8, 2011) </P></TD></TR></TABLE></DIV><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_60></A>
<P align=center>56 </P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>
    <TR vAlign=top>
      <TD align=left><B>Exhibit</B> <BR>
        <B>Number</B> </TD>
      <TD align=left width="90%" ><BR>
        <B>Description</B> </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify>10.65 </P></TD>
      <TD align=left width="90%" > <P align=justify>Form of Advisory Board Consulting
          Agreement (incorporated by reference to an exhibit to our Current Report
          on Form 8-K filed on February 28, 2011) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify>10.66 </P></TD>
      <TD align=left width="90%" > <P align=justify>Consulting Agreement dated
          March 30, 2011 with Shackleton Consulting Corp. (incorporated by reference
          to an exhibit to our Current Report on Form 8-K filed on April 13, 2011)
        </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify>10.67 </P></TD>
      <TD align=left width="90%" > <P align=justify>Form of subscription agreement
          for convertible debenture (incorporated by reference to an exhibit to
          our Current Report on Form 8-K filed on April 26, 2011) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify>10.68 </P></TD>
      <TD align=left width="90%" > <P align=justify>Form of subscription agreement
          for convertible debenture (incorporated by reference to an exhibit to
          our Current Report on Form 8-K filed on May 9, 2011) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify>10.69 </P></TD>
      <TD align=left width="90%" > <P align=justify>Form of warrant certificate
          (incorporated by reference to an exhibit to our Current Report on Form
          8-K filed on May 9, 2011) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify>10.70 </P></TD>
      <TD align=left width="90%" > <P align=justify>Amended Stock Option Agreement
          dated September 16, 2011 with Cameron Durrant (incorporated by reference
          to an exhibit to our Current Report on Form 8-K filed on September 21,
          2011) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify>10.71 </P></TD>
      <TD align=left width="90%" > <P align=justify>Consulting Agreement dated
          effective October 10, 2011, with George Tidmarsh (incorporated by reference
          to an exhibit to our Current Report on Form 8-K filed on October 14,
          2011) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify><B>(14)</B> </P></TD>
      <TD align=left width="90%" > <P align=justify><B>Code of Ethics</B> </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify>14.1 </P></TD>
      <TD align=left width="90%" > <P align=justify>Code of Conduct (incorporated
          by reference to an exhibit to our Current Report on Form 8-K filed on
          September 28, 2007) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify><B>(21)</B> </P></TD>
      <TD align=left width="90%" > <P align=justify><B>Subsidiaries</B> </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify>21.1 </P></TD>
      <TD align=left width="90%" > <P align=justify>Anavex Life Sciences (France)
          SA, incorporated under the laws of France </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify><B>(31)</B> </P></TD>
      <TD align=left width="90%" > <P align=justify><B>Section 302 Certifications</B>
        </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify><a href="exhibit31-1.htm">31.1* </a></P></TD>
      <TD align=left width="90%" > <P align=justify><a href="exhibit31-1.htm">Section
          302 Certification of Harvey Lalach </a></P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify><B>(32)</B> </P></TD>
      <TD align=left width="90%" > <P align=justify><B>Section 906 Certifications</B>
        </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify><a href="exhibit32-1.htm">32.1* </a></P></TD>
      <TD align=left width="90%" > <P align=justify><a href="exhibit32-1.htm">Section
          906 Certification of Harvey Lalach </a></P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify><B>(99)</B> </P></TD>
      <TD align=left width="90%" > <P align=justify><B>Additional Exhibits</B>
        </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify>99.1 </P></TD>
      <TD align=left width="90%" > <P align=justify>Insider Trading Policy Adopted
          August 27, 2010 (incorporated by reference to an exhibit to our Current
          Report on Form 8-K filed on September 27, 2010) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify><B>(101)</B> </P></TD>
      <TD align=left width="90%" > <P align=justify><B>XBRL</B> </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify>101.INS* </P></TD>
      <TD align=left width="90%" > <P align=justify>XBRL INSTANCE DOCUMENT </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify>101.SCH* </P></TD>
      <TD align=left width="90%" > <P align=justify>XBRL TAXONOMY EXTENSION SCHEMA
        </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify>101.CAL* </P></TD>
      <TD align=left width="90%" > <P align=justify>XBRL TAXONOMY EXTENSION CALCULATION
          LINKBASE </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify>101.DEF* </P></TD>
      <TD align=left width="90%" > <P align=justify>XBRL TAXONOMY EXTENSION DEFINITION
          LINKBASE </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify>101.LAB* </P></TD>
      <TD align=left width="90%" > <P align=justify>XBRL TAXONOMY EXTENSION LABEL
          LINKBASE </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left> <P align=justify>101.PRE* </P></TD>
      <TD align=left width="90%" > <P align=justify>XBRL TAXONOMY EXTENSION PRESENTATION
          LINKBASE </P></TD>
    </TR>
  </TABLE>
</DIV>
<P align=justify>* Filed herewith.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_61></A>
<P align=center>57</P>
<P align=center><B>SIGNATURES</B></P>
<P align=justify>Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><B>ANAVEX LIFE SCIENCES CORP.</B> </TD>
    <TD align=left width="50%">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>By: </TD>
    <TD align=left width="50%">&nbsp;</TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1px solid">/s/ Harvey Lalach </TD>
  <TD width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Harvey Lalach </TD>
    <TD align=left width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>President, Chief Operating Officer, Secretary, Interim
      Chief Financial Officer and Director (Principal Executive Officer,
      Principal Financial Officer and Principal Accounting Officer) </TD>
    <TD align=left width="50%"></TD></TR>
  <TR vAlign=top>
    <TD align=left>Date: December 21, 2011 </TD>
    <TD align=left width="50%">&nbsp;</TD></TR></TABLE>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
1934, this report has been signed below by the following persons on behalf of
the registrant and in the capacities and on the dates indicated. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>By: </TD>
    <TD align=left width="50%">&nbsp;</TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1px solid">/s/ Harvey Lalach </TD>
  <TD width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Harvey Lalach </TD>
    <TD align=left width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>President, Chief Operating Officer, Secretary, Interim
      Chief Financial Officer and Director (Principal Executive Officer,
      Principal Financial Officer and Principal Accounting Officer) </TD>
    <TD align=left width="50%"></TD></TR>
  <TR vAlign=top>
    <TD align=left>Date: December 21, 2011 </TD>
  <TD align=left width="50%">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>By: </TD>
    <TD align=left width="50%">&nbsp;</TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1px solid">/s/ Sean Lowry </TD>
  <TD width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Sean Lowry </TD>
    <TD align=left width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Director </TD>
    <TD align=left width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Date: December 21, 2011 </TD>
  <TD align=left width="50%">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>By: </TD>
    <TD align=left width="50%">&nbsp;</TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1px solid">/s/ Robert Chisholm </TD>
  <TD width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Robert Chisholm </TD>
    <TD align=left width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Director </TD>
    <TD align=left width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Date: December 21, 2011 </TD>
  <TD align=left width="50%">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>By: </TD>
    <TD align=left width="50%">&nbsp;</TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1px solid">/s/ George Tidmarsh </TD>
  <TD width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>George Tidmarsh </TD>
    <TD align=left width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Executive Director </TD>
    <TD align=left width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Date: December 21, 2011 </TD>
  <TD align=left width="50%">&nbsp;</TD></TR></TABLE><BR>
<HR align=center width="100%" color=black noShade SIZE=5>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
